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Summary of findings {#CD000371-sec1-0001}
===================

Summary of findings for the main comparisonMultiple doses of deworming drugs given to all children, longest follow‐up**In communities where intestinal helminths are endemic, what is the effect of multiple doses of deworming drugs given to all children?Patient or population:** School‐aged children **Settings:** Areas endemic for intestinal helminths **Intervention:** Multiple dose deworming drugs, longest follow‐up**OutcomesIllustrative comparative risks\* (95% CI)Relative effect (95% CI)No of participants (trials)Quality of the evidence (GRADE)CommentsAssumed riskCorresponding riskControlDeworming drugs (Multiple doses)Weight (kg)** Follow‐up: 6 months to 3 yearsThe mean change in weight in the control arm ranged from 1.2 kg to 4.73 kgThe mean weight gain in the intervention groups was\
**0.08 kg more** (0.11 kg less to 0.27 kg more)---38,392 (10 trials^1^)⊕⊕⊝⊝ **low**^2,3^\
Due to risk of bias and inconsistencyThere may be little or no effect on weight gain**Height (cm)** Follow‐up: 6 months to 2 yearsThe mean gain in height in the control groups ranged from\
**2.39 to 16.4 cm**The mean gain in height in the intervention groups was **0.02 cm higher** (0.14 lower to 0.17 higher)---7057 (7 trials^4^)⊕⊕⊕⊝ **moderate**^5^\
Due to risk of biasProbably little or no effect on height**Haemoglobin (g/dL)** Follow‐up: 6 months to 2 yearsThe mean change in haemoglobin in the control groups ranged from\
**0.26 to 1.75 g/dL**The mean haemoglobin in the intervention groups was **0.02 g/dL lower** (0.08 lower to 0.04 higher)---3595 (7 trials^6^)⊕⊕⊝⊝ **low**^7,8^\
Due to risk of bias and indirectnessThere may be little or no effect on haemoglobin**Formal tests of cognition** Follow‐up: 2 years---None of the trials reported a benefit of deworming across multiple tests^9^---32,486 (5 trials^10^)⊕⊕⊕⊝ **moderate**^11^\
Due to risk of biasProbably little or no effect on cognition**Physical well‐being**------------\
(0 trials)---We don\'t know if there is an effect on physical well‐being**School attendance** Follow‐up: 2 years (longest follow‐up)The mean school attendance in the control groups ranged from 66% to 90%The mean school attendance in the intervention groups was **2% higher** (‐4 lower to 8 higher)^12^---20,243 (2 trials^13^)⊕⊝⊝⊝ **very low**^14,15,16^\
Due to risk of bias and indirectnessWe don\'t know if there is an effect on school attendance**School performance**---No difference in exam performances was detected in either trial---32,659\
(2 trials)⊕⊕⊕⊝\
**moderate**^17,18^Probably little or no effect on school performance**Death**\
(between ages 1 and 6 years)**27 per 100025 per 1000RR 0.95**\
(0.89 to 1.92)1,005,135 (3 trials)^19^⊕⊕⊝⊝\
**low**^20,21^\
Due to risk of bias and indirectnessMay be little or no effect on death\*The basis for the **assumed risk** (eg the median control group risk across trials) is provided in footnotes. The **corresponding risk** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI). **CI:** Confidence interval; **RR:** risk ratio.GRADE Working Group grades of evidence **High quality:** Further research is very unlikely to change our confidence in the estimate of effect. **Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. **Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. **Very low quality:** We are very uncertain about the estimate.[^2]

Summary of findings 2Single dose of deworming drugs given to infected children**In infected children, what is the effect of a single dose of deworming drugs?Patient or population:** Children known to be infected with soil‐transmitted intestinal worms **Settings:** Areas hyper‐endemic for intestinal helminths, or children screened for infection **Intervention:** Single dose deworming drugs\
**Control:** No intervention**OutcomesIllustrative comparative risks\* (95% CI)Relative effect (95% CI)No of participants (trials)Quality of the evidence (GRADE)CommentsAssumed riskCorresponding riskControlDeworming drugs (Single dose)Weight (kg)** Follow‐up: 4 weeks to 6 monthsThe mean gain in weight in the control groups ranged from **0.54 to 2.2 kg**The gain in weight in the intervention groups ranged from **0.20 to 1.30 kg higher**Not pooled627 (5 trials)⊕⊕⊝⊝ **low**^1,2^\
Due to risk of bias and inconsistencyMay increase average weight gain**Haemoglobin (g/dL)** Follow‐up: 9 weeks to 6 monthsThe mean change in haemoglobin in the control groups ranged from\
‐**0.6 to ‐0.9 g/dL**The mean change in haemoglobin in the intervention groups was **0.10 g/dL higher** (0.65 lower to 0.86 higher)---247 (2 trials)⊕⊝⊝⊝ **very low**^1,2,3^\
Due to risk of bias, inconsistency and indirectnessWe don\'t know if there is an effect on average haemoglobin**Formal tests of cognition**------Not pooled103 (2 trials)⊕⊝⊝⊝ **very low**^4^\
Due to risk of bias and indirectnessWe don\'t know if there is an effect on cognition**Physical well‐being**------Not pooled^5^280\
(3 trials)⊕⊝⊝⊝ **very low**^5,6^\
due to risk of bias and indirectnessWe don\'t know if there is an effect on physical well‐being**School attendance**------------\
(0 trials)---We don\'t know if there is an effect on school attendance\*The basis for the **assumed risk** (eg the median control group risk across trials) is provided in footnotes. The **corresponding risk** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI). **CI:** Confidence interval.GRADE Working Group grades of evidence **High quality:** Further research is very unlikely to change our confidence in the estimate of effect. **Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. **Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. **Very low quality:** We are very uncertain about the estimate.[^3]

Summary of findings 3Single dose of deworming drugs given to all children**In communities where intestinal helminths are endemic, what is the effect of a single dose of deworming drugs given to all children?Patient or population:** All children **Settings:** Areas endemic for intestinal helminths **Intervention:** Single dose deworming drugs\
**Control:** No intervention**OutcomesIllustrative comparative risks\* (95% CI)Relative effect (95% CI)No of participants (trials)Quality of the evidence (GRADE)CommentsAssumed riskCorresponding riskControlDeworming drugs (Single dose)Weight (kg)** Follow‐up: 7 weeks to 1 yearThe mean weight gain in the control groups ranged from\
**0.45 kg to 1.19 kg**The mean weight gain in the intervention groups was\
**0.04 kg less**\
(0.11 kg less to 0.04 kg more)---2719 (7 trials)⊕⊕⊕⊝ **moderate**^1^\
Due to risk of biasProbably little or no effect on average weight gain**Haemoglobin (g/dL)** Follow‐up: 9 weeks to 6 monthsThe mean haemoglobin in the control groups ranged from\
**12.01 to 12.12 g/dL**The mean haemoglobin in the intervention groups was **0.06 g/dL higher** (0.05 lower to 0.17 higher)---1005 (3 trials)⊕⊕⊕⊝ **moderate**^1^\
Due to risk of biasProbably little or no effect on average haemoglobin**Formal tests of cognition**---One trial reported that deworming had no effect, and the other that deworming reduces cognitive scoresNot pooled1361 (2 trials)⊕⊕⊝⊝ **low**^1,2^\
due to risk of bias and indirectnessThere may be little or no effect on cognition**Physical well‐being**------------\
(0 trials)---We don\'t know if there is an effect on physical well‐being**School attendance**------------\
(0 trials)---We don\'t know if there is an effect on school attendance\*The basis for the **assumed risk** (eg the median control group risk across trials) is provided in footnotes. The **corresponding risk** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI). **CI:** Confidence interval.GRADE Working Group grades of evidence **High quality:** Further research is very unlikely to change our confidence in the estimate of effect. **Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. **Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. **Very low quality:** We are very uncertain about the estimate.[^4]

Background {#CD000371-sec1-0002}
==========

Description of the condition {#CD000371-sec2-0001}
----------------------------

The three soil‐transmitted helminth (STH) infections, ascariasis (roundworm), trichuriasis (whipworm), and hookworm, are the main intestinal helminth infections in humans ([@CD000371-bbs2-0092]; [@CD000371-bbs2-0109]). Specialists estimate that each type of infection causes between 600 to 800 million cases worldwide each year ([@CD000371-bbs2-0109]; [@CD000371-bbs2-0126]), with more than a quarter of the world\'s population infected with one or more of the soil‐transmitted intestinal worms ([@CD000371-bbs2-0100]). Estimates from 2003 suggest that global prevalence of STH infections is declining, with marked improvement in the Americas and Asia, but a static picture in sub‐Saharan Africa ([@CD000371-bbs2-0109]). STH infections particularly affect children living in poverty, where inadequate sanitation, overcrowding, low levels of education, and lack of access to health care make them particularly susceptible ([@CD000371-bbs2-0092]; [@CD000371-bbs2-0109]). In 1993, the World Bank ranked STH infection as a greater cause of ill health in children aged five to 15 years than any other infection ([@CD000371-bbs2-0147]), but there has been considerable variation in the quoted estimates of global burden ([@CD000371-bbs2-0109]), which are currently being updated.

Policy makers are concerned that the long‐term effects of worm infestation impair childhood nutritional status, school performance, and long‐term cognitive development ([@CD000371-bbs2-0092]). It is thought that iron status may mediate these effects, since hookworm and whipworm disease are associated with iron‐deficiency anaemia ([@CD000371-bbs2-0104]; [@CD000371-bbs2-0108]), and a fall in blood haemoglobin levels is associated with increasing intensity of infection ([@CD000371-bbs2-0105]). Furthermore, hookworm‐induced iron‐deficiency anaemia has been associated with decreased physical activity and worker productivity ([@CD000371-bbs2-0105]).

Worms are associated with malnutrition, impaired growth, and poor school performance. Roundworms obtain their nutrition from gastrointestinal contents. The association with malnutrition is possibly mediated through impaired fat digestion, reduced vitamin absorption (particularly vitamin A), and temporary lactose intolerance ([@CD000371-bbs2-0140]). Whipworm infection has been associated with malnutrition, although the precise mechanism for this is unclear ([@CD000371-bbs2-0098]). Some suggest that the effects on nutrition are through appetite suppression, increased nutrient loss, and decreased nutrient absorption and utilization ([@CD000371-bbs2-0108]; [@CD000371-bbs2-0139]).

Roundworm, hookworm, and whipworm disease have all been associated with impaired growth in school children ([@CD000371-bbs2-0108]). Observational trials have reported an association between worm infection and lower scores on tests of school performance ([@CD000371-bbs2-0130]; [@CD000371-bbs2-0136]). In a multiple‐regression model based on cross‐sectional data, [@CD000371-bbs2-0136] found that hookworm infection was associated with worse scores in six out of 14 cognitive tests in Indonesian school children. Severe whipworm (*Trichuris* dysentery syndrome) was associated with low intelligence quotient (IQ), school achievement, and cognitive function after a four‐year follow‐up of a specific group of Jamaican children with severe infection ([@CD000371-bbs2-0097]).

While these associations would suggest potential benefits of deworming, the associations could equally be caused by the confounding factor of poverty. Even with adjustment for known confounding factors, residual confounding could be a problem. Furthermore, the causal link between chronic infection and impaired childhood development is extrapolated from the recorded improvement in these features after deworming ([@CD000371-bbs2-0092]). Hence, reliable randomized controlled trials (RCTs) are required to assess whether policies are effective. These can examine the effectiveness of treating worm infection in an individual, as evidence of efficacy, and treatment in schools or communities, as evidence of the effectiveness of programmes. The latter trials are ideally cluster‐RCTs, and thus able to detect any externalities (benefits to other children) accruing as a result of reduced transmission.

Description of the intervention {#CD000371-sec2-0002}
-------------------------------

Public health interventions to reduce worm infection include improved sanitation and hygiene and drug therapy for populations or targeted groups in the community, often coupled with health education. The work of the Rockefeller Sanitary Commission in the early 1900s in the USA with a grant of USD 11 million in the Southern States was combined with efforts to improve schooling. This led to the belief that sanitary reform was needed alongside chemotherapeutic approaches to eradicate hookworm to rid children of lethargy and improve their health ([@CD000371-bbs2-0094]; [@CD000371-bbs2-0124]). In Japan, worms virtually disappeared over a 20‐year period after the Second World War; this has been credited to an integrated programme of sanitary reform combined with screening and treatment of positive cases ([@CD000371-bbs2-0124]; [@CD000371-bbs2-0138]). A similar experience occurred in Korea ([@CD000371-bbs2-0138]). The current global decline in worm prevalence has been credited to economic development and deworming programmes ([@CD000371-bbs2-0109]). The impact of the chemotherapeutic element is difficult to assess. In countries where an improvement in sanitation and hygiene has occurred as a component of economic growth, a parallel decline in the prevalence of soil‐transmitted helminths has occurred: for example, in Italy between 1965 and 1980, the trichuriasis prevalence dropped from 65% to less than 5% without control activity ([@CD000371-bbs2-0138]).

The World Health Organization (WHO) recommends periodic treatment with anthelminthic (deworming) medicines, without previous individual diagnosis to almost all children living in endemic areas. The WHO does not recommend individual screening, since the cost of screening is four to 10 times that of the treatment itself. Treatment is recommended once a year when the prevalence of STH infections in the community is over 20%, and twice a year when the prevalence of STH infections in the community exceeds 50% ([@CD000371-bbs2-0146]). The strategy is to target drug treatment to at‐risk groups: pre‐school‐age children (between one and five years); school‐age children (between six and 15 years); and women of childbearing age. The strategy requires a population survey for prevalence and intensity of infection to determine the population worm burden. This determines the recommended frequency of treatment, updated in a WHO field manual in 2006 ([@CD000371-bbs2-0143]).

The policy promotes the use of schools, maternal and child health clinics, and vaccination campaigns to reach at‐risk groups. The WHO advocates school‐based programmes in particular, as it is easy to deliver medicines through teaching staff, with estimated costs varying from USD 0.05 to 0.65 per child per year for annual dosing ([@CD000371-bbs2-0138]; [@CD000371-bbs2-0140]). In areas with a high prevalence, the current policy recommends treatment three times per year ([@CD000371-bbs2-0143]), based on modelling and reinfection prevalence trials. Following drug treatment, worm populations tend to return rapidly to pretreatment levels; with roundworm and whipworm this happens in less than a year ([@CD000371-bbs2-0091]). [@CD000371-bbs2-0091] suggests that, in order to control morbidity in areas of endemic infection, targeted treatment should be repeated every three to four months for roundworm and whipworm, with longer intervals acceptable for longer‐lived species such as hookworm. The WHO recommends monitoring with a range of impact indicators, including prevalence and intensity, incidence, morbidity, and mortality ([@CD000371-bbs2-0144]). The control programme is intended to reduce the worm burden in the 10% to 15% of children who are most heavily infected in a particular population and to keep it low through repeated treatments.

It has been argued that treating individuals in communities reduces transmission in the community as a whole ([@CD000371-bbs2-0091]), and that this can lead to health and schooling benefits for the whole population, including those who have not received deworming treatment ([@CD000371-bbs2-0096]). These \'spill over\' effects, or externalities, are not captured in individually RCTs, since any benefit in the control group reduces the overall treatment effect. A cluster design is therefore required to identify these additional putative effects.

This Cochrane Review does not cover deworming and pregnancy (reviewed in [@CD000371-bbs2-0118]).

How the intervention might work {#CD000371-sec2-0003}
-------------------------------

The rationale for the effects of deworming programmes on population development depend on the assumption that they improve nutrition, haemoglobin, and cognition. As a result of these benefits, children are thought to have increased physical well‐being, with improved intellect, and are better able to attend school. As a result, performance at school is enhanced, over the long‐term this benefits society as a whole, and reduces poverty ([@CD000371-bbs2-0141], [@CD000371-bbs2-0145]). This is expressed in our conceptual framework (see [Figure 1](#CD000371-fig-0001){ref-type="fig"}). The figure provides the basis for this review: the primary outcomes sought are the main effects (increased haemoglobin, nutrition, and improved cognition); measurable aspects of the mediating pathways (school attendance and physical well‐being); and measurable aspects of impact (mortality and school performance).Figure 1

In this review we include community trials that measure effects after a single dose of deworming drugs (\'efficacy\' measures in the individual), as well as trials of multiple doses with longer follow‐up periods. Multiple dose, cluster randomized trials with long follow‐up periods are the best measure of policy effectiveness since they are likely to detect externalities within schools and potential long term benefits.

Why it is important to do this review {#CD000371-sec2-0004}
-------------------------------------

The intended impacts of deworming programmes are clearly worthwhile goals and are heavily promoted by advocates in the field such as the WHO ([@CD000371-bbs2-0133]; [@CD000371-bbs2-0140]; [@CD000371-bbs2-0143]; [@CD000371-bbs2-0145]; [@CD000371-bbs2-0146]), the World Bank ([@CD000371-bbs2-0148]), and the Bill & Melinda Gates Foundation ([@CD000371-bbs2-0120]). Furthermore, deworming with albendazole was recently endorsed in the 2012 Copenhagen consensus statement, as the fourth highest ranking solution to address \"big issues facing the planet\" in terms of cost and benefit ([@CD000371-bbs2-0103]). The widely‐cited cost‐effectiveness estimates from the Disease Control Priorities in Developing Countries (DCP2) report ([@CD000371-bbs2-0129]) state that deworming for STH infections was one of the most cost‐effective interventions for global health. However, the reliability of these estimates has been questioned by the organization GiveWell, which suggests they have been overstated by a factor of about 100 ([@CD000371-bbs2-0114]).

Advocates point to the favourable cost‐effectiveness estimates for deworming programmes, with a focus on the putative effect on schooling outcomes and productivity ([@CD000371-bbs2-0110]). The evidentiary basis for this draws on a range of trial designs, including historical econometric trials such as [@CD000371-bbs2-0093], which analysed the Rockefeller Sanitary Commission\'s campaign to eradicate hookworm in the Southern states of the USA. This showed an association between areas with higher levels of hookworm infection prior to the campaign and greater increases in school attendance and literacy after the intervention, and an association with income gains in the longer term. Another influential trial is [@CD000371-bbs2-0026], which is included in this Cochrane Review.

Current policies have become even more challenging to assess, as global specialists conflate the evidence on different helminths. The WHO, for example, describes the benefits of treating all helminths, including schistosomiasis, filariasis, and STH infections. The WHO states that deworming treatment against schistosomes and STH infections helps (1) eradicate extreme poverty and hunger; (2) achieve universal primary education; (3) promote gender equality and empower women; (4) reduce child mortality and improve maternal health; and (5) combat HIV/AIDS, malaria, and other diseases ([@CD000371-bbs2-0141]; [@CD000371-bbs2-0145]). The evidence for the benefit of treating populations with schistosomiasis is fairly clear ([@CD000371-bbs2-0106]), as the infection has a very substantive effect on health. However, this does not mean that a different drug treating a different helminth species is equally effective.

Despite the lack of rigour in considering the evidence for separate components of these policies, many countries are moving forward with large scale purchases of drugs. The current neglected tropical disease (NTD) policy focus has been on addressing \'polyparasitism\' by treating the parasites that cause ascariasis, trichuriasis, hookworm, lymphatic filariasis, onchocerciasis, schistosomiasis, and trachoma with ivermectin, albendazole, azithromycin, and praziquantel ([@CD000371-bbs2-0126]). These four drugs are donated by pharmaceutical companies, and the \'overlapping specificity\' would mean multiple pathogens would be targeted ([@CD000371-bbs2-0125]). Thus, mass drug administration for NTDs is promoted as \"one of the lowest cost and cost‐efficient mechanisms for both improving maternal child health and lifting the bottom billion out of poverty\" ([@CD000371-bbs2-0128]). Significant resources are being invested in this agenda, with the UK Department for International Development committing GBP 50 million in 2008, and the US government committing USD 65 million in 2010 as part of the US Global Health Initiative ([@CD000371-bbs2-0127]).

Given the amount of investment of public money in these programmes, it is important to be clear whether mass or targeted drug administration is able to contribute to health and development in such a substantive way. Indeed, international donors and developed country governments and tax payers are contributing to the efforts to tackle STH infections in the belief that they will improve the health of children in the way that the WHO claims ([@CD000371-bbs2-0141]). For example, Deworm the World has worked with the Indian Government to treat 140 million children across India in 2015 on the basis of the Copenhagen Consensus Statement ([@CD000371-bbs2-0112]; [@CD000371-bbs2-0134]).

Thus, this systematic review of reliable evidence from RCTs will help clarify whether existing evidence supports the conclusion that there is an impact of these drugs in populations with STH infections (ascariasis, trichuriasis, and hookworm) and will evaluate the strength of the evidence.

### History of this Cochrane Review {#CD000371-sec3-0001}

Previous editions of this Cochrane Review ([@CD000371-bbs2-0149]; [@CD000371-bbs2-0150]; [@CD000371-bbs2-0151]; [@CD000371-bbs2-0152]) have generated considerable debate ([@CD000371-bbs2-0120]; [@CD000371-bbs2-0123]; [@CD000371-bbs2-0137]).

Early on the debate was around medical outcomes, such as anaemia. More recently there has been a shift in focus from short‐term impacts of deworming to potential longer‐term developmental impacts ([Figure 1](#CD000371-fig-0001){ref-type="fig"}). Indeed, Givewell suggests that the most compelling case for deworming as a cost‐effective intervention comes from \"the possibility that deworming children has a subtle, lasting impact on their \[children\'s\] development, and thus on their ability to be productive and successful throughout life\", but further comments that \"empirical evidence on this matter is very limited\" ([@CD000371-bbs2-0115]). There have been some recent observational analyses with long‐term follow‐up of dewormed children which were considered during this update. None of these trials met the inclusion criteria of this review ([@CD000371-bbs2-0047]; [@CD000371-bbs2-0054]; [@CD000371-bbs2-0073]; described in the [Characteristics of excluded studies](#CD000371-sec2-0024){ref-type="sec"} section).

Important new trials have been published. The DEVTA trial of over one million children was completed in 2005 and published in 2013 ([@CD000371-bbs2-0005]. A second important trial with a manuscript date of 2006 of over 2500 children remains unpublished, but we have included it in this review ([@CD000371-bbs2-0017].

The development organization 3ie recently commissioned the replication of the influential econometric trial from Kenya ([@CD000371-bbs2-0026]. We highlighted concerns about the quality of the evidence for school attendance on the basis of this trial in the previous version of this Cochrane Review ([@CD000371-bbs2-0152]). The replication was published recently ([@CD000371-bbs2-0088]; [@CD000371-bbs2-0089]; [@CD000371-bbs2-0107]). The authors checked the data and corrected any errors, and then carried out an analysis using exactly the methods in the original publication. The replication highlights important coding errors and this resulted in a number of changes to the results: the previously reported effect on anaemia disappeared; the effect on school attendance was similar to the original analysis, although the effect was seen in both children that received the drug and those that did not; and the indirect effects (externalities) of the intervention on adjacent schools disappeared ([@CD000371-bbs2-0089]). The statistical replication suggested some impact of the complex intervention (deworming and health promotion) on school attendance, but this varied depending on the analysis strategy, and there was a high risk of bias. The replication showed no effect on exam performance ([@CD000371-bbs2-0107]).

In the light of the publication of the DEVTA trial of over one million children, the replication trials of the Kenya trial, the new longer term follow‐up trials, and four new RCTs, we updated [@CD000371-bbs2-0152]. We have added new trials and data, restructured the analysis, and updated the GRADE assessment of the quality of the evidence.

Objectives {#CD000371-sec1-0003}
==========

To summarize the effects of giving deworming drugs to children to treat soil‐transmitted intestinal worms on weight, haemoglobin, and cognition; and the evidence of impact on physical well‐being, school attendance, school performance, and mortality.

Methods {#CD000371-sec1-0004}
=======

Criteria for considering studies for this review {#CD000371-sec2-0005}
------------------------------------------------

### Types of studies {#CD000371-sec3-0002}

RCTs and quasi‐RCTs. We included cluster‐RCTs, provided more than two clusters were allocated to each treatment arm.

### Types of participants {#CD000371-sec3-0003}

Infected children identified by screening in community trials.

All children must have lived in endemic areas.

We defined children as aged under 16 years. We excluded trials of sick children or children being treated for malnutrition.

### Types of interventions {#CD000371-sec3-0004}

#### Intervention {#CD000371-sec4-0001}

Deworming drugs for soil‐transmitted helminths, administered at any location (including health facilities, schools, and communities). We included trials examining effects after a single dose and after multiple doses.

The deworming drugs we included are those in the WHO Model List of Essential Medicines for deworming drugs of soil‐transmitted helminths ([@CD000371-bbs2-0142]). This includes albendazole, levamisole, mebendazole, pyrantel, and ivermectin. Other drugs used are nitazoxanide, piperazine, tetrachlorethylene, and thiabendazole.

We did not exclude trials that also provided some health promotion activities supporting the deworming programmes. Studies that provided additional interventions (eg growth monitoring, micronutrient supplementation, malaria chemoprevention, or other drugs) were included when the additional intervention was given to both the control and intervention arm.

#### Control {#CD000371-sec4-0002}

Placebo or no treatment.

### Types of outcome measures {#CD000371-sec3-0005}

#### Primary outcomes {#CD000371-sec4-0003}

Weight;Haemoglobin;Formal tests of cognition.

#### Secondary outcomes {#CD000371-sec4-0004}

Other nutritional indicators:HeightMid‐upper arm circumference (MUAC)Skin fold thickness (including triceps and subscapular skin fold)Body mass index;Measures of physical well‐being (eg Harvard Step Test);School attendance:Days present at schoolNumber of children dropping out;School performance (measured by examination results);Death.

##### Adverse events {#CD000371-sec5-0001}

Serious adverse events (death, life‐threatening events, or events leading to hospitalization);Other adverse events.

Search methods for identification of studies {#CD000371-sec2-0006}
--------------------------------------------

### Electronic searches {#CD000371-sec3-0006}

The review authors and the Cochrane Infectious Diseases Group (CIDG) Information Specialist, Vittoria Lutje, attempted to identify all relevant trials regardless of language or publication status (published, unpublished, in press, and in progress). The date of the last search was 14 April 2015. The Information Specialist searched the following databases using the search terms and strategy described in [Table 11](#CD000371-tbl-0011){ref-type="table"}: CIDG Specialized Register (14 April 2015); Cochrane Central Register of Controlled Trials (CENTRAL), published in the Cochrane Library (2015, Issue 4); MEDLINE (2000 to 14 April 2015); EMBASE (2000 to 14 April 2015); and LILACS (2000 to 14 April 2015); and reference lists, and registers of ongoing and completed trials. We also searched the *meta*Register of Controlled Trials (*m*RCT) using \'helminth\* OR anthelminth\*\' (14 April 2015).Table 1Detailed search strategies**Search setCIDG SR^a^CENTRALMEDLINE^b^EMBASE^b^LILACS^b^**1helmint\*helmint\*helmint\*helmint\$helmint\*2Ancylostoma duodenaleAncylostoma duodenaleAncylostoma duodenaleAncylostoma duodenaleAncylostoma duodenale3Necator americanusNecator americanusNecator americanusNecator americanusNecator americanus4AscarisAscarisAscarisAscarisAscaris5Enterobius vermicularisEnterobius vermicularisEnterobius vermicularisEnterobius vermicularisEnterobius vermicularis6trichuristrichuristrichuristrichuristrichuris7Strongyloid\*Strongyloid\*Strongyloid\*Strongyloid\*Strongyloid\*8albendazolehookworm\*hookworm\*hookworm\$1‐7/OR9mebendazoleroundworm\*roundworm\*roundworm\$albendazole10piperazinepinworm\*pinworm\*pinworm\$mebendazole11levamisolewhipworm\*whipworm\*whipworm\$piperazine12pyrantel1‐11/OR1‐11/OR1‐11/ORlevamisole13tiabendazolealbendazolealbendazolealbendazolepyrantel14---mebendazolemebendazolemebendazoletiabendazole15---piperazinepiperazinepiperazine9‐14/OR16---levamisolelevamisolelevamisole8 and 1517---pyrantelpyrantelpyrantelLimit 16 to human18---tiabendazoletiabendazoletiabendazole---19---13 or 14 or 15 or 16 or 17 or 1813 or 14 or 15 or 16 or 17 or 1813 or 14 or 15 or 16 or 17 or 18---20---12 and 1912 and 1912 and 19---21------Limit 20 to humanLimit 20 to human---[^5]

Data collection and analysis {#CD000371-sec2-0007}
----------------------------

### Selection of studies {#CD000371-sec3-0007}

David Taylor‐Robinson (DTR) checked the search results for potentially relevant trials and retrieved full articles as required. DTR and Paul Garner (PG) independently assessed the trial eligibility using an eligibility form based on the inclusion criteria; where there was uncertainty, all five review authors participated in the decision about inclusion. We checked that trials with multiple publications were managed as one trial. We recorded reasons for the exclusion of trials and we contacted authors of unpublished trials for information on when they intended to publish their results.

### Data extraction and management {#CD000371-sec3-0008}

Nicola Maayan (NM), DTR, Sarah Donegan (SD), and Karla Soares‐Weiser (KSW) independently extracted data using data extraction forms. PG extracted and cross‐checked the data from a selection of papers. We resolved any differences in opinion by discussion. Where methods, data, or analyses were unclear or missing, we contacted trial authors for further details.

We extracted data on type of additional interventions (eg accompanying health promotion programme including programmes about hygiene and behaviour, water and sanitation; drug; or vitamin) and how this was delivered (mass media, community, or one‐to‐one); and whether these interventions were in both intervention and control groups, or only in the intervention group.

For each treatment group of each trial, we extracted the number of patients randomized. For each outcome of interest, we extracted the number of participants analysed in each treatment group of each trial.

#### RCTs that randomized individuals {#CD000371-sec4-0005}

For dichotomous outcomes, we planned to extract the number of patients with the event. For continuous outcomes, we aimed to extract means and standard deviations (SDs). Where these data were not reported, we extracted medians and ranges or any other summary statistics. Where change from baseline results were presented alongside results purely based on the end value, we only extracted the change from baseline results.

#### RCTs that randomized clusters {#CD000371-sec4-0006}

For each cluster‐RCT, we extracted the cluster unit, the number of clusters in the trial, the average size of clusters, and the unit of randomization (such as household or institution). Where possible, we extracted the statistical methods used to analyse the trial along with details describing whether these methods adjusted for clustering or other covariates.

Where a cluster‐RCT adjusted for clustering in their analysis, we extracted the cluster adjusted results. When the trial did not account for clustering in their analysis, we extracted the same data as for trials that randomize individuals.

For the analysis of [@CD000371-bbs2-0002] we took weight from the publication by Awasthi in 2008; height data from INCLEN 1995 monograph (references contained in the main reference). Means of cluster means were used in analysis; details of correspondence from previous review suggest that trial was ongoing; data for 3‐year follow‐up are provided from R. Dickson\'s correspondence with the author for the [@CD000371-bbs2-0149] Cochrane Review, but the loss to follow up is very high: only 24% analysed.

#### Replication {#CD000371-sec4-0007}

One included trial, [@CD000371-bbs2-0026], has been the subject of an independent re‐analysis, with a full report published on the 3ie website ([@CD000371-bbs2-0088]), which also includes a response from the authors ([@CD000371-bbs2-0087]); and two subsequent academic papers ([@CD000371-bbs2-0089]; [@CD000371-bbs2-0107]). In this edition of the Cochrane Review we used new information on conduct of the trial, on the thorough evaluation for potential biases, and also corrected data from the replication, including the measure of variance for school attendance ([@CD000371-bbs2-0088]).

### Assessment of risk of bias in included studies {#CD000371-sec3-0009}

DTR, PG, NM, SD, and KSW independently assessed the risk of bias ([@CD000371-bbs2-0122]). We resolved any differences through discussion. On occasion, we corresponded with trial investigators when methods were unclear.

For RCTs that randomized individuals we addressed six components: sequence generation; allocation concealment; blinding; incomplete outcome data; selective outcome reporting; and other biases. For cluster‐RCTs, we addressed additional components: recruitment bias; baseline imbalance; loss of clusters; incorrect analysis; compatibility with RCTs randomized by individual. For each component, we placed judgments of low, high, or unclear/unknown risk of bias as described in [Appendix 1](#CD000371-sec2-0016){ref-type="app"}. We displayed the results in \'Risk of bias\' tables, a \'Risk of bias\' summary, and a \'Risk of bias\' graph.

### Measures of treatment effect {#CD000371-sec3-0010}

We summarized continuous data (means and SDs) using the mean differences (MDs). We planned to use the risk ratio to compare the treatment and control groups for dichotomous outcomes. All treatment effects were presented with 95% confidence intervals (CIs).

### Unit of analysis issues {#CD000371-sec3-0011}

For a particular cluster‐RCT when the analyses had not been adjusted for clustering, we attempted to adjust the results for clustering by estimating the design effect calculated as 1+(m‐1)\*ICC where m is the average cluster size and ICC is the intra‐cluster correlation coefficient. To make the adjustment, we estimated a treatment effect that did not adjust for clustering and then multiplied the standard errors of the estimate by the square root of the design effect*.* When the true ICC was unknown, we estimated it from other included cluster‐RCTs.

### Dealing with missing data {#CD000371-sec3-0012}

We aimed to conduct a complete‐case analysis in this Cochrane Review, such that all patients with a recorded outcome were included in the analysis.

### Assessment of heterogeneity {#CD000371-sec3-0013}

We inspected the forest plots to detect overlapping CIs, applied the Chi² test with a P value of 0.10 used to indicate statistical significance, and also implemented the I² statistic with values of 30 to 60%, 59 to 90%, and 75 to 100% used to denote moderate, substantial, and considerable levels of heterogeneity, respectively.

### Assessment of reporting biases {#CD000371-sec3-0014}

We decided not to construct funnel plots to look for evidence of publication bias because there were a limited number of trials in each analysis.

### Data synthesis {#CD000371-sec3-0015}

DTR, NM, and SD analysed data with [@CD000371-bbs2-0135]. We structured the analysis into four sections

Infected children‐first dose.Infected children‐multiple dose.All children living in an endemic area‐first dose.All children living in an endemic area‐multiple doses, longest follow up.

For trials involving children living in an endemic area, trials were also grouped by prevalence and intensity (high/moderate/low). High prevalence or high intensity areas are referred to as \'high prevalence\'; moderate prevalence and low intensity are referred to as \'moderate prevalence\'; and low prevalence with low intensity are referred to as \'low prevalence\'. We used the WHO technical guidelines classification ([@CD000371-bbs2-0140]; [Table 12](#CD000371-tbl-0012){ref-type="table"}), rather than the simplified prevalence based field guide categories that are now used to determine treatment frequency ([@CD000371-bbs2-0143]; [Table 12](#CD000371-tbl-0012){ref-type="table"}). In trials where information on intensity was not provided, we estimated the community category on the basis of quoted prevalence; it is possible that the community category has been underestimated in these trials.Table 2Community diagnosis categories and recommended treatment strategies**Community category (**[@CD000371-bbs2-0140]**)Prevalence^a^Percentage^b^School intervention**1. High prevalence or high intensity\> 70%\> 10%Targeted treatment of school‐age children 2 to 3 times per year2. Moderate prevalence and low intensity\> 50% but \< 70%\< 10%Targeted treatment of school‐age children once per year3. Low prevalence and low intensity\< 50%\< 10%Selective treatment**Category (**[@CD000371-bbs2-0143]**)Prevalence^a^Action to be taken**High risk community\> 50%Targeted treatment of pre‐school and school‐age children 2 or 3 times per yearLow risk community\> 20% but \< 50%Targeted treatment of pre‐school and school‐age children once per year[^6]

When a trial reported data at multiple time points we included data collected at the longest follow‐up time in the analysis of \'after multiple doses\', because long term outcomes of multiple doses of deworming are of most relevance to policymakers, and short‐term effects are captured in the single dose results. This decision was supported by findings from an exploratory meta‐regression analysis that was applied to find out whether the intervention effect was modified by the length of follow‐up (see below).

We combined cluster‐RCTs that adjusted for clustering and RCTs that randomized individuals using meta‐analysis. We used a fixed‐effect meta‐analysis when the assessments of heterogeneity did not reveal heterogeneity. In the presence of heterogeneity, we used random‐effects meta‐analysis.

For continuous data, we combined change from baseline results with end value results providing they were from distinct trials ([@CD000371-bbs2-0101]; [@CD000371-bbs2-0121]). Labels on the meta‐analyses indicate when end values were used.

We presented data that could not be meta‐analysed in additional tables and reported on these in each section, under the heading \'other data\'.

### Subgroup analysis and investigation of heterogeneity {#CD000371-sec3-0016}

In the presence of statistically significant heterogeneity, we planned to explore the following potential sources using subgroup analyses: age group (\< five years vs ≥ five years); manufacturer; treatment setting (community, school, health post, hospital). We did not carry out these analyses because there were too few trials in the analyses.

To find out whether the intervention effect was modified by the length of follow‐up, SD and DTR performed a random‐effects meta‐regression for the outcome weight (in all children in an endemic area after multiple doses), with length of follow‐up in months as a covariate using the \'metafor\' package in R. The covariate was centred at its mean.

We also sorted the forest plot for weight (in all children in an endemic area after multiple doses) by year that the trial was carried out to visually inspect whether the intervention effect changed over time.

### Sensitivity analysis {#CD000371-sec3-0017}

We carried out sensitivity analyses including only those trials with a low risk of bias regarding allocation concealment.

#### \'Summary of findings\' tables {#CD000371-sec4-0008}

We interpreted results using \'Summary of findings\' tables, which provide key information about the quality of evidence for the included trials in the comparison, the magnitude of effect of the interventions examined, and the sum of available data on the main outcomes. Using GRADE profiler ([@CD000371-bbs2-0116]), we imported data from [@CD000371-bbs2-0135]; the GRADE display was based on a recent trial of what users prefer ([@CD000371-bbs2-0099]). We presented the primary outcomes for the review in the \'Summary of findings\' tables, and added height, school attendance, and death for multiple dose trials.

Results {#CD000371-sec1-0005}
=======

Description of studies {#CD000371-sec2-0008}
----------------------

We identified 45 trials reported in 64 articles that met the inclusion criteria (see [Figure 2](#CD000371-fig-0002){ref-type="fig"}, [Characteristics of included studies](#CD000371-sec2-0023){ref-type="sec"} and [Appendix 2](#CD000371-sec2-0017){ref-type="app"}). For a trial completed in 2006 but never published, the trial authors provided a manuscript with data we were able to use ([@CD000371-bbs2-0017]). For [@CD000371-bbs2-0001], the trial authors did not adjust the CIs to take into account clustering for the primary outcome. For this Cochrane Review, we used the corrected values supplied by the trial author.Figure 2Study flow diagram.

We excluded 40 trials (see [Characteristics of excluded studies](#CD000371-sec2-0024){ref-type="sec"}), and one trial is ongoing (see [Characteristics of ongoing studies](#CD000371-sec2-0025){ref-type="sec"}).

### Location {#CD000371-sec3-0018}

The included trials were undertaken in 23 different countries: Bangladesh (four trials); China (two trials); Ethiopia (two trials); Haiti (two trials); India (five trials); Indonesia (four trials); Jamaica (two trials); Kenya (five trials); Malaysia (two trials); Phillipines (two trials); South Africa (two trials); Uganda (two trials); Vietnam (three trials); Zanzibar (two trials); Benin, Botswana, Cameroon, Guatemala, Nigeria, Sierra Leone, Tanzania, Zaire (one trial in each); China, Philippines and Kenya; China and Myanmar (multi‐centre trials).

### Population {#CD000371-sec3-0019}

Children were recruited from school populations in 26 trials, communities in 12 trials, and in health facilities or by health workers in seven trials. One of these trials recruited children on discharge from hospital ([@CD000371-bbs2-0007]) and another recruited children whose mothers had participated in the pregnancy phase of the trial ([@CD000371-bbs2-0027]). [@CD000371-bbs2-0030] and [@CD000371-bbs2-0044] also included adolescents 17 to 19 years old, but most participants were under 16 years old.

Thirty‐seven trials were based on mass targeted treatment of an unscreened population. Eight trials studied children who were screened and selected on the basis of their having high worm loads and the purpose of three of these trials was to measure cognitive outcomes. One trial of unscreened children, [@CD000371-bbs2-0037], also studied an infected subgroup of the larger unscreened trial population for cognitive and haemoglobin outcomes. Fifteen trials were conducted in populations where worms were of high prevalence or intensity (community category 1), 12 in populations with moderate prevalence and low intensity (category 2), and 10 in populations with low prevalence and low intensity (category 3).

### Interventions {#CD000371-sec3-0020}

#### Albendazole {#CD000371-sec4-0009}

Twenty‐eight trials had albendazole only in one treatment arm; in addition, some of these trials had arms with combinations with albendazole and: praziquantel ([@CD000371-bbs2-0030]); ivermectin ([@CD000371-bbs2-0006]); and diethylcarbamazine ([@CD000371-bbs2-0009]); the additional drugs were also given to children in the control arms.

One trial included *Giardia* treatment, secnidazole, in both intervention and control arms ([@CD000371-bbs2-0013]).

One trial was a deworming programme that included deworming drugs for STHs, praziquantel to treat schistosomiasis in schools with \> 30% prevalence, and health promotion interventions ([@CD000371-bbs2-0026]).

#### Other anthelminthic drugs {#CD000371-sec4-0010}

Seven trials used mebendazole; and two trials used mebendazole in combination with pyrantel. Other deworming drugs used included pyrantel pamoate, piperazine, piperazine citrate, tetrachloroethylene, and levamisole.

#### Accompanying health promotion activities {#CD000371-sec4-0011}

Nine trials reported on a range of child health activities ([Table 13](#CD000371-tbl-0013){ref-type="table"}). In eight trials, the accompanying activities appeared to be applied to both intervention and control arms.Table 3Accompanying health promotion activities**Accompanying interventionDetails from trialTrials**To both intervention and control\"The AWC workers, usually local women (plus assistants), give pre‐school education, give nutritional supplements to malnourished children, and record births and pre‐school deaths.\"[@CD000371-bbs2-0005]\"The parents of all children aged \< 7 years were offered a range of health services at child health days, including vaccinations, vitamin A supplements, growth monitoring and promotion, and demonstrations of complementary feeding.\"[@CD000371-bbs2-0001]\"The primary job responsibilities of the AWW \[anganwadi worker\] are to run a creche and provide primary health care and supplementary nutrition for children \< six years of age and pregnant and lactating women.\"[@CD000371-bbs2-0004]All children received 10 mL of multivitamins (over two days) as an incentive at each time point. Each 5 mL of multivitamin contained: Vitamin A 3000 IU, Vitamin B2 2.0 mg, Nicotinamide 15.0 mg, Vitamin B1 1.5 mg, Vitamin B6 2.0 mg, Vitamin D2 400 IU, D panthenol 1.0 mg.[@CD000371-bbs2-0018]Children attended a mother and child health clinic[@CD000371-bbs2-0010]Children in both groups received treatment for other conditions in accordance with the IMCI guidelines.[@CD000371-bbs2-0012]Children were followed up for routine immunisations, and then quarterly, to age 5 years. Children received BCG and oral polio immunisations at birth, polio, diphtheria, pertussis, tetanus, hepatitis B and Haemophilus influenzae type B immunisations at 6, 10 and 14 weeks, and measles immunisation at 9 months.[@CD000371-bbs2-0027]Three schools received fortified soup with 20 mg elemental iron per portion, and 100 mg vitamin C per portion for 6 months.[@CD000371-bbs2-0021]Only in the intervention groupTreatment schools received worm prevention education through regular public health lectures, wall charts, and the training of teachers in each treatment school on worm prevention. Health education stressed the importance of hand washing to avoid ingesting roundworm and whipworm larvae, wearing shoes to avoid hookworm infection, and not swimming in infected fresh water to avoid schistosomiasis.[@CD000371-bbs2-0026]No additional intervention reported---37 trials

One trial had a comprehensive health promotion programme accompanying the deworming, including regular public health lectures, teacher training, and health education targeted to avoid intestinal helminths and exposure to schistosomiasis ([@CD000371-bbs2-0026].

### Control groups {#CD000371-sec3-0021}

Most trials used placebo or no treatment as a control. Others used vitamin A, vitamin C, or calcium powder.

There were 13 trials where both the treatment and control group received nutritional supplementation: multi‐nutrient, vitamin B, iron, vitamin A, or child health packages, including growth monitoring and health education ([Table 13](#CD000371-tbl-0013){ref-type="table"}).

### Trial design {#CD000371-sec3-0022}

Nine trials were cluster randomized, including one trial with quasi‐random allocation of the 75 clusters ([@CD000371-bbs2-0026]). The rest used the individual as the unit of randomization.

Six of the nine cluster‐RCTs used an appropriate method to take clustering into account. [@CD000371-bbs2-0004] and [@CD000371-bbs2-0002] used urban slums as the unit of randomization (50 and 124 respectively), and [@CD000371-bbs2-0005] used 72 rural administrative blocks. These three trials were analysed at the cluster level (mean of cluster mean values and associated SDs). [@CD000371-bbs2-0038] randomized 12 schools and adjusted for within‐school correlations using generalized estimating equations. [@CD000371-bbs2-0026] adjusted for clustering in their regression estimates, and presented robust standard errors. [@CD000371-bbs2-0044] randomized 954 households and used generalised linear mixed‐effects models that captured the data correlations induced by clustering within households.

The three remaining cluster‐RCTs did not adjust for clustering:

[@CD000371-bbs2-0001] had not adjusted the primary outcome for clustering in this trial of 48 parishes containing 27,955 children in total. Upon request, the trial authors provided the adjusted values which we have used in the analysis;[@CD000371-bbs2-0017] had 80 units of randomization (schools) containing 2659 children in total. The report presents some regression modelling that adjusts for the cluster design, but the outcomes by randomized comparison do not appear to have been adjusted. We used the ICC calculated from the [@CD000371-bbs2-0001] data to adjust the primary weight outcome for inclusion in meta‐analysis. As the average cluster size for [@CD000371-bbs2-0017] (ie 33 children) differed somewhat from that of [@CD000371-bbs2-0001] (ie 582 children), the true ICC for [@CD000371-bbs2-0017] may be different to that of [@CD000371-bbs2-0001], therefore the adjusted result for weight is merely an approximation;[@CD000371-bbs2-0032] had 13 units of randomization (villages) containing 1476 children in total and had also not adjusted for clustering, but no outcomes from this trial were suitable for meta‐analysis.

Four trials had a factorial design. [@CD000371-bbs2-0005] randomized clusters to usual care, six‐monthly vitamin A, six‐monthly 400 mg albendazole, and both vitamin A and albendazole. [@CD000371-bbs2-0021] randomized individual participants to albendazole or placebo, and, also, three of the five schools in the trial received soup fortified with vitamins and iron, and two received unfortified soup. [@CD000371-bbs2-0024] randomized individual participants to iron‐fortified noodles and mebendazole, noodles without iron fortification and mebendazole, iron‐fortified noodles and placebo, noodles without iron fortification and placebo, and iron supplementation and mebendazole. [@CD000371-bbs2-0039] randomized households to iron, with random allocation of mebendazole by child, stratified by iron allocation and age grouped households; disaggregated data for each treatment allocation group was not provided for each outcome.

Follow‐up periods for the trials that used a single dose ranged from one to 21 months, while the follow‐up periods for trials that used multiple doses ranged from post‐intervention to five years.

[@CD000371-bbs2-0026] is an cluster quasi‐randomized stepped‐wedge trial of a combined education and drug‐treatment intervention. The trial included 75 schools with a total of 30,000 pupils enrolled. In addition to helminth treatment, the phased complex intervention included public health lectures, teacher education, and child health education including handwashing, as noted above. In addition, a number of schools in the trial were also mass treated for schistosomiasis. In our previous update of the review we identified two potential quasi‐randomized comparisons that provide unbiased estimates, one in 1998 and one in 1999, in the stepped‐wedge design. Since our last review update this trial has been the subject of an independent reanalysis, with a full report published on the 3ie website ([@CD000371-bbs2-0088]), and two subsequent academic papers ([@CD000371-bbs2-0089]; [@CD000371-bbs2-0107]). In this review update we used data from these sources to assess the methodological quality of the trial. The results are primarily draw from the replication report, [@CD000371-bbs2-0088], which provides estimates corrected for coding errors in the original paper.

### Outcome measures {#CD000371-sec3-0023}

#### Nutritional status {#CD000371-sec4-0012}

Forty‐six trials measured nutritional indicators. Some trials reported absolute values, or changes in absolute values of weight and height (or other anthropometric measures). Many trials presented anthropometric data in terms of z‐scores or percentiles of weight‐for‐age, weight‐for‐height, and height‐for‐age, and compared the trial results to an external reference. Sometimes these values were dichotomised and presented as the prevalence of underweight, stunting or wasting (defined as ‐2 SD z‐scores). The external standard was usually quoted as the National Centre for Health Statistics (NCHS) standard, but a variety of references were quoted (including anthropometric computer packages or country standards). These data have not been used in the meta‐analyses as the results were already incorporated in the values for weight and height. Furthermore, in some trials, outcome data were not reported or were incomplete and could not be used in meta‐analysis. A number of reports did not provide summary outcome data for each trial arm, and the results were reported in terms of regression modelling outcomes or subgroup analyses. We have described the results of these trials in [Table 14](#CD000371-tbl-0014){ref-type="table"}.Table 4Data not included in meta‐analysis**Infected children identified by screening ‐ single dose**[@CD000371-bbs2-0029] Albendazole**Growth measured but not reported**: 9 weeks cited as too short a follow‐up period to demonstrate a change.[@CD000371-bbs2-0041]\
Albendazole**No significant differences in median change in weight and weight‐for‐height z‐scores, and for mean change in weight‐for‐age, and height‐for‐age z‐scores at 12 months follow‐up.**\
*Weight:* Median change in weight at follow‐up in treatment group 2.6 (range 1.2 to 7.2) and control group 2.5 (range 1.2 to 6.6)\
*Height‐for‐age z‐score:* Mean change at follow‐up in treatment group 1.1 (0.2) and in control group 1.1 (0.2).\
*Weight‐for‐age z‐score:* Median change at follow‐up in treatment group ‐1.0 (range 0.6 to 2.3) and in control group 0.8 (range 0.5 to 1.6).\
*Weight‐for‐height z‐score:* Mean change at follow‐up in treatment group 0.5 (0.6) and in control group 0.1 (0.6).[@CD000371-bbs2-0045]\
Albendazole**No significant differences in percentage stunted and sum of skinfolds at 6 months follow‐up.**\
*Percentage stunted (≤ ‐2 HAZ score):* Mean at follow‐up in treatment group 66% (mean change from baseline ‐7.0) and in control group 69% (mean change from baseline ‐7.4).\
*Sum of skinfolds:* Mean at follow‐up in treatment group 12 mm (mean change from baseline 1 mm) and in control group 12 mm (mean change from baseline 1 mm).**Infected children identified by screening ‐ multiple dose**[@CD000371-bbs2-0034] Albendazole**No significant difference in any reported outcome for whole group.** *Height‐for‐age z‐score* at baseline in treatment group ‐0.48 (0.95) and in placebo group ‐0.39 (0.90). At follow‐up in treatment group ‐0.48 (0.97) and in placebo group ‐0.41 (0.89). *Body mass index* (kg/m²) at baseline in treatment group 15.3 (1.3) and in placebo group 15.5 (1.3). At follow‐up in treatment group 15.6 (1.3) and in placebo group 15.8 (1.4).**All children living in endemic area‐ single dose**[@CD000371-bbs2-0006] Albendazole**A nutritional benefit of treatment was not detectable after 4 months for the entire trial population (853 participants, no figures provided)**.\
Stratification by infection demonstrated small positive effects in the treatment group for some anthropometric outcomes. In *Ascaris*‐infected children (51), height gain was 0.62 cm \> placebo in the combination treatment group (P = 0.01) at 4 months. In *Trichuris*‐infected children (158), weight gain was 0.56 kg \> placebo in the combination treatment group (P = 0.01) at 4 months.[@CD000371-bbs2-0009] Albendazole**No results provided for whole trial population.**\
Results for height and weight only presented in the narrative for subgroups infected with hookworm and *Ascaris*: no significant anthropometric changes detected (no figures quoted). In those infected with *Trichuris*, weight gain was greater in the albendazole group (difference compared to placebo 0.28 kg, P = 0.038). Adverse events: no serious adverse events (albendazole 0/46 vs placebo 0/43). Myalgia and cough were reported significantly more frequently in the placebo group compared to albendazole.[@CD000371-bbs2-0014] Piperazine citrate**Treatment group tended to show worse nutrition than placebo.**\
Comparison showed no significant difference for all measured anthropometric variables for the total group and for subgroups defined by severity of infection (no figures provided).[@CD000371-bbs2-0019] Mebendazole**No significant difference was found between the groups**.\
Results reported as the proportion of treatment or control group that improved, deteriorated, or experienced no change. Unclear which anthropological measures were used in this categorization process. Proportions in each category were not significantly different between trial arms (improved: 51% in mebendazole group vs 49% in control; deteriorated: 35% in mebendazole group vs 33% in control; no change: 14% in mebendazole group vs 18% in control; no significance test results quoted).[@CD000371-bbs2-0020] Albendazole**Significant increases in weight‐for‐height, weight‐for‐age, and height‐for‐age z‐scores recorded in rural and urban treatment groups at 6 months**. Mean increase in rural treatment group compared to placebo: weight‐for‐height z‐score 0.28 (SE 0.17) P \< 0.05; weight‐for‐age z‐score 1.04 (SE 0.03) P \< 0.05; and height‐for‐age z‐score 0.83 (SE 0.03) P \< 0.001. Mean increase in urban treatment group compared to placebo: weight‐for‐height z‐score 1.04 (SE 0.07) P \< 0.05; weight‐for‐age z‐score 1.02 (SE 0.09) P \< 0.001; and height‐for‐age z‐score 1.01 (SE 0.02) P \<0.05.[@CD000371-bbs2-0025] Tetra‐chlorethylene**No significant difference in change in mean for haemoglobin**.\
(tetrachloroethylene 0.22 g/100 mL vs placebo 0.09 g/100 mL; quoted as non‐significant) or weight for height at 5 months (tetrachloroethylene ‐1.3% of WHO reference mean vs placebo ‐0.4%; quoted as non‐significant).\
Adverse events: 17% (19/119: results not given for separate trial arms) of the children suffered adverse effects (nausea and ataxia) that began one and a half hours after treatment. All symptoms disappeared within four hours. Tetrachlorethylene is not in current use as a deworming drug.[@CD000371-bbs2-0028]\
Albendazole**No significant differences in weight‐for‐height, weight‐for‐age, and height‐for‐age z‐scores and skin fold thickness at 4 months.**\
There was no statistically significant effect of deworming on weight, height, HAZ scores, WAZ scores, or WHZ scores. There were no statistically significant differences in skin fold thickness after four months of intervention.[@CD000371-bbs2-0044]\
Albendazole**No adverse events reported.**\
**No significant difference in BMI at 21 months follow‐up in children aged 19 years and less.**\
*Body mass index (kg/m^2^):* median at follow‐up in treatment group 21.56 (IQR 19.44‐24.12) and in placebo group 22.42 (IQR 19.68 ‐ 25.56).**All children living in endemic area ‐ multiple dose**[@CD000371-bbs2-0002]\
Albendazole**During the trial there were 23 deaths, 13 were in the usual care arm and 10 were in the treatment arm.** These data were not adjusted for cluster randomization.[@CD000371-bbs2-0005]\
Albendazole**Deworming showed no effect for death**\
MD in deaths per child‐care centre at ages 1·0--6·0 was 0·16 (SE 0·11); mortality ratio 0·95, 95% CI 0·89 to 1·02).[@CD000371-bbs2-0013] Albendazole plus secnidazole**No significant differences in mean z‐scores or prevalence of stunting, underweight or wasting between the intervention groups were found, and the changes between intervals (eg between weeks 0 to 12, 0 to 24, 0 to 36, 12 to 24, etc.) did not differ significantly between groups.** *Height‐for‐age z‐score:* at baseline in treatment group ‐1.08 (1.02) and in control group ‐1.21 (1.0). At follow‐up in treatment group ‐1.59 (0.93) and in control group ‐1.70 (0.93). *Weight‐for‐age z‐score:* at baseline in treatment group ‐1.91 (1.15) and in control group ‐1.85 (1.14). At follow‐up in treatment group ‐2.62 (1.17) and in control group ‐2.59 (1.17). *Weight‐for‐height z‐score:* at baseline in treatment group ‐1.25 (1.18) and in control group ‐0.96 (1.17). At follow‐up in treatment group ‐1.55 (1.07) and in control group ‐1.83 (1.06).[@CD000371-bbs2-0016] Pyrantel pamoate Albendazole**No significant differences detected between treatment groups on basis of multivariate analyses controlling for age, sex, and 'times'.** *Change in weight‐for‐age z‐score*: placebo 0.02; pyrantel 1 x treatment 0.03; pyrantel 2 x treatments 0.08; albendazole 1 x treatment ‐0.10; albendazole 2 x treatments 0.01. *Change in height‐for‐age z‐score*: placebo 0.01; pyrantel 1 x treatment 0.00; pyrantel 2 x treatments 0.04; albendazole 1 x treatment ‐0.07; albendazole 2 x treatments 0.01. *Change in weight‐for‐height z‐score*: placebo 0.02; pyrantel 1 x treatment 0.08; pyrantel 2 x treatments 0.05; albendazole 1 x treatment ‐0.07; albendazole 2 x treatments 0.03. *Change mid‐arm circumference z‐score*: placebo ‐0.09; pyrantel 1 x treatment ‐0.11; pyrantel 2 x treatments ‐0.11; albendazole 1 x treatment ‐0.07; albendazole 2 x treatments ‐0.01.[@CD000371-bbs2-0017] Albendazole**Trial authors reported no difference in final and change in height.**\
MUAC and subscapular skinfold thickness improved significantly in the control group compared to the albendazole group (7.87 vs 7.61, P = 0.005 and 1.22 vs 1.05, P = 0.005 respectively). These results do not appear to have been adjusted for cluster randomization. The results that show no effect, however, will not remain non‐significant even after appropriate adjustment, though the CIs may change.[@CD000371-bbs2-0023] Mebendazole plus pyrantel**No difference in height or weight between treatment and control group at the end of 2‐year** follow‐up**.** SDs not provided. Results stratified for males and females: *Females*: change in height in treatment arm 12.2 cm vs change in height in placebo arm 12.4 cm; change in weight in treatment arm 5.6 kg vs change in weight in placebo arm 5.6 kg. *Males*: change in height in treatment arm 11.8 cm vs change in height in placebo arm 11.4cm; change in weight in treatment arm 5.7 kg vs change in weight in placebo arm 4.7 kg.[@CD000371-bbs2-0024] Mebendazole**No obvious trend in nutrition variable.**\
Anthropometric indices were calculated using WHO/NCHS reference data. Being wasted, stunted and underweight was defined by z‐scores ,\< ‐ 2SD for weight‐for‐height, height‐for‐age and weight‐for‐age, respectively. *Percentage underweight:* At baseline Fe 41·9, Fe + MEB 51·9, MEB 50·6, Placebo 45·1; after treatment Fe 33·7, Fe + MEB 46·8, MEB 38, Placebo 35·4. *Percentage stunted:* At baseline Fe 30·2, Fe + MEB 31·6, MEB 41·8, Placebo 31·7; after treatment Fe 29·1, Fe + MEB 27·8, MEB 29·1, Placebo 29·3. *Percentage wasted:* At baseline Fe 9·3, Fe + MEB 16·5, MEB 13·9, Placebo 12·2; after treatment Fe 5·8, Fe + MEB 17·7, MEB 13·9, Placebo 13·4.[@CD000371-bbs2-0026]\
Albendazole**No effect on nutrition or haemoglobin demonstrated**\
For haemoglobin a sample of around 4% (778/20,000) of the quasi‐randomized comparison of group 1 vs group 2 in 1998 was analysed.\
Height and weight data was collected on all individuals in standards 3‐8 (9102/20000)\
Difference in weight‐for age z‐score (treatment ‐ control): 0.00 (SE 0.04).\
Difference in height‐for‐age z‐score end value (treatment ‐ control): 0.09 (SE 0.05). Difference in haemoglobin (g/L) (treatment ‐ control): 1.6 (SE 1.4).[@CD000371-bbs2-0027]\
Albendazole**During the trial there were 16 deaths, 8 were in the placebo arm and 8 were in the treatment arm.**\
**No significant differences in mean z‐scores for weight‐for‐height, weight‐for‐age, and height‐for‐age z‐scores at 5 years of age.**\
*Height‐for‐age z‐score*: at follow‐up in treatment group ‐1.33 (1.34) and in control group ‐1.27 (1.20).\
*Weight‐for‐age z‐score:* at follow‐up in treatment group ‐0.88 (0.95) and in control group ‐0.87 (0.91).\
*Weight‐for‐height z‐score*: at follow‐up in treatment group ‐0.13 (1.28) and in control group ‐0.17 (1.19).[@CD000371-bbs2-0032] Mebendazole**ANOVAS of the change in z‐scores revealed no significant improvement with treatment**.\
Change in weight‐for‐age and weight‐for‐height z‐scores were significantly worse in the treatment group. Height‐for‐age z‐score (mebendazole 0.25 vs 0.17 in placebo group, P \'non‐significant\'), weight‐for‐age z‐score (mebendazole 0.03 vs 0.12 in placebo group, P \< 0.05), weight‐for‐height z‐score (mebendazole ‐0.25 vs ‐0.05 in placebo group, P \< 0.001), and MUAC were presented (mebendazole 0.33 vs 0.23 in placebo group, P \'non‐significant\').[@CD000371-bbs2-0039] Mebendazole**Mebendazole is reported as significantly reducing the prevalence of mild wasting malnutrition in a subgroup of children aged \< 30 months only**\
adjusted odds ratio for mebendazole 0.38 (95% CI 0.16 to 0.90) for weight‐for‐height z‐score \< ‐1. Mebendazole is reported as significantly reducing the prevalence of poor appetite across the whole group (adjusted odds ratio for mebendazole 0.52 (95% CI 0.30 to 0.89) for weight‐for‐height z‐score \< ‐1). Mebendazole had no impact on iron indices. Adjusted effect on motor scores had a tendency to favour mebendazole, but this was not significant.[@CD000371-bbs2-0038] Mebendazole**Weight gain: in a subgroup of under 10 year olds, the twice‐yearly treated group experienced significantly greater weight gain (kg) compared to control (2.38 (SE 0.08) vs 2.11 (SE 0.08), P \< 0.05)**.\
In the thrice‐yearly treatment group the difference was not significant (2.31 (SE 0.08) vs 2.11 (SE 0.08), no P value stated). *Height gain*: in under 10 year olds the thrice‐yearly treated group experienced significantly greater height gain (cm) compared to control (4.59 (SE 0.07) vs 4.29 (SE 0.07), P \< 0.01). In the twice‐yearly treatment group the difference in height gain was not significant (4.42 (SE 0.07) vs 4.29 (SE 0.07), no P value stated). There were no significant differences found in the subgroup of children aged over 10 years. *Haemoglobin change*: deworming had no effect on haemoglobin change in an adjusted analysis presented for the whole trial group (g/L): control 11.3 (SE 1.7); twice‐yearly treatment group 10.3 (SE 1.7); and thrice‐yearly group 12.7 (SE 1.7).[@CD000371-bbs2-0043] Levamisole**No statistical difference in nutrition in terms of height and weight differences between the 2 groups**.\
Growth rates presented are adjusted for a number of variables. Weight gain (kg/year) in levamisole group 2.08 vs 1.92 in placebo group (P = 0.06). Height gain (cm/year) in levamisole group 7.58 vs 7.73 in placebo group (no significance quoted).

#### Haemoglobin {#CD000371-sec4-0013}

Nineteen trials measured haemoglobin. Of these, two trials did not report the measured haemoglobin results ([@CD000371-bbs2-0030]; [@CD000371-bbs2-0035]), two trials only measured this outcome in a subset of the participants ([@CD000371-bbs2-0005]; [@CD000371-bbs2-0026]) and one trial did not report results by randomized comparisons ([@CD000371-bbs2-0037]).

#### Psychometric tests of cognition {#CD000371-sec4-0014}

Eleven trials measured intellectual development using formal tests ([Table 15](#CD000371-tbl-0015){ref-type="table"}).Table 5Trials evaluating psychometric tests of cognition**Trial detailsOutcome measuresResultsInfected children identified by screening ‐ single dose**[@CD000371-bbs2-0022]\
Mebendazole vs placebo, 1 monthCard sorting task; cancellation task (number of letter \'s\' in text deleted in a time period).Changes in cognitive scores are not clearly reported since \"the dose of mebendazole was inadequate to free children from infection\".[@CD000371-bbs2-0029] Albendazole vs placebo\
2.25 monthsDigit span (forward and backward); arithmetic and coding from Wechsler Intelligence Scale for Children; fluency; listening comprehension from the Clinical Evaluation of Language functions; matching familiar figures test.Mean test scores pre‐ and post‐intervention presented with CIs\
No comment made on significance of unadjusted data.\
Results of multiple regression suggest a greater improvement in treated children in 3/10 tests (fluency, digit span forwards, digit span backwards).**Infected children identified by screening ‐ multiple dose**[@CD000371-bbs2-0034] Albendazole vs placebo 6.5 months1. Main trial (264 children) Wide range achievement test: reading, arithmetic, and spelling sub tests;\
2. Subgroup 1 (189 children 189 infected children from original population) Digit span; verbal fluency test; visual search; number choice; French vocabulary learning;\
3. Subgroup 2 (97 children from grade 5) French learning; digit spans (forward and backward); Corsi block span; verbal fluency; picture search; silly sentences.Main trial: no difference in any reported outcome measure;Subgroup 1: no significant effect on any of the outcome measures;Subgroup 2: no significant improvement with treatment in any of the tests was found in multiple regression modelling.**All children living in endemic area ‐ single dose**[@CD000371-bbs2-0028]\
AlbendazoleCognitive performance was measured using Raven\'s Colored Matrices and also a series of cognitive tests from Wechsler\'s Intelligence Scale for Children III: digit span backward and forward, block design and coding.Deworming had no significant effect on any of the cognitive tests.[@CD000371-bbs2-0035] Albendazole vs placebo\
16 weeksCognitive ability was measured using a standardized written mental‐abilities test called the Primary Mental Abilities Test for Filipino Children (PMAT‐FC). The test covers general knowledge and comprehension, verbal relationships, fundamental mathematical comprehension and skills, numerical sequencing, and ability to perceive and apply relationships based on meaningless stimuli.Deworming had either no effect or a negative effect on mental ability scores. Data was not reported.**All children living in endemic area ‐ multiple dose**[@CD000371-bbs2-0003]\
Albendazole vs placebo, 2 years1045 participants. Developmental status (Denver Questionnaire).No difference in development between treatment groups in terms of proportion with \"normal\" development.[@CD000371-bbs2-0026]\
Deworming package including albendazole vs placebo\
1 year30,000 participants. Cognitive tests including picture search, Raven matrix, verbal fluency, digit span, Spanish learning, and a dynamic test using syllogisms measured for all three school groups in 2000.Outcome data not reported for cognitive tests, though authors state: \"Deworming treatment effects are not significantly different than zero for any component of the cognitive exam (results available on request)\".[@CD000371-bbs2-0027]\
Albendazole vs placebo, post‐treatment870 participants. Block design, Picture vocabulary scale, Sentence repetition, Verbal fluency, Counting span, Running memory, Picture search, Wisconsin card sort test, Tap once tap twice task, Shapes task, Tower of London.Deworming had no significant effect on any of the cognitive tests.[@CD000371-bbs2-0039] Mebendazole vs placebo, 1 year359 participants. Motor and language development by parents reporting gross motor and language milestones using scoring system developed specifically for the trial.Unadjusted data not reported. Treatment had no significant effect on motor or language development.[@CD000371-bbs2-0042] Albendazole vs placebo, 6 months212 participants. Interamerican vocabulary test; Interamerican reading test; Peabody picture vocabulary test.All outcome measures reported as unadjusted scores. No difference in any of the tests found between treatment groups.

#### Measures of physical well‐being {#CD000371-sec4-0015}

Three trials measured physical well‐being using the Harvard Step Test, 10 m shuttle run and VO~2~ max, grip strength and standing broad jump test ([@CD000371-bbs2-0036]; [@CD000371-bbs2-0037]; [@CD000371-bbs2-0045]; [Table 16](#CD000371-tbl-0016){ref-type="table"}).Table 6Trials evaluating measures of physical well‐being**Trial detailsOutcome measuresResultsInfected children identified by screening ‐ single dose**[@CD000371-bbs2-0045]\
AlbendazoleVO~2~ max estimate (mL kg‐1 min‐1), 20 m running laps completed grip strength (kg), standing broad jump distance (cm). Mean values reported.No effect was detected on any of the measures of physical well‐being (99 in the albendazole group and 95 in the control)[@CD000371-bbs2-0036]\
Albendazole vs placebo, 6 months follow‐upHarvard Step TestDeworming significantly improved children's physical well‐being in a non‐randomly selected subgroup of children (33/171)\
Treatment group: mean = 80, SD = 5.51, N = 18\
Placebo group: mean = 74, SD = 4.65, N = 15\
MD = 6.00, 95% CI 2.53 to 9.4[@CD000371-bbs2-0037]\
Albendazole vs placebo, 8 months follow‐upHarvard Step TestDeworming significantly improved children's physical well‐being in a non‐random subgroup of children (54/328)\
Treatment group: mean = 82, SD = 3.64, N = 27\
Placebo group: mean = 76, SD = 3.57, N = 26\
MD = 6.00, 95% CI 4.06 to 7.94

#### School attendance {#CD000371-sec4-0016}

Four trials measured school attendance ([Table 17](#CD000371-tbl-0017){ref-type="table"}).Table 7Trials evaluating school attendance (days present at school)**Trial detailsOutcome measuresInterventionControlDifferenceInfected children identified by screening ‐ multiple dose**[@CD000371-bbs2-0034] Albendazole vs placebo 6.5 monthsMean % attendance\
(class registers )\
N = 264\
 Baseline\
62.6 (SD 20.4)\
Follow‐up\
67.3 (SD 18.4)Baseline\
66.3 (SD 20.8)\
Follow‐up\
69.3 (SD 17.5)**2.0%All children living in endemic area‐ multiple dose**[@CD000371-bbs2-0021]Attendance at follow‐up only\
(class registers)\
N = 14397.2% (iron group)\
95.6%98% (iron group)\
95.2%**‐0.8%**\
**0.4%**[@CD000371-bbs2-0026]\
Group 1 vs 2+3 (1 year follow‐up)School participation\
N = 30,00084.1%73.1% (group 2)\
76.6% (group 3)**9.3%**\
**(SE 3.0%)**[@CD000371-bbs2-0026]\
Group 2 vs 3\
(1 year follow‐up)School participation\
N = 20,00071.8%66.4%**5.4%**\
**(SE 2.7%)**[@CD000371-bbs2-0026]\
Group 1 vs 3\
1999 (2 year follow‐up)School participation\
N = 20,00071.6%66.4%**5.1%**\
**(SE 2.7)**[@CD000371-bbs2-0042] 6 monthsAttendance rates of children actively attending school.\
N = 243Baseline 92%, SEM = 1\
Follow‐up 88%, SEM = 1Baseline 0.90, SEM = 1\
Follow‐up 89% SEM =1**‐3%**

#### School performance {#CD000371-sec4-0017}

[@CD000371-bbs2-0017] and [@CD000371-bbs2-0026] measured exam performance ([Table 18](#CD000371-tbl-0018){ref-type="table"}).Table 8School performance**Trial detailsOutcome measuresResultsAll children living in endemic area ‐ multiple dose**[@CD000371-bbs2-0017]\
Albendazole versus placebo, 2 years2659 participants. Mathematics test score, Vietnamese test score.No statistically significant differences in test results at start or end of trial.[@CD000371-bbs2-0026]\
Deworming package including albendazole versus placebo30,000 participants. Exam score performance (measured by Internationaal Christelijk Steunfonds Africa (ICS) administered English, Mathematics and Science‐Agriculture exams) in pupils in grades 3 to 8.In the original trial and the pure replication, the trial authors reported no significant difference, but data was not reported. In the statistical replication, this was confirmed.

#### Death {#CD000371-sec4-0018}

[@CD000371-bbs2-0027] provided data on mortality. [@CD000371-bbs2-0005] also monitored mortality although these data are not yet in the public domain so we are unable to report them.

#### Adverse events {#CD000371-sec4-0019}

Four trials provided information on adverse events ([@CD000371-bbs2-0009]; [@CD000371-bbs2-0025]; [@CD000371-bbs2-0044]; [@CD000371-bbs2-0045]).

Risk of bias in included studies {#CD000371-sec2-0009}
--------------------------------

See [Figure 3](#CD000371-fig-0003){ref-type="fig"} and [Figure 4](#CD000371-fig-0004){ref-type="fig"} for \'Risk of bias\' summaries and [Characteristics of included studies](#CD000371-sec2-0023){ref-type="sec"} section for details of the risk of bias and methods used in each trial.Figure 3Figure 4

### Allocation {#CD000371-sec3-0024}

#### Sequence generation {#CD000371-sec4-0020}

In the 38 individually RCTs, the risk of bias was low in 13 trials (see [Figure 3](#CD000371-fig-0003){ref-type="fig"} and [Figure 4](#CD000371-fig-0004){ref-type="fig"}), high in five, and unclear in the other trials. For the nine cluster‐RCTs, the risk of bias was low in two trials ([@CD000371-bbs2-0001]; [@CD000371-bbs2-0044]), high in two trials ([@CD000371-bbs2-0002]; [@CD000371-bbs2-0026]) and unclear in five trials ([@CD000371-bbs2-0004], [@CD000371-bbs2-0005], [@CD000371-bbs2-0017], [@CD000371-bbs2-0032], [@CD000371-bbs2-0038].

#### Allocation concealment {#CD000371-sec4-0021}

For the 38 individually randomized trials, seven trials were at low risk of bias regarding allocation concealment ([@CD000371-bbs2-0009]; [@CD000371-bbs2-0012]; [@CD000371-bbs2-0024]; [@CD000371-bbs2-0028]; [@CD000371-bbs2-0030]; [@CD000371-bbs2-0039]; [@CD000371-bbs2-0040]), high in two trials ([@CD000371-bbs2-0003]; [@CD000371-bbs2-0018]), and unclear in the other trials.

The risk of bias was low in one of the eight cluster‐RCTs ([@CD000371-bbs2-0017]), high in two trials ([@CD000371-bbs2-0002]; [@CD000371-bbs2-0026]), and unclear in the remaining six trials.

### Blinding {#CD000371-sec3-0025}

Fifteen trials were double blinded and judged to be at low risk of bias. Five trials were at high risk of bias as they did not use blinding. Details of blinding were unclear in the remaining 26 trials.

### Incomplete outcome data {#CD000371-sec3-0026}

Twenty nine trials appeared to have low risk of bias in relation to outcome data. Overall, the percentage of randomized participants that were evaluable ranged from 4% to 100%, with 19 trials including 90% or more of the randomized participants (low risk cut‐off). The percentage was particularly low in three of the trials measuring school performance and cognitive outcomes: 71% in [@CD000371-bbs2-0027]; 73% in [@CD000371-bbs2-0029]; and 52% in [@CD000371-bbs2-0039]; and in one trial measuring haemoglobin: 26% in [@CD000371-bbs2-0018]. In [@CD000371-bbs2-0026] for haemoglobin a sample of around 4% (778/20,000) of the quasi‐randomized comparison of group 1 vs group 2 in 1998 was analysed. Weight and height data were collected on all individuals in standards 3.8, 48% of the total comparison (9102/20000). For exam performance and cognitive tests, 34% of eligible children were included in the treatment school (group 1) and 32% in the control school (group 2 and 3). [@CD000371-bbs2-0044] did not report the number of children that were randomized, so it was not possible to calculate the percentage evaluable in this trial.

### Selective reporting {#CD000371-sec3-0027}

Fourteen trials had evidence of selective reporting and were judged to be at high risk of bias ([@CD000371-bbs2-0013]; [@CD000371-bbs2-0014]; [@CD000371-bbs2-0018]; [@CD000371-bbs2-0020]; [@CD000371-bbs2-0028]; [@CD000371-bbs2-0029]; [@CD000371-bbs2-0030]; [@CD000371-bbs2-0034]; [@CD000371-bbs2-0035]; [@CD000371-bbs2-0038]; [@CD000371-bbs2-0039]; [@CD000371-bbs2-0040]; [@CD000371-bbs2-0043]). The remaining trials did not show evidence of selective reporting.

### Other potential sources of bias {#CD000371-sec3-0028}

In general, quality of the design of the nine cluster‐RCTs was good: they were judged as low risk for recruitment bias (six trials), baseline imbalance (nine trials), loss of clusters (nine trials), compatibility with RCTs that randomized individuals (one trial).These data are included in the \"table of characteristics\").

There were problems with incorrect analysis noted above: [@CD000371-bbs2-0001] did not adjust for clustering in the published trial, but gave us the adjusted data (see trial design above), and we used this to adjust the analysis in [@CD000371-bbs2-0017].

One trial was potentially confounded by co‐interventions noted under \"accompanying health promotion activities\" under interventions (above).

Effects of interventions {#CD000371-sec2-0010}
------------------------

See: [Table 1](#CD000371-tbl-0001){ref-type="table"}; [Table 2](#CD000371-tbl-0002){ref-type="table"}; [Table 3](#CD000371-tbl-0003){ref-type="table"}

The effects were grouped into trials in children known to be infected, and trials of all children in endemic areas. In the trials treating whole populations, we stratified the results by community worm prevalence. We have detailed the prevalence strata in [Table 12](#CD000371-tbl-0012){ref-type="table"} (high prevalence or high intensity areas (referred to as \'high prevalence\'); moderate prevalence and low intensity referred to as (\'moderate prevalence\'); and low prevalence with low intensity referred to as \'low prevalence\'). Within each section, we present the results of the meta‐analysis, and then report any other data from trials that we could not include in the meta‐analysis.

### Comparison 1. Children with infection: single dose of deworming drugs vs no intervention {#CD000371-sec3-0029}

These trials screened for infection, and then included only children with proven infection; or were conducted in settings where all the children were known to be infected. None of these trials provided data for the outcomes school attendance (number of children dropping out), school performance, mortality, or adverse events. No trials appeared to have potentially confounding health promotion activities ([Table 13](#CD000371-tbl-0013){ref-type="table"}). For single dose, see [Table 2](#CD000371-tbl-0002){ref-type="table"}.

#### Nutritional measures {#CD000371-sec4-0022}

Trials measured weight (n = 5), height (n = 5), MUAC (n = 4), triceps (n = 3), subscapular skinfold (n = 2) and BMI (n = 1). Large effects were seen in two trials for weight, MUAC, and skinfold, with an average weight gain of over one kg in both trials ([@CD000371-bbs2-0036]; [@CD000371-bbs2-0037]). These trials were in a high prevalence area of Kenya. The gain in weight in the deworming group ranged from 0.2 kg to 1.3 kg more (627 participants, five trials, [Analysis 1.1](#CD000371-fig-00101){ref-type="fig"}), height gain (0.25 cm, 95% CI 0.01 to 0.49; 647 participants, five trials, [Analysis 1.2](#CD000371-fig-00102){ref-type="fig"}), and gains in MUAC, triceps and subscapular skinfold values ([Analysis 1.3](#CD000371-fig-00103){ref-type="fig"}; [Analysis 1.4](#CD000371-fig-00104){ref-type="fig"}; [Analysis 1.5](#CD000371-fig-00105){ref-type="fig"}). No difference in body mass index was detected after a single dose ([Analysis 1.6](#CD000371-fig-00106){ref-type="fig"}).

[@CD000371-bbs2-0029] did not provide data for nutritional outcomes as nine weeks was cited as too short a follow‐up period to demonstrate a change ([Table 14](#CD000371-tbl-0014){ref-type="table"}).

#### Haemoglobin {#CD000371-sec4-0023}

There was no difference in overall mean haemoglobin at the end of two trials with deworming ([Analysis 1.7](#CD000371-fig-00107){ref-type="fig"}).

#### Psychometric tests of cognition {#CD000371-sec4-0024}

Two trials reported on formal tests ([Table 15](#CD000371-tbl-0015){ref-type="table"}). [@CD000371-bbs2-0022] did not clearly report change in cognitive scores; [@CD000371-bbs2-0029] did not report unadjusted data, but results of multiple regression suggested an improvement in treated children in three of the 10 tests carried out (fluency, digit span forwards, digit span backwards).

#### Measures of physical well‐being {#CD000371-sec4-0025}

Two trials in the same high prevalence area of Kenya measured performance on the Harvard Step Test in non‐randomly selected subgroups ([@CD000371-bbs2-0036]; [@CD000371-bbs2-0037]), and both indicated benefit. [@CD000371-bbs2-0045] found no effect on any of the measures of physical well‐being ([Table 16](#CD000371-tbl-0016){ref-type="table"}).

#### Other data {#CD000371-sec4-0026}

Three trials did not provide data in a form that we could use in meta‐analysis. We have collated these data in [Table 14](#CD000371-tbl-0014){ref-type="table"}, and this information is summarized below:

[@CD000371-bbs2-0029] measured growth but did not report the results, as nine weeks was cited as too short a follow‐up period to demonstrate a change;[@CD000371-bbs2-0041] found no significant differences in median change in weight and weight‐for‐height z‐scores, and for mean change in weight‐for‐age, and height‐for‐age z‐scores at 12 month follow‐up;[@CD000371-bbs2-0045] found no significant differences in percentage stunted and sum of skinfolds at six month follow‐up.

### Comparison 2. Children with infection: multiple doses of deworming drugs vs no intervention {#CD000371-sec3-0030}

#### Nutritional measures {#CD000371-sec4-0027}

[@CD000371-bbs2-0037] demonstrated weight, MUAC, triceps, subscapular and skinfold gains, but no improvements in height ([Analysis 2.1](#CD000371-fig-00201){ref-type="fig"}; [Analysis 2.2](#CD000371-fig-00202){ref-type="fig"}; [Analysis 2.5](#CD000371-fig-00205){ref-type="fig"}; [Analysis 2.6](#CD000371-fig-00206){ref-type="fig"}; [Analysis 2.7](#CD000371-fig-00207){ref-type="fig"}). For body mass index, [@CD000371-bbs2-0034] did not demonstrate a difference ([Analysis 2.3](#CD000371-fig-00203){ref-type="fig"}). They also reported height for age z‐score and did not detect a difference ([Table 14](#CD000371-tbl-0014){ref-type="table"}).

#### Psychometric tests of cognition {#CD000371-sec4-0028}

[@CD000371-bbs2-0034] measured intellectual development using a wide range achievement test in the main trial, and digit spans and verbal fluency tests in subgroups. The trial authors reported that deworming had no effect on intellectual development scores, but did not report the data ([Table 15](#CD000371-tbl-0015){ref-type="table"}).

#### School attendance (days present at school) {#CD000371-sec4-0029}

[@CD000371-bbs2-0034] found no demonstrable effect on school attendance rates of children actively attending school (MD ‐2.00, 95% CI ‐5.49 to 1.49; 407 participants, one trial, [Analysis 2.4](#CD000371-fig-00204){ref-type="fig"}).

### Comparison 3. All children living in endemic area: single dose of deworming drugs {#CD000371-sec3-0031}

One trial had substantive health promotion activities accompanying the deworming group ([Table 13](#CD000371-tbl-0013){ref-type="table"}).

See [Table 3](#CD000371-tbl-0003){ref-type="table"}.

No trials provided data for the outcomes school attendance, physical well‐being, and mortality.

#### Nutritional measures {#CD000371-sec4-0030}

Trials measured weight in high (n = 2), moderate (n = 2), and low (n = 3) prevalence areas. The trials demonstrated no effect on weight (‐0.04 kg, 95% CI ‐0.11 to 0.04; 2719 participants, seven trials; [Analysis 3.1](#CD000371-fig-00301){ref-type="fig"}), height (‐0.12 cm, 95% CI ‐0.33 to 0.10; 1974 participants, five trials; [Analysis 3.2](#CD000371-fig-00302){ref-type="fig"}) or MUAC (0.04 cm, 95% CI ‐0.19 to 0.26; 911 participants, three trials; [Analysis 3.3](#CD000371-fig-00303){ref-type="fig"}).

#### Haemoglobin {#CD000371-sec4-0031}

Two trials were in moderate prevalence areas, and one in low prevalence areas. No effect was demonstrable in individual trials or on meta analysis (MD 0.06 g/dL, 95% CI ‐0.05 to 0.17; 1005 participants, three trials; [Analysis 3.4](#CD000371-fig-00304){ref-type="fig"}).

#### Psychometric tests of cognition {#CD000371-sec4-0032}

[@CD000371-bbs2-0035] measured cognitive ability using a standardized written mental‐abilities test, and reported that deworming had either no effect or a negative effect on mental ability scores, but did not report the data. [@CD000371-bbs2-0028] reported no effects on any cognitive tests measured ([Table 15](#CD000371-tbl-0015){ref-type="table"}).

#### Adverse events {#CD000371-sec4-0033}

[@CD000371-bbs2-0009] reported none in 46 patients given albendazole. [@CD000371-bbs2-0025] reported a number of adverse events with tetra‐chloroethylene, a drug no longer used ([Table 14](#CD000371-tbl-0014){ref-type="table"}).

#### Other data {#CD000371-sec4-0034}

Some trials did not provide data in a form that we could use in meta‐analysis. We have collated these data in [Table 14](#CD000371-tbl-0014){ref-type="table"}, and we have summarized this information below:

[@CD000371-bbs2-0006] did not detect a nutritional benefit of treatment after four months for the entire trial population (no figures provided);[@CD000371-bbs2-0009] only reported on subgroups infected with worms;[@CD000371-bbs2-0014] stated there was no significant difference for all measured anthropometric variables for the total group and for subgroups defined by severity of infection (no figures provided);[@CD000371-bbs2-0019] reported the proportion of treatment or control group that improved, deteriorated, or experienced no change, but it is not known what anthropological measures were used;[@CD000371-bbs2-0020] found significant increases in weight‐for‐height, weight‐for‐age, and height‐for‐age z‐scores recorded in rural and urban treatment groups at six months;[@CD000371-bbs2-0025] found no significant difference in change in mean for haemoglobin or weight for height at five months;Nga 2009 found not significant difference in weight‐for‐height, weight‐for‐age, and height‐for‐age z‐scores at four months.[@CD000371-bbs2-0044] found no significant difference in BMI at 21 months follow‐up in children aged 19 years and less.

#### Sensitivity analysis {#CD000371-sec4-0035}

In the sensitivity analysis including only trials where the risk of bias for allocation concealment was low, no difference between treatment and control groups in weight, height, MUAC, or haemoglobin was evident ([Analysis 5.1](#CD000371-fig-00501){ref-type="fig"}; [Analysis 5.2](#CD000371-fig-00502){ref-type="fig"}; [Analysis 5.3](#CD000371-fig-00503){ref-type="fig"}; [Analysis 5.4](#CD000371-fig-00504){ref-type="fig"}).

### Comparison 4. All children living in endemic area: multiple doses of deworming drugs, longest follow‐up {#CD000371-sec3-0032}

See [Table 1](#CD000371-tbl-0001){ref-type="table"}.

No trials provided data for adverse events.

#### Nutritional measures {#CD000371-sec4-0036}

Trials were in high (n = 2), moderate (n = 3), and low (n = 5) prevalence areas. For weight, overall there was no evidence of an effect ([Analysis 4.1](#CD000371-fig-00401){ref-type="fig"}), although one trial ([@CD000371-bbs2-0002] (low prevalence) showed a large weight gain of almost 1 kg in the treatment groups. Notably two subsequent trials in the same area as [@CD000371-bbs2-0002] did not demonstrate an effect ([@CD000371-bbs2-0003]; [@CD000371-bbs2-0004]). Overall, the meta‐analysis did not demonstrate a difference in weight gain between intervention and control (MD 0.08 kg, 95% CI ‐0.11 to 0.27; 36,038 participants from cluster trials and 2354 individually randomized participants, 10 trials), but the heterogeneity was high (I² statistic = 83%). When the trials were stratified by community category, heterogeneity was explained for the high and moderate prevalence trials, but not for the low prevalence trials. No significant effect was apparent in any subgroup. For MUAC (two trials) and triceps skinfold (one trial), no overall effects were evident ([Analysis 4.3](#CD000371-fig-00403){ref-type="fig"}; [Analysis 4.4](#CD000371-fig-00404){ref-type="fig"}). No effect on height was demonstrated in any of the trials measuring this (5384 participants from cluster trials and 1673 participants from individually randomized, seven trials; [Analysis 4.2](#CD000371-fig-00402){ref-type="fig"}).

#### Haemoglobin {#CD000371-sec4-0037}

Seven trials reported this, with no difference between intervention and control apparent ([Analysis 4.5](#CD000371-fig-00405){ref-type="fig"}). In addition, the re‐analysis of Miguel and Kremer ([@CD000371-bbs2-0089]) reported no difference in the prevalence of anaemia between the groups.

#### Psychometric tests of cognition {#CD000371-sec4-0038}

Five trials (30,000 participants from cluster trials and 2486 individually randomized participants) measured this outcome ([Table 15](#CD000371-tbl-0015){ref-type="table"}). [@CD000371-bbs2-0027] measured a range of cognitive tests, [@CD000371-bbs2-0042] measured reading and vocabulary, and [@CD000371-bbs2-0039] measured motor and language development. All reported that no effect was demonstrated. [@CD000371-bbs2-0026] also measured a range of cognitive tests. The results were not reported, but the trial authors stated that no deworming effect was demonstrated. [@CD000371-bbs2-0003] measured developmental status using the Denver Questionnaire, and did not demonstrate an effect of deworming.

#### School attendance (days present at school) {#CD000371-sec4-0039}

Three trials reported on this outcome ([@CD000371-bbs2-0021]; [@CD000371-bbs2-0026]; [@CD000371-bbs2-0042]; [Table 17](#CD000371-tbl-0017){ref-type="table"}). Watkins reported attendance rates of children actively attending school on the basis of school registers, at baseline and after treatment, and no effect was demonstrated. [@CD000371-bbs2-0026] reported on end value differences in attendance for girls under 13 years of age and all boys based on direct observation.

For outcomes measures at the longest follow‐up point we found no difference in school attendance (MD 2%, 95% CI ‐4 to 8%; [Analysis 4.6](#CD000371-fig-00406){ref-type="fig"}; 20,000 participants in cluster trials and 243 participants from an individually RCT, two trials) ). This uses the longest point of follow‐up from [@CD000371-bbs2-0026] at two years (group 1 vs group 3), in line with our analytical plan.

#### School performance {#CD000371-sec4-0040}

Two trials measured this ([@CD000371-bbs2-0017]; [@CD000371-bbs2-0026]; [Table 18](#CD000371-tbl-0018){ref-type="table"}). [@CD000371-bbs2-0026] measured exam score performance (English, Mathematics, and Science‐Agriculture exams in pupils in grades 3 to 8). Results showed no difference in performance. This included the results in the original trial analysis, [@CD000371-bbs2-0026], in the analysis after coding errors had been corrected, [@CD000371-bbs2-0089]), and in the statistical replication, [@CD000371-bbs2-0107]. [@CD000371-bbs2-0017] found no difference in test scores at the end of the trial.

#### Death {#CD000371-sec4-0041}

Deworming showed no effect in the DEVTA cluster trial of over one million children ([@CD000371-bbs2-0005]) (MD in deaths per child‐care centre at ages 1.0 to 6.0 was 0.16 (SE 0.11); mortality ratio 0.95, 95% CI 0.89 to 1.02). [@CD000371-bbs2-0027] reported that during the trial there were 16 deaths, eight in the placebo arm and eight in the treatment arm. [@CD000371-bbs2-0002] reported 23 deaths during the trial, 13 of which were in the usual care arm, and 10 were in the treatment arm.

#### Other data {#CD000371-sec4-0042}

Some trials did not provide data in a form that we could use in meta‐analysis. We have collated these data in [Table 14](#CD000371-tbl-0014){ref-type="table"} and [Table 17](#CD000371-tbl-0017){ref-type="table"}, and have summarized this information below:

[@CD000371-bbs2-0013] reported no significant differences in mean z‐scores or prevalence of stunting, underweight or wasting between the intervention groups, and the changes between intervals (ie between weeks 0 to 12, 0 to 24, 0 to 36, 12 to 24, etc.) did not differ significantly between groups;[@CD000371-bbs2-0016] reported no significant differences detected between treatment groups on basis of multivariate analyses;[@CD000371-bbs2-0017] reported no difference in final and change in height;[@CD000371-bbs2-0021] found that \"the rates of absenteeism were similar for all groups\", but no measures of variance were provided;[@CD000371-bbs2-0023] found no difference in height or weight between treatment and control group at the end of two‐year follow‐up;[@CD000371-bbs2-0024] reported no obvious trend in nutritional variable;[@CD000371-bbs2-0026] demonstrated no significant effect on weight‐for‐age z‐score, height‐for‐age z‐score, and haemoglobin;[@CD000371-bbs2-0032] reported that ANOVAS of the change in z‐scores revealed no significant improvement with treatment;[@CD000371-bbs2-0027] found no significant differences in mean z‐scores for weight‐for‐height, weight‐for‐age, and height‐for‐age z‐scores at five years of age;[@CD000371-bbs2-0039] reported that mebendazole significantly reduced the prevalence of mild wasting malnutrition in a subgroup of children aged \< 30 months;[@CD000371-bbs2-0038] reported that in a subgroup of under 10 year olds, the twice‐yearly treated group experienced significantly greater weight gain (kg) compared to control (2.38 (SE 0.08) vs 2.11 (SE 0.08), P \< 0.05);[@CD000371-bbs2-0043] reported no statistical difference in growth rates in terms of height and weight between the two groups.

### Comparisons 5 and 6. Sensitivity analysis {#CD000371-sec3-0033}

Including only trials with low risk of bias for allocation of concealment, no significant difference between treatment and control groups was detected in weight, height, or haemoglobin ([Analysis 5.1](#CD000371-fig-00501){ref-type="fig"}; [Analysis 5.2](#CD000371-fig-00502){ref-type="fig"}, [Analysis 5.3](#CD000371-fig-00503){ref-type="fig"}, [Analysis 5.4](#CD000371-fig-00504){ref-type="fig"}; [Analysis 6.1](#CD000371-fig-00601){ref-type="fig"}, [Analysis 6.2](#CD000371-fig-00602){ref-type="fig"}; [Analysis 6.3](#CD000371-fig-00603){ref-type="fig"}).

### Comparison 7. Exploring whether the intervention effect changed over time {#CD000371-sec3-0034}

The MD in weight (between deworming drugs vs control in children in an endemic area after multiple doses) did not differ by length of follow‐up (results not presented) or by publication year ([Analysis 7.1](#CD000371-fig-00701){ref-type="fig"}).

Discussion {#CD000371-sec1-0006}
==========

Summary of main results {#CD000371-sec2-0011}
-----------------------

We identified 45 trials, including nine cluster‐RCTs, that met the inclusion criteria. One trial that assessed mortality in addition to other endpoints included over one million children, and the remaining 44 trials included a total of 67,672 participants.

For infected children, deworming drugs may increase average weight gain over one to six months, but we do not know if there is an effect on haemoglobin or cognitive functioning.

In trials treating all children living in endemic areas of varying endemicity (15 in high prevalence areas, 12 in moderate prevalence, and 10 in low prevalence areas), a single dose of deworming drugs probably has little or no effect on average weight gain or average haemoglobin, and may have little or no effect on cognition or physical well‐being. For multiple doses of deworming drugs over six months to three years after the intervention started, there was little or no effect on average weight gain, height, or haemoglobin, and probably little or no effect on formal tests of cognition. We do not know if there was an effect on school attendance, but there is probably no effect on exam performance or death.

Overall completeness and applicability of evidence {#CD000371-sec2-0012}
--------------------------------------------------

Since the previous version of this review, the DEVTA trial has been published and is now included in this Cochrane Review. One further trial (of 2660 children in Vietnam from 1999) remains unpublished ([@CD000371-bbs2-0017]). In May 2015 we offered the trial investigators an opportunity to present the trial as an annex to this review, and await a response from them. Meanwhile, the data from the unpublished manuscript are included in this review.

In children infected with worms, a single dose of deworming medicine appears to result in some weight gain. This evidence comes from trials conducted in a single school in Kenya more than 20 years ago, where all of the children were infected---the majority with heavy worm loads of both hookworm and *Trichuris* ([@CD000371-bbs2-0036][@CD000371-bbs2-0037]). However, when the intervention is used in the way the WHO currently recommends --- giving treatment to whole school populations --- an overall average effect is not evident. An effect on average weight was seen in one cluster‐RCT assessing long‐term multiple dosing in a low‐burden community undertaken in 1995 in India ([@CD000371-bbs2-0002]). Trials conducted subsequently, some in the same area, including large cluster‐RCTs, have not demonstrated effects.

Some policy arguments point out that deworming programmes will not provide a detectable average effect on nutritional status, but actually will provide a substantial effect in a proportion of children with heavy worm load infections. Even if this were the case, there should be an effect on average values, and in this review treating children known to be infected may have some effect on weight gain (driven mainly by data from Kenya from a highly endemic area conducted over twenty years ago) but not other variables. If policy makers feel this is credible even in the absence of differences in average effect, then further trials are needed to evaluate this.

Ten trials measured intellectual development using formal tests. Only one of these trials demonstrated an effect on cognitive outcomes in 3/10 of the outcomes measured ([@CD000371-bbs2-0029]; [Table 15](#CD000371-tbl-0015){ref-type="table"}). The trials used a range of cognitive tests, which seems to reflect the difficulty inherent in choosing appropriate cognitive performance tests since there is no accepted test battery that can be applied across cultures and settings, and, as [@CD000371-bbs2-0026] pointed out, the mechanisms for any putative effects are unknown.

For school attendance, one quasi‐RCT reported an effect, which was apparent in only one of the two comparisons in up to a year of follow‐up, and not apparent in the one comparison after one year ([@CD000371-bbs2-0026]). [@CD000371-bbs2-0026] measured attendance outcomes directly, unlike the other two trials ([@CD000371-bbs2-0034]; [@CD000371-bbs2-0042]) which measured attendance using school registers, which may be inaccurate in some settings. Two large cluster‐RCTs measured school performance and neither demonstrated an effect of deworming ([@CD000371-bbs2-0017]; [@CD000371-bbs2-0026]).

For children living in endemic areas, in terms of the logic framework ([Figure 1](#CD000371-fig-0001){ref-type="fig"}) evidence on the desired impacts (child mortality and school performance) is absent. The evidence for school attendance is limited, and there is no evidence of effects on physical well‐being. In terms of the main effects there may be no effect on weight, and there is fairly good evidence of no impact on haemoglobin, cognition, and school performance.

### Long‐term outcomes {#CD000371-sec3-0035}

There have been some recent trials on long‐term follow‐up, none of which met the quality criteria needed in order to be included in this review ([@CD000371-bbs2-0047]; [@CD000371-bbs2-0054]; [@CD000371-bbs2-0073]; described in [Characteristics of excluded studies](#CD000371-sec2-0024){ref-type="sec"}). [@CD000371-bbs2-0047] and [@CD000371-bbs2-0073] are follow‐up trials of the [@CD000371-bbs2-0026] trial. [@CD000371-bbs2-0073] studied children in the vicinity of the [@CD000371-bbs2-0026] to assess long‐term impacts of the externalities (impacts on untreated children). However, in the replication trials ([@CD000371-bbs2-0088]; [@CD000371-bbs2-0089]; [@CD000371-bbs2-0107]), these spill‐over effects were no longer present, raising questions about the validity of a long‐term follow‐up. [@CD000371-bbs2-0047] compared children who received two years more deworming to those who received less in the [@CD000371-bbs2-0026] analysis.

[@CD000371-bbs2-0054] is a follow‐up of the [@CD000371-bbs2-0001], but assessed only 3% (1097/37,165) of the original randomized participants, and furthermore all children were offered treatment after the original follow‐up period in the [@CD000371-bbs2-0001] trial.

Overall, given the growing evidence of a lack of short‐term effects, arguments for long‐term population impacts appear implausible in our view.

### Externalities {#CD000371-sec3-0036}

There have been previous claims that deworming benefits not only the individuals, but also those around them. Whilst not ignoring this, we tried to establish first that there was a benefit to individuals; as this seems debatable, examining for externalities seems less important. [@CD000371-bbs2-0026], in their original analysis, stated their analysis demonstrated externalities. After correction of coding errors, the pure replication failed to find any evidence of externalities ([@CD000371-bbs2-0089]).

### Completeness of the analysis {#CD000371-sec3-0037}

Critics of a previous version of this review, [@CD000371-bbs2-0149], stated that the impact must be considered stratified by the intensity of the infection ([@CD000371-bbs2-0102]; [@CD000371-bbs2-0137]). We have done this comprehensively in this edition and no clear pattern of effect has emerged. Other criticisms were that trials of short‐term treatment cannot assess the long‐term benefits of regular treatment ([@CD000371-bbs2-0095]). However, this analysis clearly examines long‐term outcomes from trials conducted over the last 10 years.

### Extrapolating evidence on selective deworming to targeted deworming {#CD000371-sec3-0038}

Advocates of deworming argue that the evidence of benefit seen in selective deworming provides an evidential base for targeted deworming, because the latter reduces costs due to diagnostic screening. The argument is that population treatment benefits those infected, but this benefit is simply not detectable. Even among those children known to be infected, this Cochrane Review does not clearly demonstrate a consistent benefit on weight: there are two trials from 20 years ago in which all the children were heavily infected and had large weight gain, but this was not consistent across all trials ([Table 2](#CD000371-tbl-0002){ref-type="table"}).

### Choking {#CD000371-sec3-0039}

The WHO has raised concerns about the prevalence of choking in young children (aged between one to three years), with several pages of recommendations in a newsletter about how to administer albendazole in tablet form without children choking. Although common sense might suggest this is a rare occurrence, nevertheless some might argue there is a lack of evidence on the safety of administering deworming drugs to young children in tablet form in a community setting.

### Polyparasitism {#CD000371-sec3-0040}

Individuals and communities are often infected with more than one helminth infection ([@CD000371-bbs2-0132]) and the WHO is currently promoting the large‐scale use of \'preventive chemotherapy\'. This involves use of multiple anthelminthic drugs to treat a range of diseases, including STHs, schistosomiasis, and filariasis. [@CD000371-bbs2-0111] comments on the need for a comprehensive assessment of the impact of deworming. In the absence of such evidence, there is a need to demonstrate that a drug is effective against a particular parasite and to quantify its effects on people before combining all the drugs into a basket treatment for all helminth infections, and assuming that all components are effective.

### Secular trends in worm burden {#CD000371-sec3-0041}

Evidence of the benefit of deworming on nutrition appears to depend on three trials, all conducted more than 15 years ago, with two from the same area of Kenya where nearly all children were infected with worms and worm burdens were high. Later and much larger trials have failed to demonstrate the same effects. It may be that over time the intensity of infection has declined, and that the results from these few trials are simply not applicable to contemporary populations with lighter worm burdens.

Quality of the evidence {#CD000371-sec2-0013}
-----------------------

Conducting field trials to test this intervention is complex and challenging, and researchers have worked hard to generate this body of research evidence. There is now a reasonable amount of evidence from trials in a range of settings, including high, moderate, and low burden areas. There have also been ten trials ([Analysis 4.1](#CD000371-fig-00401){ref-type="fig"}) that have assessed the effects of multiple doses of deworming, four of which were cluster‐RCTs. These are particularly important because they can detect the \'real life\' community level effects of treatment that include possible effects from a reduction in worm transmission ([@CD000371-bbs2-0096]).

Potential biases in the review process {#CD000371-sec2-0014}
--------------------------------------

### Statistical errors in analysis {#CD000371-sec3-0042}

Of the eight cluster‐RCTs, three did not take adequate account of cluster randomization ([@CD000371-bbs2-0001]; [@CD000371-bbs2-0017]; [@CD000371-bbs2-0032]). This has the potential substantive impact on the interpretation of the trials. For example, the significant difference between intervention and control quoted on the cover of the *BMJ* for [@CD000371-bbs2-0001] assumed 27,995 children had been individually randomized. When we clarified this with the trial authors, they provided the *BMJ* with a correction, which showed that no significant difference was detected in weight gain between intervention and control groups; this corrected result has been used in the meta‐analysis in this trial.

### School attendance {#CD000371-sec3-0043}

Advocates of deworming have emphasised the potential impacts on school attendance, on the basis of the influential econometric trial [@CD000371-bbs2-0026]. The recent replication trials of [@CD000371-bbs2-0026] substantiate our concerns in the previous version of this Cochrane Review about the high risk of bias in this trial ([@CD000371-bbs2-0089]; [@CD000371-bbs2-0107]). In particular the replication trials raise concerns about the validity of combining the school attendance data across years, since this involves a non‐randomized before and after comparison. We have thus presented the corrected separate year estimates in this review, and present the longest follow‐up time point in line with our a priori analysis strategy.

[@CD000371-bbs2-0026] also reported data on school attendance at one year of follow‐up, in two groups: group 1 versus group 2+3; and group 2 versus group 3. As outlined in the previous edition of the review, it is methodologically incorrect to combine these in meta‐analysis as they are not independent ([@CD000371-bbs2-0152]). The analysis in the previous edition presents each comparison separately (Analysis 4.7 in [@CD000371-bbs2-0152]), both with modest effects, and both non‐significant in the meta‐analysis (including [@CD000371-bbs2-0042]) and this is not repeated in this edition.

### Nutritional outcomes {#CD000371-sec3-0044}

The included trials reported a range of nutritional status outcomes. For meta‐analysis, we did not use nutritional data expressed as z‐scores or percentile scores calculated on the basis of reference standards, or dichotomised z‐ or percentile scores (eg proportion stunted with height‐for‐age z‐score \< ‐2). As these data were derived from the absolute values, we used these values for evidence of benefit. We knew the nutritional data would be captured in the absolute values and wanted to reduce selective reporting through collection of multiple variables from papers that are all derived from the same basic outcomes measured in the trial. We noted that in some trials there was a discrepancy between what was measured and what was reported; eg [@CD000371-bbs2-0029] recorded but did not report anthropometric data. This is a concern as it may indicate selective reporting. However, we have systematically reported all relevant outcomes not included in meta‐analysis in [Table 14](#CD000371-tbl-0014){ref-type="table"}.

### Subgroup analyses {#CD000371-sec3-0045}

Some trials presented data from subgroups, selected on the basis of factors such as infection status ([@CD000371-bbs2-0006]; [@CD000371-bbs2-0009]; [@CD000371-bbs2-0014]), location ([@CD000371-bbs2-0020]), age ([@CD000371-bbs2-0039]), frequency of treatment ([@CD000371-bbs2-0038]), and sex ([@CD000371-bbs2-0023]). These comparisons were not randomized and have not been included in meta‐analysis. Two trials, one of which one was a cluster‐RCT, demonstrated improvements in nutritional outcomes in subgroup analyses ([@CD000371-bbs2-0038]; [@CD000371-bbs2-0039]). We have reported these data in [Table 14](#CD000371-tbl-0014){ref-type="table"}.

Agreements and disagreements with other studies or reviews {#CD000371-sec2-0015}
----------------------------------------------------------

A review and meta‐analysis by [@CD000371-bbs2-0119], funded by the World Bank, presented evidence in favour of an effect of deworming on weight gain (MD 0.21 kg, 95% CI 0.17 to 0.26, 11 trials). This analysis differs from our analyses of weight gain in a number of respects: it was not a protocol‐driven systematic review; the review excluded trials in lower prevalence areas (\< 50%); pooled results were presented without exploration of significant heterogeneity; it combined trials that included both screened and unscreened children; it included trials excluded from our review on the basis of methodological quality; it included data from subgroup analyses; and included data unadjusted for cluster randomization.

The narrative review, [@CD000371-bbs2-0090], explored the evidence for the impact of deworming on pre‐school age children, and concluded that deworming has been shown to improve growth. Their analysis differed from our analyses in a number of ways: a different population was considered, although our review considers data from this subgroup; it was not a protocol‐driven systematic review; it included trials excluded from our review; it was a narrative summary rather than meta‐analysis of data; it reported results from subgroup analyses; it reported point estimates without taking into account statistical significance; and it included data unadjusted for cluster randomization. The authors state: \"A few trials have failed to show any impact of deworming on growth\". This is at odds with our interpretation of the reliable randomized comparisons of nutritional outcomes in this review, which suggests that most trials have failed to show an effect on nutrition.

[@CD000371-bbs2-0117] undertook a systematic review of the effects of deworming on haemoglobin, and reported a marginal increase in mean values that could translate into small reduction (5% to 10%) in anaemia in a population with a high prevalence of intestinal helminths. This systematic review differs from our analysis of haemoglobin in a number of respects: it included trials in adults and pregnant women and it included trials excluded from our review on the basis of methodological quality.

Other advocates of deworming, such as [@CD000371-bbs2-0096], have argued that many of the underlying trials of deworming suffer from three critical methodological problems: treatment externalities in dynamic infection systems, inadequate measurement of cognitive outcomes and school attendance, and sample attrition. We agree with these points. However, externalities will be detected by large cluster‐RCTs and there are now nine trials such as this included in this review, and the externalities previously reported in [@CD000371-bbs2-0026] were not found in the replication analysis after various coding and classification errors had been corrected ([@CD000371-bbs2-0089]).

Authors\' conclusions {#CD000371-sec1-0007}
=====================

It is good medical practice that children known to be infected with worms should receive treatment. This is obvious and not the subject of this Cochrane Review.There is now good evidence to show that routine, repeated deworming public health programmes at a large scale have little or no benefit on average biomedical parameters or school performance. Current evidence does not support large public health programmes of deworming in developing countries.The replication of the Miguel and Kremer trial highlighted a number of errors in the original analysis which have been corrected. This demonstrates the value of replication in trials that are controversial and where there is a lack of clarity over methods and the analysis.The quality of evidence is graded as moderate on most of the outcomes, in relation to demonstrating little or no effect of community deworming. This means that research could possibly have important impact on the confidence of the results and alter the effect. Therefore, further research may be useful, but this needs to be balanced against the declining worm burdens worldwide and the absence of any good evidence of an effect given the current research.Authors of trials, whether they are small or large, should publish the results of the trials promptly irrespective of the findings, in line with the basic principles of research integrity ([@CD000371-bbs2-0113]). We encourage the authors of the Vietnam trial to publish their results.

Feedback {#CD000371-sec1-0013}
========

Ted Miguel and Michael Kremer, 11 January 2013 {#CD000371-sec2-0018}
----------------------------------------------

### Summary {#CD000371-sec3-0046}

Dear Dr. Taylor‐Robinson, Dr. Maayan, Dr. Soares‐Weiser, Dr. Donegan, and Dr. Garner:

We are writing to clarify several points that you raise in your recent 2012 Cochrane review of deworming regarding our 2004 paper \"Worms: Identifying impacts on education and health in the presence of treatment externalities\" in Econometrica.

In particular, we have four main concerns about the discussion of our piece in the recent review, and believe that they could change the assessment of the quality of the evidence presented in our paper. We list these points here in the letter below, with a brief discussion of each point. We then discuss several additional points in the attached document below, following this letter. We hope that these detailed responses to your review will start a productive discussion about the interpretation of the evidence in the Miguel and Kremer (2004) paper.

(All page numbers listed below refer to the July 2012 version of your review, with \"assessed as up‐to‐date\" as May 31, 2012.)

We recognize that writing a Cochrane review is a major undertaking, and we appreciate the time you have taken to read our paper, and the dozens of other papers covered in the review. We hope that this note can serve as the starting point for discussion, both in writing and via phone, if appropriate.

Our four points all relate to the claim made on page 6 of your review, and repeated throughout the review, about the Miguel and Kremer (2004) paper:

\"Miguel 2004 (Cluster) has a high risk of bias for sequence generation, allocation concealment, blinding, incomplete outcome data and baseline imbalance.\"

We have serious concerns about the claims you make about the risk of bias for baseline imbalance, incomplete outcome data, and sequence generation. We discuss these in turn below.

**Point (1):** A leading issue is your current assessment of the quality of evidence on school attendance and participation, which is the main outcome measure in the Miguel and Kremer (2004) trial. Several concerns are raised, including: a lack of baseline values for these measures (leading to a risk of baseline imbalance), and statistically significant impacts for only one of the comparisons considered. The quotes from your review are as follows:

\[p. 21\] \"For school attendance (days present at school): (Miguel 2004 (Cluster) Table 6; Analysis 5.4) reported on end values for attendance rates of children (1999, Group 1 versus Group 3), and found no significant effect (mean difference 5%, 95% CI ‐0.5 to 10.5). No baseline values were given so there is potential for any random differences between the groups to confound the end values.\"

\[p. 24\] \"Similarly, for school attendance, the GRADE quality of the evidence was very low. One quasi‐randomized trial (Miguel 2004 (Cluster) reported an effect, which was apparent in only one of the two comparisons in up to a year of follow up, and not apparent in the one comparison after one year. Miguel 2004 (Cluster) measured attendance outcomes directly, unlike the other two trials (Simeon 1995; Watkins 1996) which measured attendance using school registers, which may be inaccurate in some settings. However, in Miguel 2004 (Cluster), the values for school attendance were end values and not corrected for baseline. Thus random differences in baseline attendance between the two groups could have confounded any result.\"

We feel that these concerns are misplaced, and explain why here. We first discuss concerns about \"baseline imbalance\".

First, we in fact do have baseline data on school participation (our preferred measure) for one of the comparisons that you focus on. The authors of the Cochrane appear to have missed this data in our paper. In Table VIII, Panel A, there is a comparison of 1998 school participation for both Group 2 and Group 3, when both were control schools. There is no statistically significant difference in school participation across Group 2 and Group 3 in 1998, and if anything school participation is slightly lower in Group 2 (‐0.037, s.e. 0.036). This makes the difference between Group 2 and Group 3 in 1999 (0.055, s.e. 0.028), when Group 2 had become a treatment school, even more impressive, since at baseline Group 2 had slightly lower school participation. We respectfully request that the authors of the Cochrane review include this data as evidence of baseline balance in our key outcome measure, school participation, and that they edit their claim that we do not have any such evidence.

It is interesting to note that, if we take the difference between Group 2 and Group 3 at baseline seriously, then the overall effect for this \"year 1\" comparison is 3.7 + 5.5 = 9.2 percentage points. This is almost exactly the same as the 9.3 percentage point effect in the other \"year 1\" comparison that the Cochrane authors focus on (Group 1 versus Groups 2 and 3 in 1998). Taken together, this is quite striking evidence that the first year of deworming treatment significantly improves school participation. The Cochrane authors\' repeated concerns in their review about baseline balance being critical in randomized experiments suggests (to us) that they might find it methodologically preferable to use a \"difference‐in‐difference\" design that explicitly controls for any baseline differences across treatment groups, rather than the standard unbiased \"endline\" comparison across treatment groups. If this is in fact the case, then the relevant year 1 deworming treatment effect for the Group 2 versus Group 3 comparison (for which we have baseline data, as noted above) is the 9.2 percentage point estimate, which we note is significant at 99% confidence.

Second, regarding baseline data on school attendance, we discuss that there is indeed evidence from school registers that recorded attendance is indistinguishable in the three groups of schools in early 1998 (in Table I). While the register data has its weaknesses -- precisely the reason we developed the much more rigorous approach of unannounced school participation checks, combined with tracking of school transfers and drop‐outs -- it is used in other trials, and in fact the Cochrane review considers school register data sufficiently reliable to include a trial (Watkins 1996) that uses it in their meta‐analysis of school attendance.

We are puzzled as to why the evidence in the Watkins (1996) trial is included at all in the Cochrane review if similar register data is considered unreliable when Miguel and Kremer (2004) use it. If school register data is considered (largely) unreliable, then the Watkins (1996) article should be excluded from the review, in which case the \"meta‐analysis\" of school attendance and participation impacts will yield estimated effects that are much larger and statistically significant (since the Watkins impact estimates are close to zero). If the register data is considered (largely) reliable, then the Watkins (1996) trial should be included in the review, but the baseline register data in Miguel and Kremer (2004) should be considered as evidence that we do in fact have baseline balance on school participation. But there is an inconsistency in how register data is considered across the two trials. This seemingly inconsistent approach taken by the authors raises questions about the evenhandedness of the Cochrane review.

In fact, the appropriate use of school register data is more subtle than the Cochrane authors currently consider, since its use as baseline data may in fact be appropriate even if it is inappropriate for use as outcome data. There are at least two reasons why. First, one of the major weaknesses of the school register data used in Watkins (1996) is that it excludes any students who have dropped out, potentially giving a misleading picture about school participation over time. However, this concern about drop‐outs is irrelevant when we use school register data at baseline, since the universe of students considered in the Miguel and Kremer (2004) article was restricted to those currently enrolled in school in January 1998 (at the start of the school year), and thus the exclusion of drop‐outs is not a concern. Note that our use of the school register data at the start of the school year is a likely explanation for why the baseline average attendance rates we obtain using this data are much higher than the average school participation rate that we estimate over the course of the entire school year.

A second related issue is the quality of measured school attendance data conditional on student enrollment in school. Note that to the extent that differences in attendance record‐keeping prior to the introduction of the program are random across schools, they will not bias estimates of treatment impact and any \"noise\" in these measures will be correctly captured by reported standard errors. However, there are plausible concerns about the quality of school register data collected in treatment versus control schools in the context of an experimental evaluation, with a leading concern being that school officials could erroneously inflate figures in the treatment group. Yet once again these concerns are irrelevant in the Miguel and Kremer (2004) trial context since the baseline 1998 school register data that we present (in Table I, Panel B) was collected before any interventions had even been carried out in the sample schools, once again making the baseline school register data potentially more reliable than school register data used as an outcome.

While the data and measurement issues here are somewhat subtle, if anything they argue in favor of including the baseline school register data in assessing the baseline balance in the Miguel and Kremer (2004) paper, while excluding the school register outcome data in Watkins (1996) as potentially unreliable. Instead, the Cochrane authors completely dismiss the baseline register data in Miguel and Kremer (2004) as unreliable evidence for baseline balance, while including the Watkins (1996) data in their meta‐analysis of school participation impacts, giving it equal weight with the Miguel and Kremer (2004) school participation impact evidence (which uses more rigorous outcome data). Once again, the seemingly selective approach taken by the authors raises questions about the evenhandedness of the Cochrane review.

An important final point has to do with the claim that there might have been \"random differences\" across groups. Given the randomized design of Miguel and Kremer (2004), there is no systematic difference to expect there to have been such random differences. The endline comparison of outcomes across treatment groups yields unbiased treatment effect estimates. The remarkable balance across the three groups in terms of dozens academic, nutritional, and socioeconomic outcomes at baseline (Table I) makes it even more unlikely that there were large differences in school participation solely by chance. If the Cochrane authors would like to consider other characteristics (other than school participation) to gauge the likelihood that Groups 1, 2 and 3 in our trial are in fact balanced at baseline they should look at the whole range of outcomes presented in Table I of Miguel and Kremer (2004). The lack of significant baseline academic test scores across Groups 1, 2 and 3 in our sample (Table 1, Panel C) is particularly good evidence that schooling outcomes were in fact balanced at baseline, for instance. It is not clear to us why the Cochrane authors remain so concerned about baseline imbalance issues given the experimental design (which leads to unbiased estimates) and the remarkable balance we observe along so many characteristics in Table I of Miguel and Kremer (2004), and their review does not provide compelling justification for their concerns.

Moreover, in the standard statistical methods that we use, only those differences across groups that are too large to have been generated \"by chance\" are considered statistically significant impacts. In other words, the standard errors generated in the analysis itself are precisely those that address the risk of imbalance \"by chance\" given our research design and sample size. Of course, random variation that is orthogonal to treatment assignment does not alone generate bias.

Speculating about the possibility that there were simply positive impacts \"by chance\" in order to cast doubt on one set of results, but not doing the same when there are zero estimated impacts, again raises questions about the evenhandedness of the Cochrane review. (For instance, perhaps the "zero" impacts on Hb outcome measures in our sample were zero simply \"by chance\", when the real point estimates are in fact strongly positive, like the large school participation impacts we estimate. Yet this possibility is not mentioned in the Cochrane review.) In our view, the Cochrane authors do not provide sufficient justification for their fears about imbalance \"by chance\" in our sample, and we feel further concrete details about these concerns are needed to substantiate their assertions.

Taken together, the Cochrane review\'s claim that there is a \"high risk of bias for ... baseline imbalance\" (the claim made on p. 6 and p. 136, and throughout the review) appears highly misleading to us, given the: balance in school participation we observe between Group 2 and Group 3 in 1998; the balanced school attendance based on register data across Groups 1, 2 and 3 at baseline; the balance in other measures of academic performance (including academic test scores) as well as multiple socioeconomic and nutritional characteristics at baseline; and most importantly given the randomized experimental design, which implies that there is no systematic reason why the three treatment groups would differ significantly along unobservable dimensions.

We respectfully request that the authors of the review consider these factors and reconsider their assessment regarding the claimed \"high risk of bias for ... baseline imbalance\" in Miguel and Kremer (2004).

**Point (2):** There is also an important methodological point to make regarding how the authors of the Cochrane review assess the school participation evidence. At several points they note that only some of the school participation comparisons are statistically significant at 95% confidence. To be specific, the comparisons they focus on have the following estimated impacts and standard errors (from p. 130‐131 of their review):

School participation outcomes measured £ 1 year:

9.3 percentage point gain (s.e. 3.1 percentage points)

5.5 percentage point gain (s.e. 2.8 percentage points) School participation outcomes measured \> 1 year:

5.0 percentage point gain (s.e. 2.8 percentage points)

It is unclear to us why the reviewers separate out the three comparisons, rather than combining the groups in a single analysis using standard analytical methods, as their principal assessment of the impact of deworming on school participation. They give no clear methodological justification for this separation. Pooling data from three valid and unbiased \"comparisons\" still yields an unbiased treatment effect estimate, but with much greater statistical precision, and is thus a methodologically preferable approach. At a minimum, the Cochrane authors should discuss the pooled estimates (which are the focus of Miguel and Kremer 2004) in addition to the three separate comparisons.

One simple approach to doing so that maintains the \"comparisons\" above, and at least goes part of the way towards using the full sample, would be to pool 1998 and 1999 data for the Group 1 versus Group 3 comparison, since Group 1 is treatment during this entire period and Group 3 is control for the entire period. The distinction between \< 1 year and \> 1 year outcomes seems rather artificial to us, as discussed further below. It is unclear to us why the Cochrane authors never present this comparison of Group 1 versus Group 3 for 1998 and 1999 pooled together.

The preferred analysis in the Miguel and Kremer (2004) paper pools multiple years of data, and all groups, to arrive at the most statistically precise estimated impact of deworming on schooling outcomes. This includes both school participation outcomes, as well as academic test score outcomes (which the Cochrane authors currently exclude since in the paper we only present these "pooled" test score results, rather than the simple differences across treatment groups). If the Cochrane authors would like to see the simple differences across treatment groups for the academic test scores, we would be delighted to share the data with them. (To be clear, the test score impact estimates in Miguel and Kremer (2004) come from a regression analysis that relies on the experimental comparison between the treatment and control groups, and is not a retrospective analysis based on non‐experimental data.)

In our view, the Cochrane authors do not provide adequate statistical justification for splitting results into the different \"comparisons\", or into \"year 1\" versus \"year 2\" impacts. \"Pooling\" these different comparisons, as we do in the Miguel and Kremer (2004) paper, is standard with longitudinal (panel) data analysis with multi‐year panels, and is appropriate for those that care about deworming impacts at multiple time frames, ie at less than one year and at more than one year of treatment. Use of our full sample would immediately lead to the conclusion that there are in fact positive impacts of deworming on school participation in our sample, with very large impact magnitudes and high levels of statistical significance. This is the conclusion of the Miguel and Kremer (2004) paper, and a quick look at the comparisons presented above also indicate that there are strong impacts: all three of the comparisons have large impact estimates and all three are statistically significant at over 90% confidence, with one significant at over 99% confidence and another nearly significant at 95% confidence (despite the data being split up into the three different comparisons). By treating each comparison independently and in isolation, the authors are reaching inappropriate conclusions, in our view.

To illustrate why the approach taken by the current version of the Cochrane review is inappropriate, imagine the simple thought experiment of splitting up the data from Miguel and Kremer (2004) into \"quarters\" (three month intervals) rather than years of treatment. There is no obvious a priori reason why this should not be as valid an alternative approach as the \>1 year and \<1 year approach in the Cochrane review, as some other reviewers might instead have been interested in the impact of deworming treatment over intervals shorter than one year. Then we would have 2 comparisons in quarter 1 of treatment (Group 1 versus Groups 2 and 3 in early 1998, and Group 2 versus Group 3 in early 1999), 2 comparisons in quarter 2 of treatment, 2 comparisons in quarter 3, 2 comparisons in quarter 4, and 1 comparison in each quarter from 5 through 8 (Group 1 versus Group 3 in 1999). This approach would generate 12 valid \"comparisons\" of treatment and control schools over multiple time periods, but by slicing up the data ever more finely and reducing the sample size considered in each comparison, it is almost certain that none of these comparisons would yield statistically significant impacts of deworming on school participation at 95% confidence, even though the average estimated effect sizes would remain just as large. This would clearly not be an attractive methodological approach. You could even imagine considering a month by month treatment effect estimate, which would yield 36 different "comparisons", all of which would be severely underpowered statistically.

However, we view the Cochrane review\'s slicing of our full dataset into three comparisons (two for year 1 treatment, and one for year 2), rather than conducting the analysis in the full dataset in much the same way. As we show in Miguel and Kremer (2004), when the data from all valid comparisons is considered jointly, in order to maximize statistical precision using standard longitudinal (panel) data regression methods, the estimated impacts are large and highly statistically significant. Just to be clear, we do not use any controversial statistical methods, and our results do not rely on any non‐experimental comparisons. The regression analyses in our paper rely entirely on the variation in treatment status induced by the experimental design of the trial, and thus are just as appropriate analytically as the simple \"treatment minus control\" differences that the Cochrane authors focus on. In our view, the most robust analytical approach should use our full dataset, rather than the (in our view) more fragmented way of presenting the results in Table 6 of your review, which leads to less statistical precision and no greater insight.

If the Cochrane authors feel that there is a strong a prior reason to focus on year 1 treatment results separately from year 2 treatment results, then at a minimum they should consider both of the year 1 \"comparisons\" that they focus on jointly (ie Group 1 versus Groups 2 and 3 in 1998, and Group 2 versus Group 3 in 1999), in order to improve statistical precision and thus generate impact estimates with tighter confidence intervals. If they wish to strictly employ the same exact \"comparison\" groups over time, then they should at a minimum pool the 1998 and 1999 data and focus on the Group 1 versus Group 3 comparison. Doing either would yield an unambiguous positive and statistically significant impact of deworming on school participation in our sample.

We respectfully request that the authors of the review consider these suggestions and reconsider their assessment regarding the claimed lack of statistically significant school participation impacts in Miguel and Kremer (2004).

**Point (3):** The Cochrane review concludes that our trial has a \"high risk of bias for ... incomplete outcome data\" (p. 90). We believe this point is simply incorrect when applied to our school participation data, as we explain here. The review authors focus on the lack of detail in Miguel and Kremer (2004) regarding the collection of Hb data, but then unfairly use this lack of clarity to downgrade the reliability of all data in the trial, including the school participation data. The exact quote from the review is as follows:

\[p. 15\] However, results for health outcomes were presented for the 1998 comparison of Group 1 (25 schools) versus Group 2 (25 schools). Details of the outcomes we extracted and present are:

• Haemoglobin. This was measured in 4% of the randomized population (778/20,000). It was unclear how the sample were selected.

The Hb sample was a random (representative) sub‐sample of the full sample, chosen by a computer random number generator. Appendix Table AI of the Miguel and Kremer (2004) paper does discuss how the parasitological and Hb surveys were collected jointly in early 1999. Table V mentions that the parasitological data in 1999 was collected for a random sub‐sample. A random subset of those individuals sampled for parasitological tests also had Hb data collected; this was not explicitly stated but should have been. The reason for the relatively small sample for Hb testing was simply that a random (representative) sub‐sample was selected for this testing. For both Hb and parasitological tests, the time and expense of testing the entire sample of over 30,000 school children was prohibitive, hence the decision to draw a representative sub‐sample. Collection of this data for a representative sample should reduce concerns about bias due to incomplete outcome data and selective attrition.

\[p. 15\] • Weight and height. This was measured in an unknown sample of the 20,000 children. No sampling method was given.

Section 3.1 of Miguel and Kremer (2004) does state explicitly that the anthropometric data was collected during pupil questionnaires at school during 1998 and 1999. These were collected in standards (grades) 3‐8, rather than in all grades, and for that reason there is only data on a subset of the full sample. Height and weight data was collected on all individuals in standards 3‐8.

We acknowledge that the discussion of sampling for hemoglobin outcomes was unclear in Miguel and Kremer (2004). However, the fact that we only have Hb data for a random subset in no way affects the attrition rate for school participation data, which was collected for the entire sample. There is no problem with attrition in the main outcome measure in the Miguel and Kremer (2004) trial, namely, school participation. In fact the school participation data is unusually rigorous. We tracked individuals as they transferred across schools, or dropped out of schools, and collected school attendance on unannounced visit days to get a more representative picture of actual school participation. This is in sharp contrast to most other trials.

For instance, Watkins (1996), which shows smaller school attendance impacts than Miguel and Kremer (2004), only considers school attendance based on register data, among those attending school regularly, missing out on school drop‐outs and transfers entirely. Yet that trial surprisingly received equal weight with Miguel and Kremer (2004) in the meta‐analysis of school attendance carried out in this Cochrane review.

Taken together, the claim that there is a \"high risk of bias for ... incomplete outcome data\" (the claim made on p. 6 and p. 136, and throughout the review) appears incorrect to us, given the remarkably high quality of follow up data for school participation, which serves as the main outcome of the trial, and the collection of a representative sub sample for both Hb and nutritional measures.

We respectfully request that the authors of the review consider these factors and reconsider their assessment regarding the claimed "high risk of bias for ... incomplete outcome data" in Miguel and Kremer (2004), especially in regards to the school participation data.

(One small point: In the summary of findings table on page 5, it is stated that we only have school participation data for 50 clusters, rather than 75 clusters. This is incorrect, since even using the Cochrane authors\' three \"comparisons\", there are 75 distinct clusters that contribute to the year 1 evidence for Group 1 versus Groups 2 and 3 in 1998, for instance.)

**Point (4):** The Cochrane review also considers the Miguel and Kremer (2004) trial to have "a high risk of bias for sequence generation" \[p. 6\].

In particular, it discusses the quasi‐random allocation of the 75 clusters:

\[p. 14\] \"Eight trials were cluster randomized (Alderman 2006 (Cluster); Awasthi 2008 (Cluster); Awasthi 2001 (Cluster); DEVTA (unpublished); Hall 2006 (Cluster); Rousham 1994 (Cluster); Stoltzfus 1997 (Cluster)), one was a trial with quasi‐random allocation of the 75 clusters (Miguel 2004 (Cluster))\".

It is never clearly specified why the randomization approach makes the trial \"quasi‐randomized\". It may be due to the use of an alphabetical \"list randomization\" approach, rather than a computer random number generator, but if so, this is never laid out explicitly by the Cochrane authors. The remarkable baseline balance on a wide range of characteristics (educational, nutritional, socioeconomic, etc. shown in Table I of Miguel and Kremer 2004) across 75 clusters and over 30,000 individuals surely helps alleviate these concerns. We would like to obtain more detailed information from the Cochrane authors on why the research design in Miguel and Kremer (2004) is considered to have a \"high risk of bias\". This is never explicitly discussed in the review.

We respectfully request that the authors of the review consider these factors and reconsider their assessment regarding the claimed \"high risk of bias for ... sequence generation\" in Miguel and Kremer (2004).

We carefully read through the entire document and noted additional instances where we had questions and concerns below (following this letter), and note the relevant page numbers in your review.

Finally, we also would like to briefly mention two working papers that we believe could usefully be incorporated into future versions of the Cochrane review on deworming. One working paper (Baird et al.) trials long‐term impacts of deworming treatment on labor market outcomes. We are both co‐authors on this paper. We are currently finishing the write up of this paper and hope to submit it to a working paper series and a journal in 2013, and at that point we will share that paper with your group. That trial shows very large long‐run impacts of deworming treatment on labor market outcomes, up to ten years after the start of the primary school deworming project that we trial. The second is a working paper by Dr. Owen Ozier of the World Bank, which examines long‐run educational impacts on individuals who were very young children at the start of the Kenya deworming project, and finds large positive test score effects. One advantage of Ozier's trial is his ability to compare outcomes across schools and across birth cohorts within those school communities, allowing him to include \"school fixed effects\" that control for any baseline differences across schools. This methodological approach addresses any lingering concerns about baseline \"imbalance\" across treatment groups.

We look forward to starting a discussion of these issues with your team, and we thank you for the time you have taken to consider them. We realize that this is an extremely time‐consuming process for your entire team, given the detailed reading you need to carry out for literally dozens of trials, and we appreciate your willingness to consider these points.

**Additional comments on the Cochrane review: (Cochrane text noted in italics, page numbers noted)**

The Cochrane authors have the following discussion of the exam score data and school sample:

\[p. 67\] \"Participants Number analysed for primary outcome: ... Unclear for exam performance and cognitive tests Inclusion criteria: none explicitly stated. "Nearly all rural primary schools" in Busia district, Kenya, involved in a NGO deworming programme were studied, with a total enrolment of 30,000 pupils aged six to eighteen. Exclusion criteria: girls \> 13 years old\".

The claim that there was no explicit inclusion criteria stated in the paper for the exam data appears inaccurate. Section 7.2 of Miguel and Kremer (2004) discusses our attempts to test all students, including efforts to administer exams even to those students who had since dropped out of school (see footnote 52).

In terms of the inclusion of schools in the sample, there were a total of 92 primary schools in the trial area of Budalangi and Funyula divisions in January 1998. Seventy‐five of these 92 schools were selected to participate in the deworming program, and they form the analysis sample here. The 17 schools excluded schools from the program (and thus the analysis) include: town schools that were quite different from other local schools in terms of student socioeconomic background; single‐sex schools; a few schools located on islands in Lake Victoria (posing severe transportation difficulties); and those few schools that had in the past already received deworming and other health treatments under an earlier small‐scale ICS (NGO) program.

The Cochrane authors make the following point about worm infection rates, which relates to potential baseline imbalance across treatment groups:

\[p. 68\] \"Group 1 schools have an overall prevalence of 38% heavy/moderate worm infection in 1998, compared to the initial survey in control schools in 1999, where it was 52%.\"

This is a misleading comparison. The comparison of Group 1 worm infection in 1998 versus Group 2 worm infection in 1999 is simply inappropriate, given the well‐known variability across seasons and years in worm infection rates (as a function of local weather, precipitation, temperature, etc.). There is abundant health and nutritional data from pupil surveys for Groups 2 and 3 at baseline in 1998, and they indicate that these groups appear very similar to Group 1 at baseline (see Table I of Miguel and Kremer 2004) but no parasitological data was collected for Groups 2 and 3 in 1998, nor for Group 3 in 1999, since it was considered unethical to collected detailed worm infection data in a group that was not scheduled to receive deworming treatment in that year. Once again, standard errors for the comparison of outcomes among different treatment groups take into account the possibility of random differences at baseline, and thus statistical significance levels already reflect the possibility that there is some random baseline variation across schools, but this variation alone of course does not cause bias.

The Cochrane authors have the following discussion of our health data:

\[p. 68\] \"However, in a personal correspondence the authors state that there is no health data for Group 3 schools for 1999.\"

This claim is not entirely accurate, and must be the result of a misunderstanding. There is abundant health and nutritional data from pupil surveys for Group 3 in 1999, but no parasitological data was collected for Group 3 in 1999, since it was considered unethical to collected detailed worm infection data in a group that was not scheduled to receive deworming treatment in that year.

\[p. 68\] 27/75 schools were involved in other NGO projects which consisted of financial assistance for textbook purchase and classroom construction, and teacher performance incentives. The distribution of these other interventions is not clear, but the authors state that these schools were stratified according to involvement in these other programmes.

\[p. 70\] The intervention was a package including deworming drugs for soil transmitted helminths, praziquantel to treat schistosomiasis in schools with \> 30% prevalence, and health promotion interventions. In addition 27/75 schools were involved in other NGO projects which consisted of financial assistance for textbook purchase and classroom construction, and teacher performance incentives. The distribution of the latter interventions is not clear. These co‐interventions confound the potential effects of deworming drugs to treat STHs. However, the authors kindly provided a re‐analysis of their data, with the praziquantel treated schools removed from the analysis. This represents as subgroup analysis of the original quasi‐randomized comparison\".

Given that these other interventions had no measurable impacts on educational outcomes (as reported in several other articles), and that they are balanced across our treatment groups, these prior interventions are not a major concern for the analysis.

Sincerely,

**Ted Miguel and Michael Kremer**

I agree with the conflict of interest statement below:

***I certify that we have no affiliations with or involvement in any organization or entity with a financial interest in the subject matter of our feedback.***

### Reply {#CD000371-sec3-0047}

We appreciate these helpful and detailed comments. We have checked through these carefully, and responded to the key points below.

#### Risk of bias assessment contested (point 1). {#CD000371-sec4-0043}

Miguel and Kremer were concerned that we had been unduly harsh on assessing the risk of bias of their trial in several points in their comments. We have reassessed this in the light of their comments and the recent replication, which is helpful as it clarifies more details on the methods.

Baseline imbalance: We agree and now move the risk of bias in relation to imbalance at baseline to \"low\". The remaining criteria of the risk of bias remain unaltered.

Incomplete data: Thank you for your additional information about the methods. This is also contained in the replication analysis, and this has been adjusted to low.

#### Quality of the evidence in relation to schooling and advocacy of combining results (point 2). {#CD000371-sec4-0044}

Miguel and Kremer were concerned that the quality of the evidence on school attendance was ranked as \"very low\". We thank them for their concern and have revaluated the reasons for downgrading, taking into account the pure and the statistical replication. It remains ranked as very low with full justification given in the \'Summary of findings\' table footnotes.

Miguel and Kremer also advocate combining results for school participations from the three school participation results from quasi‐randomized comparisons. Just to recap, for year 1 follow‐up, there are results from:

Group 1 vs Groups 2+3;

Group 2 vs Group 3.

And at two years of follow‐up, results from Group 1 vs Group 3.

We have not combined the estimates from the quasi‐randomized comparisons in meta‐analysis because they are not independent. However the separate estimates are all documented in the review.

Due to the trial design the pooled estimate that Miguel and Kremer prefer contains a non‐randomized before and after comparison, as clarified in the replication trials.

The second point the authors raise in the paragraph \"However, we view the Cochrane\'s slicing...\". We have addressed this by combining the multiple dose trials in one analysis, using the longest follow‐up time point. Justification for this is provided in the review text. This is a helpful comment and has helped with shortening the review.

#### Losses to follow‐up on haemoglobin and school attendance (point 3). {#CD000371-sec4-0045}

Thanks for these clarifications about the sampling for height, weight, and Hb. These are noted in the review.

For school attendance, there is downgrading as stated in the table so that the GRADE assessment of the quality is very low, for risk of bias, imprecision, and indirectness. The missing data and many of the methodological issues debated here are now made much clearer in the replication trials. The other information that is highly relevant is the health promotion co‐intervention.

The GRADE table is agreed by all authors after considerable discussion. It is also checked by two other editors. This is based on information in the original trial reports and now, with your trial, the two papers concerning the replication.

#### Risk of bias on sequence generation; and additional papers (point 4). {#CD000371-sec4-0046}

Thank you for this information.

This is a quasi‐randomized method of allocation, as described in the *Cochrane Handbook for Systematic Reviews of Interventions*, and as clarified in the replication trials.

Thanks for these additional papers you mention. They were considered by the authorship team and do not meet the inclusion criteria for the review.

### Contributors {#CD000371-sec3-0048}

David Taylor‐Robinson, Paul Garner, Karla Soares‐Weiser, Sarah Donegan.

Harold Alderman, 14 January 2013 {#CD000371-sec2-0019}
--------------------------------

### Summary {#CD000371-sec3-0049}

Shortly after my paper on deworming in Uganda was published in the BMJ, I had an exchange of correspondence with Dr. Garner regarding the standard errors reported in one table. After that exchange I shared the following letter with the BMJ and with him in April 2007:

Dear Editor,

Prof. Paul Garner has kindly pointed out that, in an article published in the BMJ, my coauthors and I inadvertently failed to adjust standard errors in one of the tables for cluster based sampling. While table 2 of that paper reports means for growth in grams of 2413 \[CI=2373 ‐ 2454\] and 2259 \[CI=2216 ‐ 2301\] for the treatment and control groups respectively, once the design effect is taken into consideration the confidence intervals should, in fact, be \[CI=2295 ‐ 2533\] and \[CI=2121 ‐ 2396\].

The conclusions of the trial, however, are unaffected as they are based on the multivariate regressions reported in table 3 for which the standard errors had been corrected for cluster based sampling. For example, the confidence interval for the finding that the children who attended child health days every six months where deworming medicine was provide had a significantly greater weight gain than similar children who attended child health days at which albendazole was not provided is unaffected; the CI for the difference in weight gain remains \[59g ‐ 262 g\].\"

Recently the BMJ has invited me to submit a letter addressing the earlier comments as well as more recent variations of that theme. I believe that it is sufficient to indicate that the results presented in the multivariate analysis remain the basis for the conclusion of the trial. Given the heterogeneity of ages in the trial population and the fact that the velocity of weight gain is dependent on age, table 2 was presented for background only while the primary analysis was presented in table 3. The results in this table control for these covariates as well as the duration of time between visits or the total time a child participated in the child health days organized for his or her community. These results provide more precise estimates.

**Harold Alderman**

International food Policy Research Institute

I agree with the conflict of interest statement below:

*I certify that I have no affiliations with or involvement in any organization or entity with a financial interest in the subject matter of my feedback.*

### Reply {#CD000371-sec3-0050}

Thank you for this information which is duly noted.

### Contributors {#CD000371-sec3-0051}

David Taylor‐Robinson, Paul Garner, Sarah Donegan.

Christian Smith (Givewell ‐ Research Analyst), 4 October 2016 {#CD000371-sec2-0020}
-------------------------------------------------------------

### Summary {#CD000371-sec3-0052}

**Feedback CommentsAuthor response**Comment: The research team at GiveWell has a handful of clarifying questions for the authors of the review on deworming treatments for children.Was there a protocol for the most recent update to the Cochrane Review? If so, could it be shared?Updates are broadly guided by the original protocol and review and standard practice is to document the changes made in the "history" section.\
This protocol was first published in 1997 and the first edition of the review was published in 1998. At this time there was no online repository for Cochrane protocols; we have therefore made the original protocol available via the \"Related content\" section here: http://cidg.cochrane.org/our‐reviews\
Cochrane policy is that when a team continue updating a review where the question and inclusion criteria stay the same, the team draw on new information, comments and criticisms, and a review of the current debates, background, objectives, inclusion criteria and methods (see Table 2. In Garner et al. BMJ 2016; 354: i3507). No fresh protocol is prepared unless it is a new team, or there are substantial changes to the inclusion criteria or methods used in the analysis.\
However, the author team should ensure the changes are transparent and summarized in the "What's new/history section" and that is present.‐The \"History\" section at the end of the review notes: \"We changed the classification of Stephenson 1989 and Stephenson 1993. Previously these trials were in the 'all children in an endemic area' category, whereas now they are classified in the \'children with infection\'. This decision was based on reviewing the trials with parasitologists and examining the prevalence and intensity of the infection where clearly the whole community was heavily infected" (p. 154). Could any information be shared about the process of consulting parasitologists on this topic or the output of those consultations?'The Stephenson studies were reviewed as part of our last update, since they were a source of heterogeneity. We were examining how best to take this into account. We noted that in the methods section the authors noted: \"The subjects consisted of all available children in the lower grades (Standards I and II) in Mvindeni Primary School in Kwale District, Coast Province, Kenya, an area where our previous work had shown that virtually all of the primary schoolchildren had hookworm (predominantly Necator americanus) and T. trichiura infections and that 50% were infected with A. lumbricoides.\"We had missed this information earlier.\
We consulted with LSTM parasitologists on this. They noted that virtually everyone was infected, and most were infected with at least two parasites and at least a third with three. In addition, the average hookworm loads put all the children into the moderate/heavy infection category. This is why this population was selected for the Stephenson studies. In this respect, the population chosen were equivalent to a population that had been screened to just include infected children. These indeed were quite old studies.\
So we made a decision that these studies were wrongly included in "treating the whole community" as everyone in the study population was infected. Hence they were reclassified.‐Did you consult parasitologists about Watkins 1996? If so, how did you reach the conclusion to include that study in the "all children in an endemic area" category?Our reading of the Stephenson studies was that the intention was to include a population where all children were infected.\
You ask about some other studies and why these were not reclassified as well (Watkins, Cruz, and Pollitt 1996). These were not in such high prevalence areas, but we take the point about the need to be systematic and will indeed have a closer look at their background prevalence in the update of the review.‐Could you share any information about the rationale for the change in your classification schema from using \"target population treated\" to \"all children in an endemic area\" and \"screened for infection\" to \"children with infection\"? Does the change affect the classification of any studies included in the 2012 review other than Stephenson 1989 and Stephenson 1993?This is because we judged that this was a better way of doing it. If all the children were infected (either because of the massively high worm infection burden, or as a result of screening), this was a clear way to describe the population. This is the whole reason for carrying out updates, to refine the analysis and make it clearer for the reader.‐Is it the case that the Stephenson 1989 and Stephenson 1993 involved populations where every individual was infected? If not, was there a clear process for determining which studies fit under the \"children with infection\" classification? We are particularly curious about the rationale for including Stephenson 1993 under the \"children with infection\" classification while excluding Watkins 1996 from that classification.As above. Virtually all of the children in the Stephenson studies had hookworm and Trichuris, and half had ascaris. Indeed, the intention of the authors was to select them on this basis.‐Croke et al. reported that adding Stephenson 1993 back into a fixed effects version of Analysis 4.1 leads to a statistically significant weight effect, but they do not appear to report the random effects meta‐analysis result (Croke at al. 2016, Table 2, p. 27). How would adding the relevant Stephenson 1993 result affect the random effects meta‐analysis results in Analysis 4.1?When we realised that Stephenson 1993 was in an area where everyone included was infected we moved the study into a more appropriate comparison, as outlined above. We stand by this analysis and change.\
What you are proposing is not a sensitivity analysis, but seems to be "what would we get if we did this‐and would it be significant?" We believe it is not helpful to shift the study around or tweak the statistical analysis retrospectively as there is a risk of the analysis being driven by the outcome of the analysis rather than first principles of whether the analysis is appropriate. In addition, statistical significance is not a critical flag of whether something works: the size of the effect is also critical (see below).‐If Analysis 4.1 resulted in a statistically significant weight gain, would the authors still maintain their position that mass deworming of children in endemic areas "does not improve average nutritional status\" (p. 2)?It is not just a matter of statistical significance. There is a danger in chasing whether a result is statistically significant, this can be misleading, particularly when combined with multiple analyses of the same data. What is more important in drawing conclusions with limited and mixed data is to consider heterogeneity in the meta‐analysis, and to interpret the results in light of this. The GRADE approach is used in the review, and the assessment takes into account the effect size, the precision, the risk of bias, the directness of evidence, and heterogeneity between estimates. The GRADE assessment draws on the estimate of weight change from the main analysis (0.08 kg, 95%CI 0.11 to 0.27; analysis 4.1); and the GRADE uses a sensitivity analysis (6.1). In this analysis, which includes only studies with low risk of bias for allocation concealment, there was no evidence of an effect (0.01, 95%CI ‐0.13 to 0.15; analysis 6.1). This analysis is dominated by a single study, so to double check our inferences for this response, we conducted a further sensitivity analysis with studies at clear risk of bias excluded (Awasthi 2000, and Awasthi 1995); this provides an estimate of ‐0.01 kg (95% CI ‐0.15 to 0.13). Thus our published estimate and GRADE stand, downgraded on risk of bias and inconsistency, and we conclude "there may be little to no effect on weight\" based on the main analysis estimate.

Christian Smith,

Do you have any affiliation with or involvement in any organisation with a financial interest in the subject matter of your comment?

As of October 2016, GiveWell recommends two charities that conduct mass drug administration programs for STH and Schistosomiasis---The Schistosomiasis Control Initiative and the Deworm the World Initiative, led by Evidence Action.

### Reply {#CD000371-sec3-0053}

In the column above.

### Contributors {#CD000371-sec3-0054}

David Taylor‐Robinson, Paul Garner.

We thank all people who gave of their time and expertise to comment on this Cochrane Review and also the authors of the first version of this Cochrane Review ([@CD000371-bbs2-0149]). We are grateful to Dr. David Sinclair for his advice and assistance in preparing \'Summary of findings\' tables.

This document is an output from a project funded by the UK Department for International Development (DFID) for the benefit of developing countries. The views expressed are not necessarily those of DFID.

This 2015 review update was partly supported by a grant from the Evidence and Programme Guidance Unit, Department of Nutrition for Health and Development, WHO.

The academic editors for this Cochrane Review are Hellen Gelband and David Sinclair.

**Potential biasAuthors\' judgementRandom sequence generation (selection bias)***High* -- not randomized or quasi‐randomized\
*Unclear* -- states \"randomized\", but does not report method\
*Low* -- describes method of randomization**Allocation concealment (selection bias)***High* -- not concealed, open label trial for individually randomized, method of concealment not adequate\
*Unclear*  -- details of method not reported or insufficient details\
*Low* -- central allocation, sequentially numbered opaque sealed envelopes**Blinding (performance bias and detection bias)***High* -- personnel, participants or outcome assessors not blinded\
*Unclear* -- no details reported, insufficient details reported\
*Low* -- personnel, participants and outcome assessors blinded**Incomplete outcome data (attrition bias)***High* -- losses to follow‐up not evenly distributed across intervention and control group, high attrition rate  (20% or more for the main outcome)\
*Unclear* ‐ no details reported, insufficient details reported\
*Low* -- no losses to follow‐up, losses below 20% and evenly distributed across groups, ITT analysis used.\
Note: for cluster‐RCTs, the loss relates to the clusters**Selective reporting (reporting bias)***High* -- did not fully report measured or relevant outcomes\
*Unclear* -- not enough information reported to judge\
*Low* -- all stated outcomes reported**Other bias***Low* -- no obvious other source of bias of concern to reviewers\
*High* -- major source of bias such as unexplained differences in baseline characteristics

**TrialID CountryWho was treated? (Age)How long was the follow‐up?Trialdesign? (No. of participants^a^)Was it a cluster‐RCT? (No. of clusters)What intervention? (Dose)Co‐interventions?^b^What control?How long was the treatment?Endemic area? (Community category number)**[@CD000371-bbs2-0001]\
**Uganda**Children (1 to 7 years)3 yearsRCT (27,995)Yes (48)Albendazole (400 mg)Child health package -- both groupsNo treatmentEvery 6 monthsYes (2)[@CD000371-bbs2-0002]\
**India**Children (1 to 4 years)2 yearsQuasi‐RCT (3712)Yes (50)Albendazole (400 mg)NonePlaceboEvery 6 monthsYes (3)[@CD000371-bbs2-0003]\
**India**Children (1.5 to 3.5 years)2 yearsQuasi‐RCT (1045)NoAlbendazole (600 mg)NonePlaceboEvery 6 monthsYes (3)[@CD000371-bbs2-0004]\
**India**Children (1 to 4 years)1.5 yearsRCT (1672)Yes (124)Albendazole ± vitamin A (100,000 units)Child health package -- both groupsPlacebo + vitamin AEvery 6 monthsYes (3)[@CD000371-bbs2-0005]\
**India**Children (≤ 5 years)5 yearsRCT factorial (8338)Yes (72)Albendazole (400 mg) ± vitamin AChild health package -- both groupsUsual careEvery 6 monthsYes (3)[@CD000371-bbs2-0006]\
**Haiti**Children (grades 1 to 4)4 monthsRCT (853)NoAlbendazole (400 mg)\
Ivermectin (200 to 400 μg/kg)NonePlacebo + vitamin C (250 mg)Single doseYes (3)[@CD000371-bbs2-0007]\
**Zaire**Children (0 to 72 months)1 yearRCT (222)NoMebendazole (500 mg)NonePlacebo + vitamin A (60 mg)\
No treatmentEvery 3 monthsYes (3)[@CD000371-bbs2-0008]\
**Benin**Children (3 to 5 years)10 monthsRCT (65)NoAlbendazole (200 mg) ± ironNonePlaceboRepeated 1 month laterYes (2)[@CD000371-bbs2-0009]\
**Haiti**Children (5 to 11 years)6 monthsRCT (626)NoAlbendazole (400 mg) ± vitamin C (250 mg)\
Diethylcarbamazine (DEC, 6 mg/kg)NonePlaceboSingle doseYes (2)[@CD000371-bbs2-0010]\
**Ethiopia**Children (1.5 to 5 years)28 daysQuasi‐RCT (13)NoPiperazine (3 g)Child health package -- both groupsPlaceboSingle doseInfected children (unclear)[@CD000371-bbs2-0011]\
**Ethiopia**Children (1 to 5 years)34 daysQuasi‐RCT (44)NoPiperazine (3 g x 2)NonePlaceboSingle doseInfected children (3)[@CD000371-bbs2-0012]\
**Kenya**Children (2 to 4 years)6 monthsRCT (347)NoMebendazole (500 mg)Child health package -- both groupsPlaceboSingle doseYes (2)[@CD000371-bbs2-0013]\
**Bangladesh**Children (≤ 11 months)36 weeksRCT (410)NoAlbendazole (200 mg) ± secnidazole (0.5 mL/kg, anti‐*Giardia*)NonePlaceboEvery 12 weeksYes (2)[@CD000371-bbs2-0014]\
**Bangladesh**Children (1.5 to 8 years)11 monthsRCT (152)NoPiperazine citrate (80 mg/kg)NonePlaceboTwo doses in 2 weeksYes (1)[@CD000371-bbs2-0015]\
**Indonesia**Children (6 to 10 years)7 weeksRCT (64)NoPyrantel pamoate (10 mg/kg)NonePlaceboSingle doseYes (1)[@CD000371-bbs2-0016]\
**Indonesia**Children (± 8.3 years)1 yearRCT (330)NoAlbendazole (400 mg)\
Pyrantel pamoate (10 mg/kg)NonePlaceboSingle dose or every 6 monthsYes (1)[@CD000371-bbs2-0017]\
**Vietnam**Children (± 104.5 months)2 yearsRCT (2,659)Yes (80)Albendazole (400 mg) ± retinol (200,000 IU)NonePlaceboEvery 6 monthsYes (1)[@CD000371-bbs2-0018]\
**Nigeria**Children (1 to 5 years)14 monthsRCT (320)NoAlbendazole (200 to 400 mg)Child health package -- both groupsPlaceboEvery 4 monthsYes (3)[@CD000371-bbs2-0019]\
**Cameroon**Children (1 to 8 years)10 monthsRCT (337)NoMebendazole (100 mg x3)NonePlacebo3 doses in 3 daysYes (1)[@CD000371-bbs2-0020]\
**Sierra Leone**Children (6 to 10 years)6 monthsRCT (187)NoAlbendazole (400 mg)NonePlaceboSingle doseYes (2)[@CD000371-bbs2-0021]\
**South Africa**Children (6 to 8 years)11 monthsRCT (74)NoAlbendazole (400 mg) ± soup fortified with iron and vitamin CChild health package -- both groupsPlaceboRepeated at 4 monthsYes (3)[@CD000371-bbs2-0022]\
**South Africa**Children (primary school)1 monthRCT (unclear)NoMebendazole (500 mg)NonePlaceboSingle doseInfected children (1)[@CD000371-bbs2-0023]\
**Malaysia**Children (8 years)2 yearsRCT (314)NoMebendazole (100 mg) + pyrantel (200 mg)NonePlaceboEvery 3 monthsYes (1)[@CD000371-bbs2-0024]\
**Vietnam**Children6 monthsRCT factorial (510)NoMebendazole (500 mg)Iron‐fortified noodlesPlaceboTwice 3 months apartYes (2)[@CD000371-bbs2-0025]\
**Botswana**Children (5 to 14 years)5 monthsRCT (121)NoTetrachloroethylene (0.1 mL/kg)NonePlaceboSingle doseYes (1)[@CD000371-bbs2-0026]\
**Kenya**Children (8 years)2 yearsRCT (9102)Yes (65)Albendazole (400 to 600 mg)Child health package -- only intervention groupNo treatmentEvery 6 monthsYes (1)[@CD000371-bbs2-0027]\
**Uganda**Children (± 15 months)Post‐treatmentRCT factorial (1423)NoAlbendazole (200 to 400 mg)Child health package -- both groupsPlacebo??Yes (3)[@CD000371-bbs2-0028]\
**Vietnam**Children (6 to 8 years)4 monthsRCT (510)NoAlbendazole (400 mg) ± multi‐micronutrient fortified biscuitNonePlaceboSingle doseYes (2)[@CD000371-bbs2-0029]\
**Jamaica**Children (9 to 12 years)9 weeksRCT (103)NoAlbendazole (400 mg x3)NonePlaceboSingle doseInfected children (1)[@CD000371-bbs2-0030]\
**China, Philippines and Kenya**Children (school children)6 monthsRCT (103)NoAlbendazole (400 mg) ± praziquantel (40 mg/kg)NonePlaceboSingle doseYes (1)[@CD000371-bbs2-0031]\
**Indonesia**Children (2 to 5 years)9 weeksRCT (191)NoAlbendazole (400 mg)IronIron (30 mg weekly)Single doseYes (2)[@CD000371-bbs2-0032]\
**Bangladesh**Children (2 to 6 years)18 monthsRCT (1,402)Yes (13)Mebendazole (500 mg)\
Pyrantel pamoate (10 mg/kg)NonePlaceboEvery 2 monthsYes (1)[@CD000371-bbs2-0033]\
**Bangladesh**Children (2 to 12 years)16 weeksRCT (81)NoPyrantel pamoate (11 mg/kg)NonePlaceboSingle doseInfected children (1)[@CD000371-bbs2-0034]\
**Jamaica**Children (6 to 12 years)26 weeksRCT (392)NoAlbendazole (800 mg)NonePlaceboRepeated 3 to 6 months afterInfected children (1)[@CD000371-bbs2-0035]\
**Philippines**Children (grades 1 to 6)16 weeksRCT (851)NoAlbendazole (400 mg) ± multivitamin and ironNonePlaceboRepeated 3 to 6 months afterYes (2)[@CD000371-bbs2-0036]\
**Kenya**Children (grades 1 to 2)6 monthsRCT (150)NoAlbendazole (400 mg)NonePlaceboSingle doseYes (1)[@CD000371-bbs2-0037]\
**Kenya**Children (grades 1 to 5)8 monthsRCT (284)NoAlbendazole (600 mg)NonePlaceboRepeated 3 to 6 months afterYes (1)[@CD000371-bbs2-0038]\
**Tanzania, Zanzibar**Children (± 10.5 years)12 monthsRCT (3063)Yes (12)Mebendazole (500 mg, 2x or 3x)NonePlaceboEvery 4 or 6 monthsYes (1)[@CD000371-bbs2-0039]\
**Tanzania, Zanzibar**Children (6 to 59 months)12 monthsRCT factorial (359)NoMebendazole (500 mg) ± ironNonePlaceboEvery 3 monthsYes (2)[@CD000371-bbs2-0040]\
**India**Children (2 to 5 years)12 monthsRCT (683)NoAlbendazole (400 mg) ± vitamin BNonePlaceboEvery 6 monthsYes (2)[@CD000371-bbs2-0041]\
**Malaysia**Children12 monthsRCT (33)NoAlbendazole (400 mg x 2)NonePlaceboSingle doseYes (NA)[@CD000371-bbs2-0042]\
**Guatemala**Children (7 to 12 years)6 monthsRCT (226)NoAlbendazole (400 mg)NonePlaceboRepeated at 12 weeksYes (1)[@CD000371-bbs2-0043]\
**Tanzania**Children (6 to 91 months)12 monthsRCT (268)NoLevamisole (2.5 mg/kg)NonePlaceboEvery 3 monthsYes (3)[@CD000371-bbs2-0044]\
**Indonesia**Children and adults ≥ 2 years21 monthsRCT (855)Yes (954)Albendazole (400 mg x 3)NonePlaceboSingle doseYes (1)[@CD000371-bbs2-0045]\
**Myanmar, China**Children (9 to 12 years)6 monthsRCT (194)NoAlbendazole (400 mg x 3)NonePlaceboSingle doseInfected children (NA)

^a^Number of participants analysed for primary outcome. ^b^For details on \"child health package\" please see [Table 13](#CD000371-tbl-0013){ref-type="table"}: Accompanying health promotion activities.

Comparison 1Infected children ‐ Single doseOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 Weight (kg)](#CD000371-fig-00101){ref-type="fig"}Analysis 1.1Comparison 1 Infected children ‐ Single dose, Outcome 1 Weight (kg).5627Mean Difference (IV, Random, 95% CI)0.75 \[0.24, 1.26\][2 Height (cm)](#CD000371-fig-00102){ref-type="fig"}Analysis 1.2Comparison 1 Infected children ‐ Single dose, Outcome 2 Height (cm).5647Mean Difference (IV, Random, 95% CI)0.25 \[0.01, 0.49\][3 Mid‐upper arm circumference (cm)](#CD000371-fig-00103){ref-type="fig"}Analysis 1.3Comparison 1 Infected children ‐ Single dose, Outcome 3 Mid‐upper arm circumference (cm).4396Mean Difference (IV, Fixed, 95% CI)0.49 \[0.39, 0.58\][4 Triceps skin fold thickness (mm)](#CD000371-fig-00104){ref-type="fig"}Analysis 1.4Comparison 1 Infected children ‐ Single dose, Outcome 4 Triceps skin fold thickness (mm).3352Mean Difference (IV, Random, 95% CI)1.34 \[0.72, 1.97\][5 Subscapular skin fold thickness (mm)](#CD000371-fig-00105){ref-type="fig"}Analysis 1.5Comparison 1 Infected children ‐ Single dose, Outcome 5 Subscapular skin fold thickness (mm).2339Mean Difference (IV, Fixed, 95% CI)1.29 \[1.13, 1.44\][6 Body mass index](#CD000371-fig-00106){ref-type="fig"}Analysis 1.6Comparison 1 Infected children ‐ Single dose, Outcome 6 Body mass index.1Mean Difference (IV, Fixed, 95% CI)Totals not selected[7 Haemoglobin (g/dL)](#CD000371-fig-00107){ref-type="fig"}Analysis 1.7Comparison 1 Infected children ‐ Single dose, Outcome 7 Haemoglobin (g/dL).2247Mean Difference (IV, Random, 95% CI)0.10 \[‐0.65, 0.86\]

Comparison 2Infected children ‐ Multiple dose, longest follow‐upOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 Weight (kg)](#CD000371-fig-00201){ref-type="fig"}Analysis 2.1Comparison 2 Infected children ‐ Multiple dose, longest follow‐up, Outcome 1 Weight (kg).1Mean Difference (Fixed, 95% CI)Totals not selected[2 Height (cm)](#CD000371-fig-00202){ref-type="fig"}Analysis 2.2Comparison 2 Infected children ‐ Multiple dose, longest follow‐up, Outcome 2 Height (cm).1Mean Difference (IV, Fixed, 95% CI)Totals not selected[3 Body mass index](#CD000371-fig-00203){ref-type="fig"}Analysis 2.3Comparison 2 Infected children ‐ Multiple dose, longest follow‐up, Outcome 3 Body mass index.1Mean Difference (IV, Fixed, 95% CI)Totals not selected[4 School attendance (days present at school)](#CD000371-fig-00204){ref-type="fig"}Analysis 2.4Comparison 2 Infected children ‐ Multiple dose, longest follow‐up, Outcome 4 School attendance (days present at school).1Mean Difference (IV, Fixed, 95% CI)Totals not selected[5 Mid‐upper arm circumference (cm)](#CD000371-fig-00205){ref-type="fig"}Analysis 2.5Comparison 2 Infected children ‐ Multiple dose, longest follow‐up, Outcome 5 Mid‐upper arm circumference (cm).1Mean Difference (IV, Fixed, 95% CI)Totals not selected[6 Triceps skin fold thickness (mm)](#CD000371-fig-00206){ref-type="fig"}Analysis 2.6Comparison 2 Infected children ‐ Multiple dose, longest follow‐up, Outcome 6 Triceps skin fold thickness (mm).1Mean Difference (IV, Fixed, 95% CI)Totals not selected[7 Subscapular skin fold thickness (mm)](#CD000371-fig-00207){ref-type="fig"}Analysis 2.7Comparison 2 Infected children ‐ Multiple dose, longest follow‐up, Outcome 7 Subscapular skin fold thickness (mm).1Mean Difference (IV, Fixed, 95% CI)Totals not selected

Comparison 3All children living in endemic area ‐ first doseOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 Weight (kg)](#CD000371-fig-00301){ref-type="fig"}Analysis 3.1Comparison 3 All children living in endemic area ‐ first dose, Outcome 1 Weight (kg).72719Mean Difference (IV, Fixed, 95% CI)‐0.04 \[‐0.11, 0.04\]1.1 High prevalence2290Mean Difference (IV, Fixed, 95% CI)0.02 \[‐0.15, 0.18\]1.2 Moderate prevalence2873Mean Difference (IV, Fixed, 95% CI)0.08 \[‐0.10, 0.27\]1.3 Low prevalence31556Mean Difference (IV, Fixed, 95% CI)‐0.09 \[‐0.19, 0.01\][2 Height (cm)](#CD000371-fig-00302){ref-type="fig"}Analysis 3.2Comparison 3 All children living in endemic area ‐ first dose, Outcome 2 Height (cm).51974Mean Difference (IV, Random, 95% CI)‐0.12 \[‐0.33, 0.10\]2.1 High prevalence1227Mean Difference (IV, Random, 95% CI)0.06 \[‐0.08, 0.20\]2.2 Moderate prevalence1191Mean Difference (IV, Random, 95% CI)‐0.20 \[‐0.47, 0.07\]2.3 Low prevalence31556Mean Difference (IV, Random, 95% CI)‐0.26 \[‐0.74, 0.21\][3 Mid‐upper arm circumference (cm)](#CD000371-fig-00303){ref-type="fig"}Analysis 3.3Comparison 3 All children living in endemic area ‐ first dose, Outcome 3 Mid‐upper arm circumference (cm).3911Mean Difference (IV, Random, 95% CI)0.04 \[‐0.19, 0.26\]3.1 High prevalence1207Mean Difference (IV, Random, 95% CI)0.09 \[‐0.03, 0.21\]3.2 Moderate prevalence1482Mean Difference (IV, Random, 95% CI)0.19 \[‐0.01, 0.40\]3.3 Low prevalence1222Mean Difference (IV, Random, 95% CI)‐0.3 \[‐0.52, ‐0.08\][4 Haemoglobin (g/dL)](#CD000371-fig-00304){ref-type="fig"}Analysis 3.4Comparison 3 All children living in endemic area ‐ first dose, Outcome 4 Haemoglobin (g/dL).31005Mean Difference (IV, Fixed, 95% CI)0.06 \[‐0.05, 0.17\]4.1 Moderate prevalence2658Mean Difference (IV, Fixed, 95% CI)0.06 \[‐0.06, 0.17\]4.2 Low prevalence1347Mean Difference (IV, Fixed, 95% CI)0.06 \[‐0.24, 0.36\]

Comparison 4All children living in endemic area ‐ Multiple dose, longest follow‐upOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 Weight (kg)](#CD000371-fig-00401){ref-type="fig"}Analysis 4.1Comparison 4 All children living in endemic area ‐ Multiple dose, longest follow‐up, Outcome 1 Weight (kg).102656Mean Difference (Random, 95% CI)0.08 \[‐0.11, 0.27\]1.1 High prevalence2306Mean Difference (Random, 95% CI)0.04 \[‐0.08, 0.16\]1.2 Moderate prevalence3859Mean Difference (Random, 95% CI)0.11 \[‐0.03, 0.25\]1.3 Low prevalence51491Mean Difference (Random, 95% CI)0.06 \[‐0.46, 0.57\][2 Height (cm)](#CD000371-fig-00402){ref-type="fig"}Analysis 4.2Comparison 4 All children living in endemic area ‐ Multiple dose, longest follow‐up, Outcome 2 Height (cm).71847Mean Difference (IV, Fixed, 95% CI)0.02 \[‐0.14, 0.17\]2.1 High prevalence1227Mean Difference (IV, Fixed, 95% CI)0.06 \[‐0.13, 0.25\]2.2 Moderate prevalence1129Mean Difference (IV, Fixed, 95% CI)0.10 \[‐0.46, 0.66\]2.3 Low prevalence51491Mean Difference (IV, Fixed, 95% CI)‐0.14 \[‐0.46, 0.18\][3 Mid‐upper arm circumference (cm)](#CD000371-fig-00403){ref-type="fig"}Analysis 4.3Comparison 4 All children living in endemic area ‐ Multiple dose, longest follow‐up, Outcome 3 Mid‐upper arm circumference (cm).3534Mean Difference (IV, Random, 95% CI)‐0.03 \[‐0.25, 0.18\]3.1 High prevalence1207Mean Difference (IV, Random, 95% CI)0.08 \[‐0.06, 0.22\]3.2 Moderate prevalence1129Mean Difference (IV, Random, 95% CI)0.06 \[‐0.22, 0.33\]3.3 Low prevalence1198Mean Difference (IV, Random, 95% CI)‐0.35 \[‐0.65, ‐0.05\][4 Triceps skin fold thickness (mm)](#CD000371-fig-00404){ref-type="fig"}Analysis 4.4Comparison 4 All children living in endemic area ‐ Multiple dose, longest follow‐up, Outcome 4 Triceps skin fold thickness (mm).1Mean Difference (IV, Random, 95% CI)Subtotals only4.1 Moderate prevalence1130Mean Difference (IV, Random, 95% CI)‐0.30 \[‐1.28, 0.68\][5 Haemoglobin (g/dL)](#CD000371-fig-00405){ref-type="fig"}Analysis 4.5Comparison 4 All children living in endemic area ‐ Multiple dose, longest follow‐up, Outcome 5 Haemoglobin (g/dL).73595Mean Difference (IV, Fixed, 95% CI)‐0.02 \[‐0.08, 0.04\]5.1 Moderate prevalence2464Mean Difference (IV, Fixed, 95% CI)0.02 \[‐0.15, 0.19\]5.2 Low prevalence53131Mean Difference (IV, Fixed, 95% CI)‐0.02 \[‐0.09, 0.04\][6 School attendance (days present at school)](#CD000371-fig-00406){ref-type="fig"}Analysis 4.6Comparison 4 All children living in endemic area ‐ Multiple dose, longest follow‐up, Outcome 6 School attendance (days present at school).2293Mean Difference (Random, 95% CI)0.02 \[‐0.04, 0.08\]6.1 High prevalence2293Mean Difference (Random, 95% CI)0.02 \[‐0.04, 0.08\]

Comparison 5All children living in endemic area ‐ Single dose (low risk of bias for allocation concealment)Outcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 Weight (kg)](#CD000371-fig-00501){ref-type="fig"}Analysis 5.1Comparison 5 All children living in endemic area ‐ Single dose (low risk of bias for allocation concealment), Outcome 1 Weight (kg).21029Mean Difference (IV, Fixed, 95% CI)0.04 \[‐0.11, 0.19\]1.1 Moderate prevalence1682Mean Difference (IV, Fixed, 95% CI)0.5 \[‐0.28, 1.28\]1.2 Low prevalence1347Mean Difference (IV, Fixed, 95% CI)0.02 \[‐0.13, 0.17\][2 Height (cm)](#CD000371-fig-00502){ref-type="fig"}Analysis 5.2Comparison 5 All children living in endemic area ‐ Single dose (low risk of bias for allocation concealment), Outcome 2 Height (cm).1Mean Difference (IV, Fixed, 95% CI)Totals not selected2.1 Low prevalence1Mean Difference (IV, Fixed, 95% CI)0.0 \[0.0, 0.0\][3 Mid‐upper arm circumference (cm)](#CD000371-fig-00503){ref-type="fig"}Analysis 5.3Comparison 5 All children living in endemic area ‐ Single dose (low risk of bias for allocation concealment), Outcome 3 Mid‐upper arm circumference (cm).1Mean Difference (IV, Fixed, 95% CI)Subtotals only3.1 Moderate prevalence1482Mean Difference (IV, Fixed, 95% CI)0.19 \[‐0.01, 0.40\][4 Haemoglobin (g/dL)](#CD000371-fig-00504){ref-type="fig"}Analysis 5.4Comparison 5 All children living in endemic area ‐ Single dose (low risk of bias for allocation concealment), Outcome 4 Haemoglobin (g/dL).2814Mean Difference (IV, Fixed, 95% CI)0.05 \[‐0.07, 0.17\]4.1 Moderate prevalence1467Mean Difference (IV, Fixed, 95% CI)0.05 \[‐0.08, 0.17\]4.2 Low prevalence1347Mean Difference (IV, Fixed, 95% CI)0.06 \[‐0.24, 0.36\]

Comparison 6All children living in endemic area ‐ Multiple dose (low risk of bias for allocation concealment), longest follow‐upOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 Weight (kg)](#CD000371-fig-00601){ref-type="fig"}Analysis 6.1Comparison 6 All children living in endemic area ‐ Multiple dose (low risk of bias for allocation concealment), longest follow‐up, Outcome 1 Weight (kg).2Mean Difference (Fixed, 95% CI)0.01 \[‐0.13, 0.15\]1.1 High prevalence1Mean Difference (Fixed, 95% CI)0.0 \[‐0.14, 0.14\]1.2 Moderate prevalence1Mean Difference (Fixed, 95% CI)0.5 \[‐0.42, 1.42\][2 Height (cm)](#CD000371-fig-00602){ref-type="fig"}Analysis 6.2Comparison 6 All children living in endemic area ‐ Multiple dose (low risk of bias for allocation concealment), longest follow‐up, Outcome 2 Height (cm).1Mean Difference (IV, Fixed, 95% CI)Totals not selected2.1 Low prevalence1Mean Difference (IV, Fixed, 95% CI)0.0 \[0.0, 0.0\][3 Haemoglobin (g/dL)](#CD000371-fig-00603){ref-type="fig"}Analysis 6.3Comparison 6 All children living in endemic area ‐ Multiple dose (low risk of bias for allocation concealment), longest follow‐up, Outcome 3 Haemoglobin (g/dL).1Mean Difference (IV, Fixed, 95% CI)Subtotals only3.1 Moderate prevalence1326Mean Difference (IV, Fixed, 95% CI)‐0.02 \[‐0.21, 0.16\]

Comparison 7All children living in endemic area ‐ All multiple ordered by yearOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 Weight (kg)](#CD000371-fig-00701){ref-type="fig"}Analysis 7.1Comparison 7 All children living in endemic area ‐ All multiple ordered by year, Outcome 1 Weight (kg).10Mean Difference (Random, 95% CI)0.09 \[‐0.10, 0.28\]

**DateEventDescription**13 January 2017Feedback has been incorporatedComments were received for this review in October 2016. The authors have responded to the queries in the appropriate section of this review. A full update of the review is pending.13 January 2017AmendedFeedback received and responded to.

Protocol first published: Issue 3, 1997 Review first published: Issue 2, 1998

**DateEventDescription**27 July 2015AmendedWe added an external source of support, the Evidence and Programme Guidance Unit, Department of Nutrition for Health and Development, World Health Organization (WHO), to the [Acknowledgements](#CD000371-sec1-0010){ref-type="ack"} and [Sources of support](#CD000371-sec1-0018){ref-type="sec"} sections.8 July 2015New citation required but conclusions have not changedA new search was conducted and new trials added. We also responded to feedback.26 February 2015New search has been performedWe added four new trials: two in the category children infected and two in an endemic area.The results from the [@CD000371-bbs2-0005] (DEVTA) trial were added.We used the replication ([@CD000371-bbs2-0089]) to correct the errors in the primary publication by [@CD000371-bbs2-0026]); and used the statistical replication ([@CD000371-bbs2-0107]) to inform risk of bias and interpretation.We took account of comments and criticisms from Miguel and Kremer in the analysis. This included a proposal to use single set of follow‐up outcomes. After performing new analyses in this review, we found that there was no evidence that the intervention effect varied with length of follow‐up, and therefore consolidated the analysis of (ie \< 1 year and \> 1 year) in the previous Cochrane Review ([@CD000371-bbs2-0152]) into one set.We changed the classification of [@CD000371-bbs2-0036] and [@CD000371-bbs2-0037]. Previously these trials were in the \"all children in an endemic area\" category, whereas now they are classified in the \"children with infection\". This decision was based on reviewing the trials with parasitologists and examining the prevalence and intensity of the infection where clearly the whole community was heavily infected.We noticed that the trial Adams 1994 was actually a sub‐trial of [@CD000371-bbs2-0037] and therefore merged with [@CD000371-bbs2-0037] (the full citation to Adams 1994 can be found in [@CD000371-bbs2-0037]). The total number of trials in the review has changed accordingly. The data previously contributed to the review by Adams 1994 has been removed, since more complete outcome data for the whole [@CD000371-bbs2-0037] trial is reported in the other articles.We adjusted the \'Summary of findings\' tables, review text, and conclusions in the light of these changes.10 October 2012New citation required but conclusions have not changedWe updated the \'Summary of findings\' tables, updated the abstract, and made minor corrections.10 October 2012New search has been performedIn September 2012, we identified a minor data entry error with a haemoglobin value, which we corrected.\
We also received feedback on the GRADE assessments. This led to changes in the assessment of the quality of the evidence for several outcomes. Most changes were towards higher quality evidence. We refined the table by adding additional footnotes to clarify the classification. The specific changes were:\
For single dose weight screened, GRADE moved from moderate to low;For single dose haemoglobin GRADE moved from low to moderate, after data entry corrected; and for formal tests, GRADE moved from very low to low;For multiple dose (\< 1 year), formal tests and schooling moved from very low to low, following upgrading of study quality;For multiple doses (\> 1 year), weight and haemoglobin moved from very low to low, following upgrading of study quality; and cognition moved from very low to low.\
We adjusted the wording in the abstract to take these changes into account.31 May 2012New search has been performedSubstantive update:\
We added a logic framework to the background.We replaced Awasthi 1995 (unpublished data) with the published data ([@CD000371-bbs2-0002]). We received clarification on methods and results from Miguel and Kremer and included this study in the review ([@CD000371-bbs2-0026]). Also, we tried to include the [@CD000371-bbs2-0005] completed in 2006 but were unable to as it remains unpublished as of May 2012.We added haemoglobin as a primary outcome and we added all trials measuring haemoglobin. We merged end values and change values to simplify the review. We reanalysed the school attendance data. In addition, we brought the sensitivity analysis in line with current best practice (by only including trials with evidence of allocation concealment).We added \'Summary of findings\' tables. We adjusted the wording in line with our policy of using standard words to correspond to quality of the evidence.In the light of these changes, we rewrote the review entirely.31 May 2012New citation required but conclusions have not changedWe updated the review and added new studies.7 May 2008AmendedThere are two alterations to the review:\
We have corrected an error in the discussion. The sentence that read \"There was a weight gain of 2.413 kg in the treatment parishes and 2.474 kg in the control parishes at an unspecified follow‐up point.\" now reads \"There was a weight gain of 2.413 kg in the treatment parishes and 2.259 kg in the control parishes at an unspecified follow‐up point.\"We have detailed our correspondence to date with Michael Kremer and Edward Miguel in the discussion.12 August 2007New citation required and conclusions have changed2007, Issue 4 (substantive update): author team changed; we modified the review title from the original title of \"Anthelmintic drugs for treating worms in children: effects on growth and cognitive performance\"; we updated methods, reapplied the inclusion criteria, repeated data extraction, added new trials, and included additional analyses as recommended by policy specialists.31 March 2000New citation required and conclusions have changed2000, Issue 2 (substantive update): we added new trials and updated the review.

Not applicable.

Characteristics of included studies \[ordered by study ID\] {#CD000371-sec2-0023}
===========================================================

[@CD000371-bbs2-0001]MethodsCluster‐RCT\
Method to adjust for clustering: Not adjusted\
Cluster unit: parish\
Average cluster size: 560\
ICCs: not reported but calculated from adjusted and unadjusted figures to be 0.01.\
Length of follow‐up: 3 yearsParticipantsAll children living in endemic area\
Number analysed for primary outcome: 48 parishes randomized containing 27,995 children\
Age range: 1 to 7 years\
Inclusion criteria: children aged 1 to 7 in 50 parishes in Uganda selected by the government on the basis that around 60% of children aged 5 to 10 years in these parishes were infected with intestinal nematodes\
Exclusion criteria: sick childrenInterventionsMultiple dose vs no treatment\
Albendazole: 400 mg tablet (Zentel, GSK) every 6 months, although in the event a year elapsed between the first and second treatment round; given in conjunction with a child health package including vaccinations, vitamin A, and health promotion;Child health package including vaccinations, vitamin A, and health promotion.OutcomesMean change in weight post‐treatment.NotesLocation: Uganda\
Community category: 2\
Weight gain data taking into account the effects of cluster randomization provided by the author.\
Source of funding: the nutrition and early child development project, government of Uganda, the Institute of Public Health and the research committee of the World Bank.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskCoin toss \"The randomization was done by a member of the research team (HA) by assigning numbers to all of the parishes and converting these to base two and then determining which of the parishes were to be in the treatment by coin flips\".Allocation concealment (selection bias)Unclear riskNo details reported.Blinding (performance bias and detection bias) All outcomesHigh riskNone. \"It was not possible for us to carry out a double blind trial because of the scale of the programme and because we aimed to assess the effectiveness of giving albendazole \[...\] during standard child health days without any trial specific inputs\".Incomplete outcome data (attrition bias) All outcomesHigh risk75% (27,995/37,165) of randomized participants were evaluated.Selective reporting (reporting bias)Low riskAll stated outcomes reported.Other biasLow riskRecruitment bias: low risk\
Baseline imbalance: characteristics similar (low risk)\
Loss of clusters: nil (low risk)\
Incorrect analysis: primary outcome in paper not adjusted for clustering (personal communication Harold Alderman), but Cochrane Review adjusts this (low risk)\
Comparability with RCTs randomizing individuals: unclear[@CD000371-bbs2-0002]MethodsCluster‐quasi‐RCT\
Method to adjust for clustering: cluster used as unit of analysis\
Cluster unit: urban slum\
Average cluster size: 74\
ICCs: not reported.\
Length of follow‐up: 2 yearsParticipantsAll children living in endemic area\
Number analysed for primary outcome: 50 slums randomized containing 3712 children\
Age range: 1 to 4 years\
Inclusion criteria: children aged 1 to 4 from 50 urban slums in Lucknow selected on the basis of geographic convenience\
Exclusion criteria: none statedInterventionsMultiple doses vs placebo\
Albendazole plus placebo: 400 mg albendazole plus 2 mL vitamin A every 6 months;Placebo: 2 mL vitamin A every 6 months.OutcomesMean change in weight post‐treatmentMean change in height post‐treatmentNotesLocation: Lucknow, India\
Community category: 3\
Trial carried out in 1995 and published in 2008.\
Source of funding: Clinical Trial Service Unit (CTSU), University of Oxford, United Kingdom, and co‐funded by the International Clinical Epidemiology Network Inc., Philadelphia, United States of America. Albendazole was donated by SmithKline Beecham (now GlaxoSmithKline).***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)High riskQuasi‐randomized: \"Random allocation was done by SA, listing the anganwadi centers of each slum area serially in alphabetical order, numbering them from 1 to 50, and then generating a single random number by computer that allocated either all odd or all even numbers to a specific intervention type\"Allocation concealment (selection bias)High riskNot concealed.Blinding (performance bias and detection bias) All outcomesHigh riskCluster‐RCT with health staff and participants knowing which group they were allocated to.Incomplete outcome data (attrition bias) All outcomesLow risk1852/1968 children in the treatment group completed all follow‐up visits; 1860/1967 children in the usual care group completed all follow‐up visits. Inclusion of all randomized participants (number evaluable/number randomized): 94% (3712/3935).Selective reporting (reporting bias)Low riskAll stated outcomes reported.Other biasLow riskRecruitment bias: unclear (Not known if children shift clinics in the light of the intervention)\
Baseline imbalance: unclear\
Loss of clusters: low (none reported)\
Incorrect analysis: cluster adjusted (low risk)\
Comparability with RCTs randomizing individuals: unclear[@CD000371-bbs2-0003]MethodsQuasi‐RCT\
Length of follow‐up: 2 yearsParticipantsAll children living in endemic area\
Number analysed for primary outcome: 1045\
Age range: 1.5 to 3.5 years\
Inclusion criteria: children living in 32 randomly selected urban slums; registered with an Anganwadi worker (health worker); between 1.5 to 3.5 years of age\
Exclusion criteria: none statedInterventionsMultiple doses vs placebo\
Albendazole powder: 600 mg every 6 months for 2 years;Placebo: calcium powderOutcomesMean weight post‐treatment;Mean change in weight post‐treatment;Mean height post‐treatment;Mean change in height post‐treatment;Developmental status (Denver Questionnaire): reported as proportion with normal development;Haemoglobin.\
Not included in review: prevalence of underweight and stunting over 2 years as defined by z‐scores, haemoglobin (visual colour estimation), stool examination (non‐concentration method), incidence of illness, and deathNotesLocation: Lucknow, India\
Community category: 3\
Source of funding: International Clinical Epidemiology Network (INCLEN), Philadelphia, USA grant \#2002‐94‐623 under the Clinical Economics Small Grants Program.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)High risk32 Anganwadi centres randomly selected, and then children allocated to a serial number; those with odd or non‐zero ending numbers were assigned to placebo.Allocation concealment (selection bias)High riskNot concealed.Blinding (performance bias and detection bias) All outcomesUnclear riskSingle blind.Incomplete outcome data (attrition bias) All outcomesLow risk9/610 children in the albendazole group and 7/451 in the placebo group were lost to follow‐up.\
Inclusion of all randomized participants (number evaluable/number randomized): 98% (1045/1061).Selective reporting (reporting bias)Low riskAll stated outcomes reported.Other biasLow riskNo other obvious source of bias.[@CD000371-bbs2-0004]MethodsCluster‐RCT\
Method to adjust for clustering: cluster used as unit of analysis.\
Cluster unit: urban slums\
Average cluster size: 13.5\
ICCs: not reported.\
Length of follow‐up: 1.5 yearsParticipantsAll children living in endemic area\
Number analysed for primary outcome: 124 slums randomized containing 1672 children\
Age range/ mean age: 0.8 years\
Inclusion criteria: clusters selected if they had functional community workers in slum areas of Lucknow; within each cluster, children recruited if aged between 0.5 and 1 year, on basis of survey register held by each worker of their particular area\
Exclusion criteria: none statedInterventionsMultiple doses vs placebo\
Albendazole plus placebo: albendazole suspension (concentration not stated) (Zentel, SZB) every 6 months and 100,000 units of vitamin A every 6 monthsPlacebo: 100,000 units of vitamin A every 6 monthsOutcomesMean weight post‐treatmentMean change in weight post‐treatmentMean height post‐treatmentMean change in height post‐treatment (not used due to question over quoted standard error)\
Not included in review: stool smear for *Ascaris* prevalence on a subsample of the group; death ratesNotesLocation: Lucknow, India\
Community category: 3\
Means of cluster means used in analysis. The results (weight gain) in the abstract differ from the text.\
Source of funding: International Clinical Epidemiological Network (INCLEN) Inc, USA and Clinical Trials Unit (CTSU), Oxford, UK.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskCluster‐randomized trial, no further details.Allocation concealment (selection bias)Unclear riskNo details reported.Blinding (performance bias and detection bias) All outcomesUnclear riskNo details reported.Incomplete outcome data (attrition bias) All outcomesLow riskIntention‐to‐treat (ITT) analysis; 13.9% lost to follow‐up in albendazole group and 16.2% in the placebo group. Inclusion of all randomized participants (number evaluable/number randomized): 83% (1672/2010).Selective reporting (reporting bias)Low riskAll stated outcomes reported.Other biasLow riskRecruitment bias: unclear (Not known if children shift clinics in the light of the intervention)\
Baseline imbalance: characteristics similar (low risk)\
Loss of clusters: no loss reported (low risk)\
Incorrect analysis: cluster adjusted (low risk)\
Comparability with RCTs randomizing individuals: low[@CD000371-bbs2-0005]MethodsCluster‐RCT\
Method to adjust for clustering: cluster used as unit of analysis (\'means of block‐specific numbers of deaths per AWC\')\
Cluster unit: a block of 10,000 to 20,000 children\
Average cluster size: 9259 approximately (under‐5 population 1 million/108 clusters).\
ICCs: not reported\
Length of follow‐up: 5 yearsParticipantsAll children living in endemic area\
Number analysed for primary outcome: total population of 1 million children at any one time, with a total of 2 million children ever in the trial\
Age range: 1 to 6 years\
Inclusion criteria: all preschool children then aged 1 to 6.0 years in 72 participating blocks near Lucknow that were considered to have a well‐functioning ICDS system with willing district and block directors and with paid workers in most of the block\'s anganwadi centres\
Exclusion criteria: severe anaemia (haemoglobin \< 75 g/L)InterventionsMultiple doses vs placebo\
Factorial design in four arms:\
Usual care -- no placebo;6‐monthly vitamin A \[for 5 years\];6‐monthly 400 mg albendazole;Both 6‐monthly vitamin A and 6‐monthly 400 mg albendazole.OutcomesMortality\
Not included in review: A subset of 5165 children were assessed for other outcomes (height, weight, BMI, haemoglobin, prevalence of illness in past 4 weeks)NotesLocation: Lucknow, India\
Community category: 3\
Annually about 30 non‐randomly selected preschool children were surveyed for growth, nutritional and morbidity outcomes from one randomly selected AWC per block (10,000 to 20,000 children in about 120 AWCs per block).\
Source of funding: UK Medical Research Council, USAID OMNI project, World  Bank. Albendazole (Zentel) was donated by SmithKlineBeecham.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear risk\"randomly allocated\"; \"Randomisation (in Oxford) was stratified in groups of 4 neighbouring blocks, where possible in the same district.\"Allocation concealment (selection bias)Unclear riskSee above.Blinding (performance bias and detection bias) All outcomesUnclear riskAll cause mortality is the outcome.Incomplete outcome data (attrition bias) All outcomesLow risk89 AWCs (2%) in the albendazole block lost to follow‐up, 86 AWCs (2%) in the placebo block lost to follow‐up. \"Loss to follow‐up is defined by having only 1‐6 follow‐up visits (mean only 3, as against 12 in the included AWCs), and was generally because the AWC had ceased to function.\" Inclusion of all randomized participants (number evaluable/number randomized): Denominator for mortality was all children. A subset of 5165 non‐randomly selected children were assessed for other outcomes.Selective reporting (reporting bias)Low riskMortality is the single outcome for this trial.Other biasLow riskRecruitment bias: unclear\
Baseline imbalance: unclear\
Loss of clusters: unclear\
Incorrect analysis: Cluster adjusted (low risk)\
Comparability with RCTs randomizing individuals: unclear[@CD000371-bbs2-0006]MethodsRCT\
Length of follow‐up: 4 monthsParticipantsAll children living in endemic area\
Number analysed for primary outcome: 853\
Age range/ mean age: 5 to 11 years\
Inclusion criteria: all children attending 5 schools (grades 1 to 4)\
Exclusion criteria: haematocrit \< 22%InterventionsSingle dose vs placebo\
Albendazole: 400 mg (SmithKlineBeecham, Philadelphia or generic BeltaPharm, Milan);Ivermectin: 200 to 400 µg/kg (mean 282.7 µg/kg) (Merck, West Point, PA);Albendazole plus ivermectin;Placebo: 250 mg vitamin C.OutcomesHeightWeightStool examination for helminth prevalence and intensity (geometric mean)HaematocritNotesLocation: Haiti\
Community category: 3\
Results presented in a stratified analysis as per individual infection: disaggregated results not presented; measures of error not given in tables.\
Source of funding: USAID. Invermectin provided by Philippe Gaxotte (Merck, Inc.) and albendazole by John Horton (SmithKline Beecham).***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskRandom number table.Allocation concealment (selection bias)Unclear riskNo details reported.Blinding (performance bias and detection bias) All outcomesLow riskParticipants, provider, and assessors were blind.Incomplete outcome data (attrition bias) All outcomesLow risk29/229 were lost to follow‐up in the placebo group and 25/244 were lost to follow‐up in the albendazole group. Inclusion of all randomized participants (number evaluable/number randomized): 88.4% (853/965).Selective reporting (reporting bias)Low riskAll stated outcomes reported.Other biasLow riskNo other obvious source of bias.[@CD000371-bbs2-0007]MethodsRCT\
Length of follow‐up: 1 yearParticipantsAll children living in endemic area\
Number analysed for primary outcome: 222\
Age range: 0 to 72 months\
Inclusion criteria: children aged 0 to 72 months eligible on discharge from hospital where primary cause for admission is malnutrition\
Exclusion criteria: none statedInterventionsMultiple doses vs placebo and no treatment\
Mebendazole: 500 mg at start and every 3 months;Placebo: 60 mg vitamin A at start and 3 months;No treatment.OutcomesMean weight post‐treatment;Mean change in weight post‐treatment;Mean height post‐treatment;Mean change in height post‐treatment;Mean MUAC;Mean change in MUAC.\
Not included in review: vitamin A levels; z‐scores for height‐for‐age, weight‐for‐age, weight‐for‐height (NCHS reference); egg counts (eggs/g: Kato Katz method).NotesLocation: Zaire\
Community category: 3\
Unadjusted data not provided in original paper; results of multiple‐regression models presented on basis of stratifications into vitamin A status and sex; results in meta‐analysis from R Dickson\'s correspondence with author when preparing the [@CD000371-bbs2-0149] Cochrane Review.\
Source of funding: Fonds de la Recherche Scientifique et Medicale (FRSM), contract 3.4505.94 and the David and Alice Van Buuren Foundation.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear risk\"randomized\". No further details reported.Allocation concealment (selection bias)Unclear riskNo details reported.Blinding (performance bias and detection bias) All outcomesUnclear riskNo details reported.Incomplete outcome data (attrition bias) All outcomesLow riskOverall, 6% of children were lost to follow‐up, with approximately equal proportions from each group. During the follow‐up period, 25 children died. The final sample included 311 children Inclusion of all randomized participants (number evaluable/number randomized): 86% (311/358).Selective reporting (reporting bias)Low riskAll stated outcomes reported.Other biasLow riskNo other obvious source of bias.[@CD000371-bbs2-0008]MethodsRCT\
Length of follow‐up: 10 monthsParticipantsAll children living in endemic area\
Number analysed for primary outcome: 65\
Age range: 3 to 5 years\
Inclusion criteria: children aged 3 to 5 years; not acutely unwell\
Exclusion criteria: none statedInterventionsMultiple doses vs placebo:\
Albendazole plus iron: 200 mg albendazole per day for 3 consecutive days repeated 1 month later plus iron;Placebo plus iron;Albendazole: 200 mg per day for 3 consecutive days repeated 1 month later plus iron placebo;Placebo plus placebo.OutcomesMean change in weight post‐treatment;Mean change in height post‐treatment;Mean change in MUAC;Mean change in triceps skinfold thickness;Mean haemoglobin post‐treatment.\
Not included in review: weight‐for‐height z‐score and height‐for‐age z‐score at 3 and 10 months (both after 2 doses).\
Measured but not reported: z‐scores for weight‐for‐height, height for age using NCHS reference data; egg count (arithmetic and geometric mean); prevalence, intensity; food intake over 3 days in subset at end of trial (not at baseline).NotesLocation: Benin\
Community category: 2\
Source of funding: The Nestle Foundation (Lausanne, Switzerland).Smithkline Beecham provided the deworming and placebo tablets.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear risk\"Randomly assigned\". No further details provided.Allocation concealment (selection bias)Unclear riskNo details reported.Blinding (performance bias and detection bias) All outcomesUnclear risk\"Double‐blind\". No further details provided.Incomplete outcome data (attrition bias) All outcomesHigh risk175/177 children finished the trial, but 140 were included in the final analysis: "One child was treated for severe worm infection and 34 children received other pills during the trial period (iron, vitamins/minerals or deworming pills that were not provided by our research team)." Inclusion of all randomized participants (number evaluable/number randomized): 79% (140/177).Selective reporting (reporting bias)Low riskAll stated outcomes reported.Other biasHigh riskNo obvious other source of bias.[@CD000371-bbs2-0009]MethodsRCT\
Length of follow‐up: 6 monthsParticipantsAll children living in endemic area\
Number analysed for primary outcome: 626\
Age range: 5 to 11 years\
Inclusion criteria: children aged 5 to 11 years attending any of 12 primary schools in Haiti where no other deworming activity was taking place\
Exclusion criteria: none statedInterventionsSingle dose vs placebo\
Albendazole 400 mg plus placebo (250 mg vitamin C tablet);6 mg/kg diethylcarbamazine (DEC) plus placebo (250 mg vitamin C tablet);Albendazole 400 mg plus single dose of 6 mg/kg diethylcarbamazine (DEC);Placebo plus placebo (2 x 250 mg vitamin C tablets).OutcomesWeight: final and change in weight;Height: final and change in height;Adverse effects.\
Not included in review: worm intensity and prevalence; microfilarial density.NotesLocation: Haiti\
Community category: 2\
Weight and height outcomes are only presented for a subgroup of children infected with *Trichuris*\
Source of funding: Emerging Infections Program of the Centers for Disease Control and Prevention (CDC) and an Institutional Strengthening Grant from the WHO to the Hopital Sainte Croix.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskRandom‐number table.\
 Allocation concealment (selection bias)Low riskCentrally‐coded allocation system broken after baseline measures taken.\
 Blinding (performance bias and detection bias) All outcomesLow risk\"Double‐blind\". Laboratory personnel, measurement teams and personnel evaluating students for adverse reactions were all blinded.\
 Incomplete outcome data (attrition bias) All outcomesLow risk626/646 participants analysed for the primary outcome. Reasons for loss to follow‐up unclear.\
Inclusion of all randomized participants (number evaluable/number randomized): 97% (626/646).Selective reporting (reporting bias)Low riskAll stated outcomes reported.Other biasLow riskNo obvious other source of bias.[@CD000371-bbs2-0010]MethodsQuasi‐RCT\
Length of follow‐up: 28 daysParticipantsInfected children identified by screening\
Number analysed for primary outcome: 13\
Age range: 1.5 to 5 years\
Inclusion criteria: boys attending mother and child clinic with *Ascaris* on stool smear; aged 1.5 to 5 years with no history of diarrhoea for preceding 2 weeks; no fever; no respiratory symptoms; no signs of severe disease\
Exclusion criteria: children diagnosed with other parasites; excluded girls to eliminate the contamination of samples with urineInterventionsSingle dose vs placebo\
Piperazine: 3 g single dose;Placebo syrup: single dose.OutcomesWeight;MUAC;Triceps skinfold thickness.\
Not included in review: *Ascaris* worm countNotesLocation: Ethiopia\
Community category: N/A\
The trial authors mention that boys were matched in pairs so that if there were drop outs they could be replaced. They do not indicate if there were any drop outs. SDs calculated from individual data.\
[@CD000371-bbs2-0010] and [@CD000371-bbs2-0010]i were reported in the same article.\
Source of funding: Semper Nutrition Fund, Stockholm; Swedish Medical Research Council.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)High riskQuasi‐RCT: boys matched into pairs of equal age and nutritional status.Allocation concealment (selection bias)Unclear riskNo details reported.Blinding (performance bias and detection bias) All outcomesUnclear riskDescribed as double blind, no further details reported.Incomplete outcome data (attrition bias) All outcomesUnclear risk100% (13/13) of enrolled participants were evaluated. The authors mention that boys were matched in pairs so that if there were drop outs they could be replaced. They do not indicate if there were any drop outs. Inclusion of all randomized participants (number evaluable/number randomized): 100% (13/13).Selective reporting (reporting bias)Low riskAuthors had intended to measure bicep and tricep skinfolds, but staff were unable to take these measurements.Other biasLow riskNo obvious other source of bias.[@CD000371-bbs2-0011]MethodsQuasi‐RCT\
Length of follow‐up: 34 daysParticipantsInfected children identified by screening\
Number analysed for primary outcome: 44\
Age range: 1 to 5 years\
Inclusion criteria: 92 children 1 to 5 years from a community morbidity trial\
Exclusion criteria: none statedInterventionsSingle dose vs placebo\
Piperazine: 3 g/day for 2 days;Placebo: for 2 days.OutcomesMUAC;Morbidity.\
Not included in review: weight in % of Harvard standard; authors had intended to measure bicep and tricep skinfolds, but staff were unable to take these measurementsNotesLocation: Ethiopia\
Community category: 3\
[@CD000371-bbs2-0010] and [@CD000371-bbs2-0010]i were reported in the same article.\
Source of funding: Semper Nutrition Fund, Stockholm; Swedish Medical Research Council.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)High riskQuasi‐RCT: children matched into pairs of equal age and nutritional status.Allocation concealment (selection bias)Unclear riskNo details reported.Blinding (performance bias and detection bias) All outcomesUnclear riskDescribed as double blind, no further details reported.Incomplete outcome data (attrition bias) All outcomesLow risk100% (44/44) of enrolled participants were evaluated. Inclusion of all randomized participants (number evaluable/number randomized): 100% (44/44).Selective reporting (reporting bias)Low riskTrial authors had intended to measure bicep and tricep skinfolds, but staff were unable to take these measurements.Other biasLow riskNo obvious other source of bias.[@CD000371-bbs2-0012]MethodsRCT\
Length of follow‐up: 6 monthsParticipantsAll children living in endemic area\
Number analysed for primary outcome: 347\
Age range: 2 to 4 years\
Inclusion criteria: sick children 2 to 4 years old presenting to 3 government health centres in Bungamo district, without palmar pallor\
Exclusion criteria: children with palmar pallorInterventionsSingle dose vs placebo\
Mebendazole: 500 mg (Vermox, Janssen, Belgium);Placebo: sucrose starch capsule.OutcomesMean weight post‐treatment;Mean change in weight post‐treatment;Mean height post‐treatment;Mean change in height post‐treatment;Mean haemoglobin post‐treatment;Mean change in haemoglobin post‐treatment.\
Not included in review: z‐scores for weight‐for‐age, height‐for‐age, and weight‐for‐height; egg count (formol‐ethyl acetate concentration method) in categories of intensity.NotesLocation: Kenya\
Community category: 3\
Source of funding: the CDC, Atlanta, USA.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskComputer‐generated list of random numbers.Allocation concealment (selection bias)Low riskDrugs kept in envelope until after baseline assessment.Blinding (performance bias and detection bias) All outcomesHigh risk\"the trial was not double‐blinded\". Assessors were blinded; participants unclear; provider not blinded.Incomplete outcome data (attrition bias) All outcomesLow risk93% (347/370) of randomized participants were evaluated, loss to follow‐up balanced across groups. Inclusion of all randomized participants (number evaluable/number randomized): 93% (347/370).Selective reporting (reporting bias)Low riskAll stated outcomes included.Other biasLow riskNo obvious other source of bias.[@CD000371-bbs2-0013]MethodsRCT\
Length of follow‐up: 36 weeksParticipantsAll children living in endemic area\
Number analysed for primary outcome: 410\
Age range: 0 to 11 months\
Inclusion criteria: infants under 11 months of age in the local area\
Exclusion criteria: not statedInterventionsMultiple doses vs placebo\
Anti‐*Giardia* (secnidazole every 4 weeks) and anthelminthic (albendazole every 12 weeks);Anti‐*Giardia* treatment only (secnidazole every 4 weeks) and placebo;Placebo and placebo.\
Secnidazole: a 70 mg/mL suspension with about 0.5 g of sweetener was made up, and 0.5 mL per kg body weight was given by spoon. If the infant was sick immediately, secnidazole was re‐administrated.\
Albendazole: a 200 mg (5 mL) suspension given by spoon.OutcomesHaemoglobin (g/L) (endpoint week 36).\
Not included in review:\
Height‐for‐age z‐score (endpoint week 36);Weight‐for‐age z‐score (endpoint week 36);Weight‐for‐height z‐score (endpoint week 36);Plasma albumin (g/L) (endpoint week 36);IgG (g/L) (endpoint week 36);Alpha‐1‐acid glycoprotein (g/L) (endpoint week 36);*Giardia*‐specific IgM titre (endpoint week 36);Lactulose/mannitol ratio (endpoint week 36);Prevalence of*Giardia*‐specific IgM titre, *%* (week 0, 12, 24, 36);Prevalence of *Giardia* cysts, *%* (week 0, 12, 24, 36);Prevalence of *Ascaris/Trichuris, %* (week 0, 12, 24, 36);Prevalence of Intestinal mucosal damage, *%* (week 0, 12, 24, 36);Prevalence *of* Anaemia,*%* (week 0, 12, 24, 36).NotesLocation: Dhamrai Upazila, located 40 km northwest of Dhaka, Bangladesh.\
Community category: 3. \"Prevalences and intensities of geohelminths were consistently low throughout the intervention\".\
Drug source: Dhaka, Bangladesh (Essential Drugs Company Ltd for secnidazole; Square Pharmaceuticals Ltd for the secnidazole placebo; Opsonin Chemical Industries Ltd for albendazole; and UniMed and UniHealthManufacturing Ltd for albendazole placebo).***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskComputer generated.\
Randomized on the basis of their age, sex, height‐for‐age, weight‐for‐age and weight‐for‐height z‐scores, socio‐demographic and economic data and presence of any parasitic infection.Allocation concealment (selection bias)Unclear riskUnclear whether the allocation was concealed since patients were randomized by their characteristics.Blinding (performance bias and detection bias) All outcomesLow riskDouble‐blind.\
\"Bottles containing the two medications and placebo suspensions were labelled with different colours corresponding to the three intervention groups, but the assistants did not know the relationship between the colour codings and the contents of the bottles.\"Incomplete outcome data (attrition bias) All outcomesLow risk394/410 (96.10%) of randomized participants were evaluated.\
\"A total of 16 infants were excluded from the trial, as they had either moved away from the trial area (*n* = 12), or were absent during the trial period (*n* = 2) or the parents subsequently refused to participate (*n* = 2). Of the infants who completed the trial (*n* = 394), data on 96 infants was incomplete (ie they did not provide information for all the ten z‐scores and four intestinal permeabilities, serological variables and prevalences of parasite infections), and severe anaemic infants were also omitted from the trial\". Inclusion of all randomized participants (number evaluable/number randomized): 96% (394/410).Selective reporting (reporting bias)Low riskAll stated outcomes reported.Other biasLow riskNo obvious other source of bias.[@CD000371-bbs2-0014]MethodsRCT\
Length of follow‐up: 11 monthsParticipantsAll children living in endemic area\
Number analysed for primary outcome: 152 aged 1.5 to 8 years\
Age range: 1.5 to 8 years\
Inclusion criteria: children aged 1.5 to 8 years living in Nandipara, Bangladesh; 50% entered into trial; only those who provided stool sample and had anthropometric measurements taken at first visit entered\
Exclusion criteria: none statedInterventionsSingle dose vs placebo\
Piperazine citrate: 80 mg/kg added to flavoured syrup; 2 doses in 2‐week period;Placebo: syrup only.OutcomesCure rates;Reinfection rates;Weight‐for‐height;Height‐for‐age (NCHS reference);Weight‐for‐age (graphically);Other measured parameters not reported: weight; height; triceps skinfold thickness; MUAC; chest circumference; abdominal girth; egg counts (Dunn\'s method); prevalence; triceps skinfold for age; MUAC for age (Tanner reference charts).NotesLocation: Bangladesh\
Community category: 1\
Groups stratified by intensity of *Ascaris* infection\
Source of funding not reported.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear risk\"Randomly assigned\", no further details provided.Allocation concealment (selection bias)Unclear riskNo details reported.Blinding (performance bias and detection bias) All outcomesUnclear risk\"Double‐blind\". Participants blinded both placebo and treatment given as a flavoured syrup, no information about provider and assessor blinding.Incomplete outcome data (attrition bias) All outcomesLow risk82% (152/185) of randomized participants were evaluated. Reasons for leaving the trial early not reported. Inclusion of all randomized participants (number evaluable/number randomized): 82% (152/185).Selective reporting (reporting bias)High riskNot all stated outcomes reported.Other biasLow riskNo obvious other source of bias.[@CD000371-bbs2-0015]MethodsQuasi‐RCT\
Length of follow‐up: 1.75 months (7 weeks)ParticipantsAll children living in endemic area\
Number analysed for primary outcome: 64\
Age range: 6 to 10 years\
Inclusion criteria: boys aged 6 to 10 years attending second grade at 3 primary schools; completed assessment and provided a stool sample; randomized by descending hookworm count (all treated)\
Exclusion criteria: none statedInterventionsSingle dose vs placebo\
Pyrantel pamoate: 10 mg/kg;Placebo.OutcomesMean weight post‐treatment;Appetite: consumption test (mL porridge) and self assessment.\
Not included in review: egg counts arithmetic and geometric means (Kato‐Katz); weight‐for‐age (NCHS reference)NotesLocation: Indonesia\
Community category: 1\
Large drops in geometric mean egg counts in placebo noted\
Source of funding not reported.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskRandomized: \"Randomly assigned\" by descending *A. lubricoides* egg count\"Allocation concealment (selection bias)Unclear riskNo details reported.Blinding (performance bias and detection bias) All outcomesUnclear risk\"Double‐blind\". Participants blinded both placebo and treatment identical round white tablets, no information about provider and assessor blinding.Incomplete outcome data (attrition bias) All outcomesLow risk85% (64/75) of randomized participants were evaluated. Reasons for loss to follow‐up included: moved away, refused to be examined, did not return a stool sample, absent during examination. Not clear how many lost from each treatment group. Inclusion of all randomized participants (number evaluable/number randomized): 85% (64/75).Selective reporting (reporting bias)Low riskAll stated outcomes reported.Other biasLow riskNo obvious other source of bias.[@CD000371-bbs2-0016]MethodsRCT\
Length of follow‐up: 12 monthsParticipantsAll children living in endemic area\
Number analysed for primary outcome: 330; mean age 8.3 years\
Inclusion criteria: all primary school children in grades 1, 2, and 3 in 2 schools in slum areas in Indonesia; randomized according to *Ascaris* egg count and age\
Exclusion criteria: children \> 11; signs of puberty; signs of severe protein energy malnutritionInterventionsMultiple doses vs placebo\
Pyrantel pamoate: 10 mg/kg;Pyrantel pamoate: 10 mg/kg repeated at 6 months;Albendazole: 400 mg;Albendazole: 400 mg repeated at 6 months;Placebo.OutcomesStool (Kato‐Katz) prevalence and intensity;Weight;Height;MUAC;z‐scores: weight‐for‐age, height for age, weight‐for‐height, and MUAC.\
Results of multivariate analysis using z‐scores presented and could not be used in meta‐analysis; unadjusted results not reportedNotesLocation: Indonesia\
Community category: 1\
Placebo group showed an unexplained drop in egg counts at the 3‐month exam\
Source of funding: Directorate of Higher Education, Department of Education and Culture, Government of Indonesia through Hibah Bersaing Project I & II**.** Albendazole and placebo provided by Smithkline Beecham Pharmaceuticals Indonesia. ***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskRandomly assigned \"by sex and egg count\".Allocation concealment (selection bias)Unclear riskNo details reported.Blinding (performance bias and detection bias) All outcomesUnclear riskNo details reported.Incomplete outcome data (attrition bias) All outcomesHigh risk65% (330/507) of randomized participants were evaluated, number lost from each treatment group not reported. Inclusion of all randomized participants (number evaluable/number randomized): 65% (330/507).Selective reporting (reporting bias)Low riskAll stated outcomes reported.Other biasLow riskNo obvious other source of bias.[@CD000371-bbs2-0017]MethodsCluster‐RCT\
Method to adjust for clustering: not adjusted (review authors adjusted using the ICC from Alderman 2006)\
Cluster unit: school\
Average cluster size: 33\
ICCs: not reported\
Length of follow‐up: 2 yearsParticipantsAll children living in endemic area\
Number analysed for primary outcome: 80 schools randomized containing 2659 children in class 3\
Mean age: 104.5 months\
Inclusion criteria: children from class 3 and born in 1990 of 80/81 schools in the Red River delta of north Vietnam\
Exclusion criteria: none statedInterventionsMultiple doses vs placebo\
Albendazole (GlaxoSmithKline): 400 mg every 6 months and 200,000 IU retinol after first 6 months only;Retinol: 200,000 IU after first 6 months followed by inert placebo every 6 months.OutcomesMeasured:\
Hookworm, *Trichuris*, and *Ascaris* prevalence;Eggs/g faeces;Weight and height;Mathematics test score, Vietnamese test score.NotesLocation: Vietnam\
Community category: 1\
It is unclear what is meant by \"randomization was adjusted so that there were equal numbers of schools in each district of the trial group\". It is also appears as if the analysis has not taken into account the effects of cluster randomization.\
Source of funding not reported.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear risk\"randomization was adjusted so that there were equal numbers of schools in each district of the trial group\" (unclear what this means)Allocation concealment (selection bias)Low riskCentral allocation. \"\...using a list provided by the Ministry of Education\".Blinding (performance bias and detection bias) All outcomesUnclear riskPlacebo was used, blinding not reported.Incomplete outcome data (attrition bias) All outcomesUnclear riskInsufficient reporting of attrition/exclusions. 80 schools containing 56,444 pupils randomized, and those from class 3 used in trial. Inclusion of all randomized participants (number evaluable/number randomized): unclear; 80 schools containing 56,444 pupils randomized, and those from class 3 used in trial.Selective reporting (reporting bias)Low riskAll stated outcomes reported.Other biasLow riskAlthough not adjusted for clustering, we used estimates to adjust in the review.\
Recruitment bias: low (schools)\
Baseline imbalance: low (characteristics similar)\
Loss of clusters: low (no loss reported)\
Incorrect analysis: not cluster adjusted (high risk)\
Comparability with RCTs randomizing individuals: unclear[@CD000371-bbs2-0018]MethodsRCT\
Length of follow‐up: 14 monthsParticipantsAll children living in endemic area Number analysed for primary outcome: 320\
Age range: 12 to 59 months\
Inclusion criteria: pre‐school children aged 12 to 59 months, either sex\
Exclusion criteria: severe anaemia \< 5 g/dL, severe malariaInterventionsMultiple doses vs placebo\
Albendazole;Placebo.\
Treatment strategy: 200 mg (one tablet) albendazole was given to children aged 1 year, 400 mg (two tablets) albendazole was given to children aged 2, 3, and 4 years. Children who were in the placebo group were given one or two (1 year) placebo (2 to 4 years) tablets. Treatment or placebo was given at baseline, 4, 8, and 12 months and then followed up for the last time at 14 months. Children in the placebo group were treated with albendazole at 14 months.OutcomesHaemoglobin, measured at baseline and 4, 8, 12, and 14 months.\
Unable to use: nutritional status and anthropometric measures, at baseline and 14 months, no data was reported for these outcomes.\
Not included in review: infection with STHs, measured at baseline and 4, 8, 12, and 14 months (eggs or worms in stool sample). Incidence of malaria and malaria attacks, measured at baseline and 4, 8, 12, and 14 months. Adverse events not fully reported for albendazole treatment vs placebo.NotesLocation: 4 semi‐urban villages, Osun State, Nigeria\
Community category: 3\
No adverse events reported in the albendazole treatment group. Not reported for control group.\
Source of funding: Health Research Board (HRB) (Ireland). GlaxoSmithKline sponsored the drug albendazole which was used in the trial.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)High riskQuasi‐randomized, \"During the first assessment each alternate child was assigned tablet B\".Allocation concealment (selection bias)High riskAlternation, one of the investigators \"placed the albendazole and placebo tablets in containers labelled either A or B\" later \"The treatment coordinator \[\...\] oversaw the allocation of treatments to the children\".Blinding (performance bias and detection bias) All outcomesLow riskParticipants and key personnel were blinded. \"Experienced physicians \[...\] enrolled all participants, measured all trial endpoints, and were kept masked to treatment allocation of children. Field workers involved in data collection and mothers of participating children were also masked to the treatment allocation.\" \"Albendazole and placebo tablets were identical\".Incomplete outcome data (attrition bias) All outcomesHigh risk320 children (out of 1228, 26.1%) complied with all the follow‐up assessments and were included in the analyses. Inclusion of all randomized participants (number evaluable/number randomized): 26% (320/1228).Selective reporting (reporting bias)High riskNutritional status and anthropometric measures not reported. Main paper states these outcomes are reported in the companion paper; no data reported for these outcomes in the companion paper.Other biasLow riskNo obvious other source of bias.[@CD000371-bbs2-0019]MethodsRCT\
Length of follow‐up: 10 monthsParticipantsAll children living in endemic area\
Number analysed for primary outcome: 337; unclear how many randomized\
Age range: 1 to 8 years old\
Inclusion criteria: enlisted from 9 rural communities in Pariquera‐Acu state of Sao Paulo\
Exclusion criteria: none statedInterventionsSingle dose vs placebo\
Mebendazole: 100 mg twice per day for 3 days;Placebo.OutcomesWeight;Height;Head, chest, and mid‐arm circumference;Triceps skinfold;Stool egg counts (Kato‐Katz).NotesLocation: Cameroon\
Community category: 1\
Results reported as changes in nutritional status grouped into 3 categories: improved, deteriorated, no change (unclear on basis of which parameter), and proportions compared\
Source of funding: Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP).***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear risk\"Randomized\", no further details provided.Allocation concealment (selection bias)Unclear riskNo details reported.Blinding (performance bias and detection bias) All outcomesUnclear riskDescribed as double blind, no details reported.Incomplete outcome data (attrition bias) All outcomesUnclear riskNo details about losses to follow‐up reported; \"the present report only deals with those 337 that could be followed throughout the entire 10 months\". Inclusion of all randomized participants (number evaluable/number randomized): unclear (337 analysed).Selective reporting (reporting bias)Low riskAll stated outcomes reported.Other biasLow riskNo obvious other sources of bias.[@CD000371-bbs2-0020]MethodsRCT\
Length of follow‐up: 6 monthsParticipantsAll children living in endemic area\
Number analysed for primary outcome: 187\
Age range: 6 to 10 years\
Inclusion criteria: selected (unclear how) urban and rural school primary children aged 6 to 10 years\
Exclusion criteria: not statedInterventionsSingle dose vs placebo\
Albendazole: 400 mg;Placebo.OutcomesPrevalence and intensity (arithmetic mean eggs/g);z‐scores (no reference category stated): weight‐for‐height, weight‐for‐age, and height‐for‐age.NotesLocation: Sierra Leone\
Community category: 2\
Source of funding: Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP).***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear risk\"Randomized\", no further details provided.Allocation concealment (selection bias)Unclear riskNo details reported.Blinding (performance bias and detection bias) All outcomesUnclear riskNo details reported.Incomplete outcome data (attrition bias) All outcomesHigh risk76% (187/247) of randomized participants were evaluated. Reasons for loss to follow‐up not reported. Inclusion of all randomized participants (number evaluable/number randomized): 76% (187/247).Selective reporting (reporting bias)Low riskAll stated outcomes reported.Other biasLow riskNo obvious other sources of bias.[@CD000371-bbs2-0021]MethodsRCT\
Length of follow‐up: 11 monthsParticipantsAll children living in endemic area\
Number analysed for primary outcome: 74\
Age range: 6 to 8 years\
Inclusion criteria: 65 pupils in first year of school randomly selected from each of 5 primary schools; schools included in a feeding scheme\
Exclusion criteria: age \> 9 years; current use of iron supplements; inclusion in an iron fortification trial; infection (raised white cell count)InterventionsMultiple doses vs placebo\
Albendazole: 2 x 200 mg repeated at 4 months, daily unfortified soup;Placebo: daily unfortified soup.\
Also: whole population 3/5 schools also allocated soup fortified with 20 mg elemental iron per day, and 100 mg vitamin C for 6 months; unclear whether this intervention was cluster randomized. All schools taking part in feeding programme providing bread, soup, and peanut butter to all pupils.OutcomesMean change in weight post‐treatment;Mean change in height post‐treatment;Mean change in haemoglobin post‐treatment;School attendance.\
Not included in review: other iron indices; stool egg counts (Visser filter method); z‐scores for weight‐for‐age, height for age, and weight‐for‐height.NotesLocation: South Africa\
Community category: 3\
In the [@CD000371-bbs2-0149] Cochrane Review, the data were combined irrespective of the possible confounding effects of iron allocation; data extracted for albendazole‐iron placebo vs placebo‐placebo groups only for this review.\
Data stratified by baseline iron stores into 2 groups that were combined for meta‐analysis.\
Source of funding: Fortified and unfortified soup provided by Funa Foods, Zentel and placebo provided by SmithKline Beecham Pharmaceuticals (Pty) Ltd.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear risk\"Randomly assigned\", no further details provided.Allocation concealment (selection bias)Unclear riskNo details reported.Blinding (performance bias and detection bias) All outcomesUnclear riskNo details reported.Incomplete outcome data (attrition bias) All outcomesHigh risk72% (179/247) of randomized participants were evaluated. Reasons for loss to follow‐up not reported. Inclusion of all randomized participants (number evaluable/number randomized): 72% (179/247).Selective reporting (reporting bias)Low riskAll stated outcomes reported.Other biasLow riskNo obvious other source of bias.[@CD000371-bbs2-0022]MethodsRCT\
Length of follow‐up: 1 monthParticipantsInfected children identified by screening\
Number analysed for primary outcome: unclear\
Age range: unclear\
Inclusion criteria: most severely infected 100 children in a primary school\
Exclusion criteria: children with schistosomiasisInterventionsSingle dose vs placebo\
Mebendazole: 500 mg;Placebo.OutcomesCognition tests: card sorting task (coloured cards; cancellation task ‐ striking out of letter \'s\' in text, number done in a period)\
Not included in review: height; weight at baseline; standardized using NCHS standards; stool examination (intensity index designed for this trial); no nutritional outcomes reported that can be used in the reviewNotesLocation: South Africa\
Community category: 1\
No data used in meta‐analysis since SDs not provided.\
Source of funding: Janssen Pharmaceutica, South African Medical Research Council.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear risk\"Assigned randomly\", no further details provided.Allocation concealment (selection bias)Unclear riskNo details reported.Blinding (performance bias and detection bias) All outcomesUnclear risk\"A \'blind\' procedure was adopted; the research assistant did not know whether a particular child had received drug or placebo\". No further details provided.Incomplete outcome data (attrition bias) All outcomesUnclear riskNo details reported. Inclusion of all randomized participants (number evaluable/number randomized): unclear.Selective reporting (reporting bias)Low riskAll stated outcomes reported.Other biasLow riskNo obvious other source of bias.[@CD000371-bbs2-0023]MethodsQuasi‐RCT\
Length of follow‐up: 2 yearsParticipantsAll children living in endemic area\
Number analysed for primary outcome: 314\
Mean age: 8 years\
Inclusion criteria: school children aged 8 who provided a stool sample\
Exclusion criteria: concurrent illness; anthelminth treatment in previous 3 monthsInterventionsMultiple doses vs placebo\
Mebendazole plus pyrantel: 100 mg mebendazole and 200 mg pyrantel every 3 months for 2 years;Placebo: every 3 months for 2 years.OutcomesMeasured:\
Hookworm, *Trichuris*, and *Ascaris* prevalence;Eggs/g faeces;Weight and height.NotesLocation: Malaysia\
Community category: 1\
No data used in meta‐analysis since SDs not provided\
Source of funding not reported.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)High riskQuasi‐randomized: block assignment design by school, then by sex, then by presence of worms as none, light, or moderate/heavy, and then by rank order of body weight in the group; used odd and even numbers; in urban area the odd numbered children were assigned to treatment; in the peri‐urban area the even numbered children were assigned to the treatment group.Allocation concealment (selection bias)Unclear riskNo details reported.Blinding (performance bias and detection bias) All outcomesHigh riskParticipants were blinded; trial staff not blinded to group assignment.Incomplete outcome data (attrition bias) All outcomesLow risk89% (314/353) of randomized participants were evaluated.\
Inclusion of all randomized participants (number evaluable/number randomized): 89% (314/353).Selective reporting (reporting bias)Low riskAll stated outcomes reported.Other biasLow riskNo obvious other sources of bias.[@CD000371-bbs2-0024]MethodsRCT\
Length of follow‐up: 6 monthsParticipantsAll children living in endemic area (children screened for anaemia then randomized and all children treated)\
Number analysed for primary outcome: 510 randomized\
Mean age: ˜7.3 years\
Inclusion criteria: children in Grades 1 to 3 with haemoglobin \< 110 g/L but not \< 70 g/L\
Exclusion criteria: haemoglobin concentrations \< 70 g/LInterventionsMultiple dose vs placebo\
Factorial design\
Mebendazole 500 mg at 0 and 3 months\
Iron‐fortified noodles and mebendazole 500 mg;Noodles without iron fortificant and mebendazole 500 mg;Iron‐fortified noodles and placebo;Noodles without iron fortificant and placebo; andIron supplementation and mebendazole 500 mg.OutcomesHaemoglobin ‐ change;Prevalence of underweight, stunting and wasting  (defined as ‐2SD for weight‐for‐height, height‐for‐age and weight‐for‐ age using WHO/NCHS reference data).\
Not included in review: Ferritin; serum transferrin; worm prevalence; CRP.NotesLocation: Vietnam\
Community category: 2\
Source of funding: Neys‐van Hoogstraten Foundation, Ellison Medical Foundation and the Ministry of Education and Training, Vietnam.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskRandomized, no further details.Allocation concealment (selection bias)Low riskCentral allocation. \"Randomization was carried out by a researcher \[\...\] who did not know the children and could not introduce bias in the randomization\".Blinding (performance bias and detection bias) All outcomesLow riskParticipants and key personnel blinded. \"Children, teachers and researchers were blinded to the treatment\".\
Placebo identical to intervention drug.Incomplete outcome data (attrition bias) All outcomesLow risk409/425 participants were evaluated. Reason for drop‐out: refusal (n = 16, intervention: 4.7%, placebo: 2.3%). Inclusion of all randomized participants (number evaluable/number randomized): 96% (409/425).Selective reporting (reporting bias)Low riskPre‐specfied outcomes reported.Other biasLow riskNo obvious other sources of bias.[@CD000371-bbs2-0025]MethodsRCT\
Length of follow‐up: 5 monthsParticipantsAll children living in endemic area\
Number analysed for primary outcome: 121 for nutritional outcomes\
Age range: 5 to 14 years\
Inclusion criteria: children from a school identified as having high prevalence of hookworm on the basis of a previous survey\
Exclusion criteria: children with height above 137 cm girls and 145 cm for boys since these were the upper limits in the reference rangesInterventionsSingle dose vs placebo\
Tetrachloroethylene: 0.1 mL/kg (max 5 mL dose);Placebo: children\'s cough medicine.OutcomesMeasured:\
Stool: prevalence in subgroup;Haemoglobin;Weight;Height;Weight‐for‐height (WHO reference median 1983).\
Reported:\
Stool prevalence (graph) with 95% CIs;Haemoglobin mean and difference (no SD);Weight‐for‐height %, mean and difference (no SD).NotesLocation: Botswana\
Community category: 1\
Source of funding not reported.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear risk\"Random sample of half the children\" were give the treatment and the remaining the placebo; no further details reported.Allocation concealment (selection bias)Unclear riskNo details reported.Blinding (performance bias and detection bias) All outcomesUnclear riskNo details reported.Incomplete outcome data (attrition bias) All outcomesHigh risk53% (121/228) of randomized participants were evaluated. Inclusion of all randomized participants (number evaluable/number randomized): 53% (121/228).Selective reporting (reporting bias)Low riskPre‐specfied outcomes reported.Other biasLow riskNo obvious other sources of bias.[@CD000371-bbs2-0026]MethodsCluster quasi‐randomized stepped‐wedge trial\
Method to adjust for clustering: CIs adjusted for clustering in regression modelling, robust standard errors presented (confirmed in correspondence with authors) Cluster unit: schools Average cluster size: 400 ICCs: not reported Length of follow‐up: one year for phased quasi‐randomized comparisons for health outcomes. Two years for school attendanceParticipantsAll children living in endemic area\
Number analysed for primary outcomes: 75 primary schools randomized containing 778 children analysed for haemoglobin. 9102 children analysed for weight and height, 32% and 34% of eligible population analysed for exam performance and cognitive tests, and 100% of eligible population analysed for school attendance\
Age range/mean age: school children 12 years or under\
Inclusion criteria: children from 75 primary schools in the trial area\
Exclusion criteria: girls \> 13 years oldInterventionsDeworming package of interventions vs no treatment\
Albendazole 600 mg (Zentel, SZB) every 6 months in 1998 intervention, and albendazole 400 mg (Zentel, SZB) in 1999; plus a) worm prevention education b) schools with schistosomiasis prevalence over 30% were mass treated with praziquantel (40 mg/kg Bayer) annually; 6/25 schools treated with praziquantel in 1998, and 16/50 treated with praziquantel in 1990;No treatment.OutcomesWeight‐for‐age z‐score ‐ change;Haemoglobin ‐ change;Exam score performance (ICS administered English, Mathematics and Science‐Agriculture exams in pupils in grades 3 to 8);Cognitive tests including picture search, Raven matrix, verbal fluency, digit span, Spanish learning, and a dynamic test using syllogisms;Height‐for‐age z‐score ‐ change;School participation rate based on external NGO assessment at unannounced visit.\
Not included in review: worm prevalence and intensity, self reported sickness, worm prevention behaviours: proportion \"clean\" as per health worker observation, proportion wearing shoes as per health worker observation, self‐reported contact with fresh‐water in past week, access to home latrine, malaria/fever.NotesLocation: Kenya\
Community category: 1\
Source of funding: Sponsored by the World Bank and the Partnership for Child Development.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)High riskSchools in a deworming project were stratified by zone, their involvement with other NGO programmes, and then listed alphabetically and every third school assigned to start the programme in 1998, to start it in 1999, or to be a control.Allocation concealment (selection bias)High riskNot concealed (see above).Blinding (performance bias and detection bias) All outcomesHigh riskPragmatic cluster implementation trial with no blinding.Incomplete outcome data (attrition bias) All outcomesLow riskFor haemoglobin, weight and height the outcomes have been measured on a random sub‐sample of the quasi‐randomized population.Selective reporting (reporting bias)Low riskOutcome data not reported for cognitive tests, though authors state: Deworming treatment effects are not significantly different than zero for any component of the cognitive exam (results available on request).Other biasHigh riskRecruitment bias: low (no asymmetric migration between schools)\
Baseline imbalance: low\
Loss of clusters: low (none reported)\
Incorrect analysis: low (correctly adjusted for clustering).\
Comparability with RCTs randomizing individuals: low\
Other sources of bias: high for confounding due to a co‐intervention. The drug intervention is accompanied by intensive health promotion that could account for some of the effects with key outcomes such as school attendance.[@CD000371-bbs2-0027]MethodsRCT\
Length of follow‐up: 5 yearsParticipantsAll children living in endemic area\
Number analysed for primary outcome: 1423\
Mean age: 15 months (randomized at 1.5 years)\
Inclusion criteria: 15 month old children whose mothers participated in the pregnancy phase of the trial (pregnant healthy women from the area, planning to deliver at Entebbe Hospital)\
Exclusion criteria: none statedInterventionsMultiple dose vs placebo\
Factorial design^a^\
Albendazole: 200 mg quarterly from age 15 to 21 months; 400 mg quarterly from age 2 to 5 years;Matching placebo.\
^a^Mothers when pregnant had been randomized in a 1:1:1:1 ratio to receive single‐dose albendazole (400 mg) + praziquantel (40 mcg/kg), albendazole + praziquantel placebo, albendazole placebo + praziquantel, or albendazole placebo + praziquantel placebo.OutcomesWeight‐for‐age z‐score;Height‐for‐age z‐score;Weight‐for‐height z‐score;Haemoglobin;Cognitive tests including Block design, Picture vocabulary scale, Sentence repetition, Verbal fluency, Counting span, Running memory, Picture search, Wisconsin card sort test, Tap once tap twice task, Shapes task, Tower of London;Serious adverse events;Death.\
Not included in review: immune response at age 5 years to BCG and tetanus immunisation, incidence of malaria, diarrhoea, pneumonia, measles, and tuberculosis, measures of fine motor function and gross motor function.NotesLocation: Entebbe, Uganda\
Community category: 3\
Source of funding: Wellcome Trust***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskRandomization code generated by statistician using Stata version 7.Allocation concealment (selection bias)Unclear riskNo details reported.Blinding (performance bias and detection bias) All outcomesUnclear riskParticipants and provider blinded. Not reported for assessors.Incomplete outcome data (attrition bias) All outcomesHigh riskInclusion of all randomized participants (number evaluable/number randomized): 71% (1423/2016) of randomized participants.Selective reporting (reporting bias)High riskSerious adverse events not reported.Other biasLow riskNo other obvious source of bias.[@CD000371-bbs2-0028]MethodsRCT\
Length of follow‐up: 4 monthsParticipantsAll children living in endemic area\
Number analysed for primary outcome: 510 randomized\
Age range: 6 to 8 years\
Inclusion criteria: school children aged 6 to 8 years and written informed consent from parents/caregivers\
Exclusion criteria: haemoglobin concentrations \< 80 g/L, chronic illness, congenital abnormalities, mental or severe physical handicap, severe malnutrition (\[z‐scores for weight‐for‐height (WHZ) \< ‐3.0 SD), obesity (BMI ≥ 25 or z‐scores for WHZ \> +2 SD), or receiving deworming within the previous 6 monthsInterventionsSingle dose vs placebo\
Non‐fortified biscuit plus placebo deworming‐treatment (placebo);Multi‐micronutrient--fortified biscuit plus placebo deworming‐treatment;Non‐ fortified biscuit plus deworming treatment with albendazole (400 mg);Multi‐micronutrient--fortified biscuits plus deworming treatment with Albendazole (400 mg).OutcomesHaemoglobin;Mean MUAC;Cognitive function;Change in weight‐for‐age (WAZ), height‐for‐age (HAZ), and WHZ, using the EpiInfo program (version 6.0, CDC) and the National Center for Health Statistics/WHO nutritional reference data.\
Not included in review: changes in zinc, iodine, and ferritin concentration; worm prevalence\
Measured but not reported: weight and height recorded at baseline and end point but only baseline data reported. Skin fold thickness recorded at baseline and end point, but no data reported.NotesLocation: Vietnam\
Community category: 2\
This trial was supported by the Neys‐van Hoogstraten Foundation, The Netherlands, and the Ellison Medical Foundation.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskComputer generated. \"pupils were allocated to 1 of the 4 intervention groups based on a computer generated list, matched on age (12‐mo age groups) and sex, and using a block size of 8 by one of the researchers not involved in the field work\".Allocation concealment (selection bias)Low riskCentral allocation.Blinding (performance bias and detection bias) All outcomesLow riskParticipants and key personnel were blinded. \"All investigators, field assistants, teachers, and children did not know the codes of the trial groups\".\
Placebo identical to treatment (orange chewable tablet).Incomplete outcome data (attrition bias) All outcomesLow risk482/510 randomized participants were evaluated. Reasons for drop‐out: moved (n =12), surgery (n = 2), refusal to participate (n = 14), balanced across intervention groups. Inclusion of all randomized participants (number evaluable/number randomized): 94.5% (482/510).Selective reporting (reporting bias)High riskThree outcomes (weight, height and skin fold thickness) not reported adequately.Other biasLow riskNo obvious other source of bias.[@CD000371-bbs2-0029]MethodsRCT\
Length of follow‐up: 2.25 months (9 weeks)ParticipantsInfected children identified by screening\
Number analysed for primary outcome: 103\
Age range: 9 to 12 years\
Inclusion criteria: children from 3 schools in Mandeville; *Trichuris* egg counts \> 1900, but low hookworm counts on 2 occasions before the trial separated by 3 months\
Exclusion criteria: twins; severe illness; physical handicaps; neurological disordersInterventionsSingle dose vs placebo\
Albendazole: 400 mg daily for 3 days (SmithKlineBeecham);Placebo: identical.OutcomesCognitive tests: digit span forwards/backwards; arithmetic and coding from Wechsler Intelligence Scale for Children; fluency and listening comprehension from the Clinical Evaluation of Language functions; and matching familiar figures test.\
Not included in review: stool egg counts at baseline and 10 days (prevalence and arithmetic mean); height and weight (expressed as % NCHS standard) iron status; school attendance; IQ; socioeconomic status; educational opportunity measures at baseline.\
Outcomes not reported: nutritional outcomes at 9 weeks cited as too short a follow‐up period to demonstrate a change;school attendance only measured at baseline.NotesLocation: Jamaica\
Community category: 1\
There was an infected placebo group and an \"uninfected control group\"\
Source of funding not reported.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear risk\"Randomly assigned\"; no further details reported.Allocation concealment (selection bias)Unclear riskNo details reported.Blinding (performance bias and detection bias) All outcomesUnclear riskNo details reported.Incomplete outcome data (attrition bias) All outcomesHigh risk73% (103/140) of randomized participants were evaluated. Inclusion of all randomized participants (number evaluable/number randomized): 73% (103/140).Selective reporting (reporting bias)Unclear riskPyschometric tests reported; other outcomes such as nutrition not reported.Other biasLow riskNo obvious other source of bias.[@CD000371-bbs2-0030]MethodsRCT\
Length of follow‐up: 6 months for randomized comparisonParticipantsAll children living in endemic area\
Number analysed for primary outcome: 1518 randomized, 90% followed up at 6 months\
Age range/mean age: 10.5 years\
Inclusion criteria: school age children\
Exclusion criteria: failure to submit 2 stool specimens prior to the initial treatment, known allergy to either drug, treatment with either drug within 6 months, lack of consent, and marriage or possible pregnancyInterventionsSingle dose vs placebo\
Albendazole (400 mg) plus praziquantel (40 mg/kg)\
Praziquantel plus an albendazole placebo\
Albendazole plus a praziquantel placebo\
Both placebosOutcomesNo useable data.\
Not included in review: ultrasound, physical examination and history findings, duplicate stool and urine measurements of egg counts\
Measured but not reported: weight, height, skinfold thickness (subscapular, triceps, and abdominal) and haemoglobin recorded at baseline and end point but only baseline data reported; data for side effects not useable in reviewNotesLocation: China, Philippines and Kenya\
Community category: 1 randomized comparison up to 6 months at which point all infected children were treated as needed, and followed up until one year.\
There was no difference between the side effect rate from albendazole or the double placebo\
Result text: \"No statistically significant improvement was seen in haemoglobin after albendazole treatment. In the trial population as a whole, no significant differences between treatment groups were seen in any of the growth and anthropometric measurements.\"\
Source of funding: Tropical Disease Research of the WHO.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskComputer generated. \"Randomization lists were prepared by WHO/TDR using a randomized block design with a block size of 80\".Allocation concealment (selection bias)Low riskCentral allocation.Blinding (performance bias and detection bias) All outcomesLow riskParticipants, key personnel, and outcome assessment was blinded. \"The randomization code was not broken until after the 6‐month results were tabulated and submitted to WHO\".Incomplete outcome data (attrition bias) All outcomesLow risk1518 participants, 90% at 6 months follow‐up, 83% at one year, no further details. Inclusion of all randomized participants (number evaluable/number randomized): 90% (1366/1518).Selective reporting (reporting bias)High riskWeight, height, skinfold thickness, and haemoglobin recorded at baseline and end point but only baseline data reported.Other biasLow riskNo obvious other source of bias.[@CD000371-bbs2-0031]MethodsRCT\
Length of follow‐up: 9 weeks (2.25 months)ParticipantsAll children living in endemic area\
Number analysed for primary outcome: 191\
Age range: 2 to 5 years\
Inclusion criteria: children ages 2 to 5 years registered at village health centres\
Exclusion criteria: none statedInterventionsSingle dose vs placebo\
Albendazole: 400 mg plus 30 mg elemental iron weekly;Elemental iron: 30 mg weekly.OutcomesMean change in weight post‐treatment;Mean change in height post‐treatment;Mean change in haemoglobin post‐treatment;Mean haemoglobin post‐treatment.\
Not included in review: z‐scores for height‐for‐age, weight‐for‐age, and weight‐for‐height (NCHS reference)NotesLocation: Java, Indonesia\
Community category: 2\
Source of funding: Kimia Farma Indonesia.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear risk\"The children were randomly divided into three, equal‐sized treatment groups\". No further details reported.Allocation concealment (selection bias)Unclear riskNo details reported.Blinding (performance bias and detection bias) All outcomesUnclear riskDescribed as double blind. Participants were blinded, unclear whether provider and assessor were blinded.Incomplete outcome data (attrition bias) All outcomesLow risk97% (289/299) of enrolled participants were evaluated. Inclusion of all randomized participants (number evaluable/number randomized): 97% (289/299).Selective reporting (reporting bias)Low riskPre‐specfied outcomes reported.Other biasLow riskNo obvious other source of bias.[@CD000371-bbs2-0032]MethodsCluster‐RCT\
Method to adjust for clustering: not adjusted\
Cluster unit: village\
Average cluster size: 114\
ICCs: not reported\
Length of follow‐up: 18 monthsParticipantsAll children living in endemic area\
Number analysed for primary outcome: 13 villages randomized containing 1402 children\
Age range: 2 to 6 years\
Inclusion criteria: children ages 2 to 6 years from 13 villages surrounding a mother and child health centre; subgroup living in 8 villages within waking distance of health centre analysed for additional outcomes\
Exclusion criteria: none statedInterventionsMultiple doses vs placebo\
Mebendazole: 500 mg (Janssen) every 2 months;Placebo;Pyrantel pamoate and mebendazole: initial dose of 10 mg/kg pyrantel pamoate (Combantrin, Pfizer, UK) then mebendazole 500 mg bimonthly for 8 months (4 doses).OutcomesANOVAs for change in z‐scores for z‐scores for height‐for‐age, weight‐for‐age, and weight‐for‐height (NCHS reference);Change in MUAC at 6, 12, and 18 months (no SD);Other outcomes measured but not reported: height; weight; stool examination for prevalence and intensity in subgroup (eggs/g: modified sedimentation technique); subgroup also analysed for intestinal permeability, albumin, alpha‐1‐antichymotrypsin, total protein every 2 months.NotesLocation: Bangladesh\
Community category: 1\
No adjustment made for cluster randomization\
Source of funding: the Overseas Development Administration and the University of Cambridge Maintenance Fund.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskThe trial was described as randomized, no further details reported.Allocation concealment (selection bias)Unclear riskNo details reported.Blinding (performance bias and detection bias) All outcomesLow riskParticipants and field workers were blinded, unclear if assessment was blinded. \"The treatment and placebo tablets were given in a double‐blind manner; neither the fieldworkers nor the parents were aware of the group to which they belonged\".Incomplete outcome data (attrition bias) All outcomesLow risk94% (1402/1476) of enrolled participants were evaluated. Inclusion of all randomized participants (number evaluable/number randomized): 94% (1402/1476).Selective reporting (reporting bias)Low riskNot all pre‐specified outcomes reported.Other biasLow riskRecruitment bias: unclear (not known if children shift clinics in the light of the intervention)\
Baseline imbalance: low (no differences apparent)\
Loss of clusters: low (none reported)\
Incorrect analysis: not adjusted (high risk)\
Comparability with RCTs randomizing individuals: unclear[@CD000371-bbs2-0033]MethodsRCT\
Length of follow‐up: 4 months (16 weeks)ParticipantsInfected children identified by screening\
Number analysed for primary outcome: 81\
Age range: 2 to 12 years\
Inclusion criteria: children ages 2 to 12 living in Mirpur slum infected with *Ascaris*\
Exclusion criteria: none statedInterventionsSingle dose vs placebo\
Pyrantel pamoate: 11 mg/kg (Combantrin, Pfizer, Bangladesh);Placebo.OutcomesMean change in weight post‐treatment;Mean weight post‐treatment;Mean change in height post‐treatment;Mean height post‐treatment.\
Not included in review: median % weight‐for‐age, weight‐for‐height, and height‐for‐ageNotesLocation: Bangladesh\
Community category: 1\
Source of funding: research grant from the World Bank and was funded by the Bangladesh National Nutrition Council.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low risk\"Random table\".Allocation concealment (selection bias)Unclear riskNo details reported.Blinding (performance bias and detection bias) All outcomesLow risk\"Double‐blind\"; \"The syrups were identical in appearance and flavor and were packaged in identical containers. Randomized patient numbers were labeled on the bottles to maintain the double blind design\".Incomplete outcome data (attrition bias) All outcomesLow risk94% (81/85) of randomized participants were evaluated. Inclusion of all randomized participants (number evaluable/number randomized): 94% (81/85).Selective reporting (reporting bias)Low riskPre‐specfied outcomes reported.Other biasLow riskNo obvious other source of bias.[@CD000371-bbs2-0034]MethodsRCT\
Length of follow‐up: 6.5 months (26 weeks)ParticipantsInfected children identified by screening\
Number analysed for primary outcome: 392\
Age range: 6 to 12 years\
Inclusion criteria: children in grades 2 to 5 of 14 schools in Jamaica with intensities of *Trichura* \> 1200 eggs/g\
Exclusion criteria: children with mental handicaps identified by their teachersInterventionsMultiple doses vs placebo\
Albendazole: 800 mg (400 mg in each of 2 days), repeated at 3 months and 6 months;Identical placebo.Outcomes1. Main trial (264 children) Wide range achievement test: reading, arithmetic, and spelling subtests; school attendance from children with class registers pre‐ and post‐intervention, height‐for‐age z‐score, body mass index pre‐ and post‐intervention 2. Subgroup 1 (189 infected children from original population) Digit span; verbal fluency test; visual search; number choice; French vocabulary learning 3. Subgroup 2 (97 children from grade 5) French learning; digit spans (forward and backward); Corsi block span; verbal fluency; picture search; silly sentences\
Other outcomes measured but not reported: stool at baseline and at 8 weeks after second treatment round (Kato): prevalence and intensity, weight, height, z‐scores (NCHS standard)NotesLocation: Jamaica\
Community category: 1\
Source of funding: grant from the James S. McDonnell Foundation.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskRandom‐numbers table.Allocation concealment (selection bias)Unclear riskNo details reported.Blinding (performance bias and detection bias) All outcomesUnclear riskParicipants blinded; unclear whether assessors were blinded.Incomplete outcome data (attrition bias) All outcomesLow risk96% (392/407) of randomized participants were evaluated. Inclusion of all randomized participants (number evaluable/number randomized): 96% (392/407).Selective reporting (reporting bias)Low riskAll stated outcomes reported.Other biasLow riskNo obvious other source of bias.[@CD000371-bbs2-0035]MethodsRCT\
Length of follow‐up: 16 weeksParticipantsAll children living in endemic area\
Number analysed for primary outcome: 808/851\
Age range/ mean age: 10 years\
Inclusion criteria: Children in grades 1 to 6\
Exclusion criteria: Children with Haemoglobin \< 8 g/dLInterventionsSingle dose vs placebo\
Fortified beverage (multivitamin and iron) twice per day for 16 weeks with anthelmintic therapy (Albendazole 400 mg);Fortified beverage with placebo anthelmintic therapy;Non‐fortified beverage with anthelmintic therapy (400 mg);Non‐fortified beverage with placebo anthelmintic therapy.OutcomesNo useable data\
Not included in review: urine iodine, stool egg count.\
Measured but not reported: weight, height, haemoglobin, physical fitness (Harvard step test), heart rate, cognitive ability measured by the Primary Mental Abilities Test for Filipino Children. The test measures verbal, non verbal and quantitative skills.NotesLocation: Philippines\
Community category: 2\
Narrative results:\
No significant difference in change in weight. Deworming improved the iron status of a subgroup of moderately to severely subjects. Deworming had either no effect or a negative effect on fitness scores, and the effect on heart rate was inconclusive. Deworming had either no effect or a negative effect on mental ability scores.\
Sources of support: The Nutrition Center of the Philippines, The Procter & Gamble Co.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskRandomization at individual level, no further details.Allocation concealment (selection bias)Unclear riskNo details reported.Blinding (performance bias and detection bias) All outcomesLow riskDouble‐blind trial. \"Both the researchers and the trial participants were blinded to the treatment assignment of each child\".\
\"Placebo beverage and placebo anthelmintic pills were indistinguishable from their counterparts in appearance, smell and taste\".Incomplete outcome data (attrition bias) All outcomesLow risk808/851 (95%) enrolled participants were evaluated, no reasons for withdrawal reported. Inclusion of all randomized participants (number evaluable/number randomized): 95% (808/851).Selective reporting (reporting bias)High riskNutritional and haemoglobin outcomes not fully reported.Other biasLow riskNo obvious other source of bias.[@CD000371-bbs2-0036]MethodsRCT\
Length of follow‐up: 6 monthsParticipantsInfected children (all children in the school were known to be infected)\
Number analysed for primary outcome: 150\
Age range/mean age: 8.5 years\
Inclusion criteria: all available children in lower grades (standards 1 and 2) in Mvindeni Primary School, Kwale district (unscreened); subgroup of 36 boys chosen; haemoglobin \> 8 g/dL; willing to co‐operate in physical tests; pre‐pubertal\
Exclusion criteria: haemoglobin \< 8 g/dLInterventionsSingle dose vs placebo\
Albendazole: 2 x 200 mg (SmithKline and French);Placebo: identical.OutcomesMean weight post‐treatment;Mean change in weight post‐treatment;Mean height post‐treatment;Mean change in height post‐treatment;Mean MUAC;Mean change in MUAC;Mean triceps skinfold thickness;Mean change in triceps skinfold thickness;Mean subscapular skinfold thickness;Mean change in subscapular skinfold thickness;Harvard step test.\
Not included in review: all above converted to % median for sex and age; prevalence and mean egg counts (arithmetic and geometric means) Test heart rates and score for subgroupNotesLocation: Kenya\
Community category: 1\
Source of funding: Smith Kline & French Laboratories, Ltd., and the Edna McConnell Clark Foundation, grant 284‐0120.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear risk\"allocated at random within sex\", no further details reported.Allocation concealment (selection bias)Unclear riskNo details reported.Blinding (performance bias and detection bias) All outcomesLow riskParticipants blinded, tablets identical for treatment and placebo; \"Both examinations were carried out with the same team of workers, each doing the same procedures, and were done in a blind fashion\".Incomplete outcome data (attrition bias) All outcomesLow risk88% (150/171) of randomized participants were evaluated, reasons for losses to follow‐up not reported. Inclusion of all randomized participants (number evaluable/number randomized): 88% (150/171).Selective reporting (reporting bias)Low riskPre‐specified outcomes reported.Other biasLow riskNo obvious other source of bias.[@CD000371-bbs2-0037]MethodsRCT\
Length of follow‐up: 3.6 months (subgroup) and 8.2 months (main trial)ParticipantsInfected children (all children in the school were known to be infected)\
Number analysed for primary outcome: 284\
Age range/ mean age: 7 to 13 years\
Inclusion criteria: all school children (unscreened) in grades 1 to 5 in Mvindeni Primary School\
Subgroup (53 analysed) of 60 boys chosen because haemoglobin \> 80 g/L, willing to cooperate in physical tests and appetite tests, pre‐pubertal, infected with at least 1 of helminths (screened), hookworm \< 20,000 eggs/g; hookworm or *Trichuris* count \> 1000 eggs/g or *Ascaris* \> 4000 eggs/g\
Exclusion criteria: Severe anaemia (haemoglobin \< 75 g/L)InterventionsMultiple doses vs placebo\
Albendazole (single dose) plus placebo: 600 mg (3 x 200 mg) SmithKline Beecham at outset, identical placebo at 3.6 months;Albendazole (multiple doses): single dose 600 mg repeated at 3.6 months;Placebo: identical placebo.OutcomesMean weight post‐treatment;Mean change in weight post‐treatment;Mean height post‐treatment;Mean change in height post‐treatment;Mean MUAC;Mean change in MUAC;Mean triceps skinfold thickness;Mean change in triceps skinfold thickness;Mean subscapular skinfold thickness;Mean change in subscapular skinfold thickness;Mean haemoglobin post‐treatment;Mean change in haemoglobin post treatment;Harvard step test.\
Not included in review: prevalence, eggs/g: geometric and arithmetic mean; converted to percentage of median for age and sex using NCHS references; % weight‐for‐age, % height for age; % weight‐for‐height; % arm circumference for age; % triceps for age; % subscapular for age; appetite (self‐rating and snack consumed intake in kJ)NotesLocation: Kwale, Kenya\
Community category: 1\
Source of funding: supported in part by Thrasher Research Fund and SmithKline Beecham, Ltd. ***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear risk\"at random within sex by descending hookworm egg count\".Allocation concealment (selection bias)Unclear riskNo details reportedBlinding (performance bias and detection bias) All outcomesLow riskParticipants blinded, tablets identical for treatment and placebo; \"Both examinations were conducted by the same team, each doing the same procedures, and were done in a blind fashion\".Incomplete outcome data (attrition bias) All outcomesLow risk86% (284/328) of randomized participants were evaluated, reasons for losses to follow‐up not reported. Inclusion of all randomized participants (number evaluable/number randomized): 86% (284/328).Selective reporting (reporting bias)Low riskPre‐specified outcomes reportedOther biasLow riskNo obvious other source of bias[@CD000371-bbs2-0038]MethodsCluster‐RCT\
Method to adjust for clustering: generalised estimating equations\
Cluster unit: school\
Average cluster size: 255\
ICCs: not reported\
Length of follow‐up: 12 monthsParticipantsAll children living in endemic area\
Number analysed for primary outcome: 12 schools randomized containing 3063 children\
Mean age: 10.5 years\
Inclusion criteria: children in grades 1 to 5 from 12 randomly selected schools on Pemba island; only grades 1 to 4 included in evaluation of nutritional effect\
Exclusion criteria: none statedInterventionsMultiple doses vs placebo\
Mebendazole: 500 mg twice yearly;Mebendazole: 500 mg 3 times a year;Placebo.OutcomesWeight gain;Height gain;Change in haemoglobin at 12 months.\
Estimates are provided from multiple regression models taking into account various baseline differences for 2 subgroups above and below 10 years old. Unadjusted outcomes not presented. (These 2 groups were combined in the [@CD000371-bbs2-0149] Cochrane Review.)\
Other outcomes measured but not reported: micronutrient status (blood) for protoporphyrin and serum ferritin; stool egg count (Kato‐Katz); z‐scores for height‐for‐age and weight‐for‐height; body mass index.NotesLocation: Zanzibar, Tanzania\
Community category: 1\
Appropriate adjustment made for cluster randomization using general estimating equation\
Source of funding: funded through cooperative agreement DAN‐5116‐1‐00‐8051‐00 between The Johns Hopkins University and the Office of Health and Nutrition, United States Agency for International Development.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear risk3 schools randomly selected from each of the 4 districts, and then allocated.Allocation concealment (selection bias)Unclear riskNo details reported.Blinding (performance bias and detection bias) All outcomesUnclear riskNo details reported.Incomplete outcome data (attrition bias) All outcomesLow risk84% (3063/3605) of randomized participants were evaluated, reasons for losses to follow‐up not reported. Inclusion of all randomized participants (number evaluable/number randomized): 84% (3063/3605).Selective reporting (reporting bias)High riskNot all pre‐specified outcomes reported adequately.Other biasLow riskRecruitment bias: low (Unlikely to change schools)\
Baseline imbalance: low (no differences apparent)\
Loss of clusters: low (none reported)\
Incorrect analysis: cluster adjusted (low risk)\
Comparability with RCTs randomizing individuals: unclear[@CD000371-bbs2-0039]MethodsRCT (factorial design)\
Length of follow‐up: 12 monthsParticipantsAll children living in endemic area\
Number analysed for primary outcome: 359 in Mebendazole arm aged 6 to 59 months\
Age range: 3 to 56 months\
Inclusion criteria: all children in Kengeja village, with age reported as 3 to 56 months by parents; 3 months before planned start of trial (pre‐school children)\
Exclusion criteria: severe anaemia (\< 70 g/L)InterventionsMultiple doses vs placebo\
Mebendazole: 500 mg given every 3 months at home visits;Placebo: identical.\
Treatment strategy: randomized and treated all children\
Both groups also received: 0.5 mL ferrous sulfate (20 mg/mL); 10 mg iron daily for 1 year or placebo as per factorial designOutcomesCognitive outcomes: motor and language development by parents reporting gross motor and language milestones using scoring system developed specifically for the trial;Anthropometric measures presented in a stratified manner: (\< 30 months, \> 30 months), and presented as proportion of children with small arm circumference, mild wasting, and stunting;Proportion of children with poor appetite, and proportion with severe anaemia are presented for the whole group;Iron indices (not disaggregated, independent of the iron randomization).\
Not included in review: prevalence and egg counts (no SD/SEM); motor and language scores (results of multiple regression and correlations; raw data not reported) haemoglobin (results not reported by randomized comparisons)\
Others measured but not reported: stool (Kato‐Katz); weight; height; malaria film; ferritin; appetite as reported by mothersNotesLocation: Zanzibar, Tanzania\
Community category: 2\
Factorial design, with households randomized to iron, random allocation of mebendazole by child, stratified by iron allocation and age grouped households. An iron with mebendazole treatment term was tested in all regression models, but it did not reach significance\
Source of funding: Thrasher Research Fund between The Johns Hopkins University and the United States Agency for International Development, AL Pharma, Baltimore, MD, and Pharmamed, Malta.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskRandomized by \"blocks of 4\", no further details reported.Allocation concealment (selection bias)Low riskPills in bottles with unique treatment codes, assigned by 1 investigator, codes kept in sealed envelopes.Blinding (performance bias and detection bias) All outcomesUnclear riskParticipants and provider were blinded; unclear whether assessor was blinded.Incomplete outcome data (attrition bias) All outcomesHigh risk52% (359/684) enrolled participants were evaluated. Inclusion of all randomized participants (number evaluable/number randomized): 52% (359/684 = 52%).Selective reporting (reporting bias)Low riskAll prespecified outcomes reported.Other biasHigh riskNo obvious other source of bias.[@CD000371-bbs2-0040]MethodsRCT\
Length of follow‐up: 12 monthsParticipantsAll children living in endemic area\
Number analysed for primary outcome: 683\
Age range: 2 to 5 years\
Inclusion criteria: all children aged 2 to 5 in slum area of Tiljala identified and enrolled\
Exclusion criteria: major illnesses; birth defects; and unwillingness to participateInterventionsMultiple doses vs placebo\
Albendazole: 400 mg in a vitamin B complex base liquid; repeated at 6 months;Placebo: vitamin B complex base.OutcomesMean weight post‐treatment (presented graphically).\
Other outcomes measured but not reported: stool samples from random sample of 30% (formalin concentration technique) for prevalence of *Ascaris*; weight‐for‐age; diarrhoeal episodesNotesLocation: India\
Community category: 2\
Source of funding: Indian Council of Medical Research, New Delhi, India.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskComputer‐generated random numbers sequence.Allocation concealment (selection bias)Low riskIdentical coded bottles.Blinding (performance bias and detection bias) All outcomesLow riskParticipants and key personnel were blinded.Incomplete outcome data (attrition bias) All outcomesLow risk97% (683/702) of enrolled participants were evaluated. Inclusion of all randomized participants (number evaluable/number randomized): 97% (683/702).Selective reporting (reporting bias)High riskIncomplete reporting of some outcomes (prevalence of *Ascaris* in stools; weight‐for‐age; diarrhoeal episodes).Other biasLow riskNo obvious other source of bias.[@CD000371-bbs2-0041]MethodsRCT\
Length of follow‐up: 12 monthsParticipantsInfected children identified by screening\
Mean age: 7.3 years\
Number analysed for primary outcome: 33\
Inclusion criteria: children with confirmed *Trichus trichiura* in a rural school\
Exclusion criteria: none reportedInterventionsSingle dose vs placebo\
Albendazole: 2 x 400 mg doses on 2 consecutive days;Placebo.OutcomesMean change in height;Median change in weight;Weight‐for‐age z‐score;Height‐forage z‐score;Weight‐for‐height z‐score.\
Not included in review: urinary TNF‐alpha levelsNotesLocation: Sekolah Rendah Kebangsaan Tawang, Kelantan, Malaysia\
Community category: NA\
Source of funding: Universiti Sains Malaysia Short Term Grant.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskRandomization software was used.Allocation concealment (selection bias)Unclear riskNo details reported.Blinding (performance bias and detection bias) All outcomesUnclear riskFor participants and assessors, no details were reported. \"\
Both the active drug and placebo were repackaged by a pharmacist blinded to the trial groups\".Incomplete outcome data (attrition bias) All outcomesLow risk33/37 participants analysed for the primary outcome; reasons for loss to follow‐up unclear.\
Inclusion of all randomized participants (number evaluable/number randomized): 89% (33/37).Selective reporting (reporting bias)Low riskAll stated outcomes reported.Other biasLow riskNo obvious other source of bias.[@CD000371-bbs2-0042]MethodsRCT\
Length of follow‐up: 6 monthsParticipantsAll children living in endemic area\
Number analysed for primary outcome: 226 for nutritional outcomes, reduced for cognitive outcomes\
Age range: 7 to 12 years\
Inclusion criteria: children attending grades 1 to 4 in primary schools in the Guatemalan highlands\
Exclusion criteria: \> 12 years; deworming medicine in last yearInterventionsMultiple doses vs placebo\
Albendazole: 2 x 200 mg at baseline and 12 weeks;Placebo: identical at baseline and 12 weeks.OutcomesMean weight post‐treatment;Mean change in weight post‐treatment;Mean height post‐treatment;Mean change in height post‐treatment;School performance: attendance rates of children actively attending school measured using attendance books, dropout rates;Mean MUAC;Mean change in MUAC;Cognitive tests: Interamerican vocabulary test, Interamerican reading test, Peabody picture vocabulary test.\
Not included in review: egg counts (Kato‐Katz: arithmetic and geometric mean); z‐scores (NCHS‐CDC‐WHO reference) for weight‐for‐age, change in weight‐for‐age, height, change in height, height‐for‐age, change in height‐for‐age, weight‐for‐height, and change in height‐for‐age.NotesLocation: Guatemala\
Community category: 1\
Source of funding: Pew Charitable Trusts, the US Agency for International Development University Development and Linkage Program, the Children's Miracle Network Telethon, and the ARCS Foundation.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear risk\"stratified by gender and age and then randomly assigned\".Allocation concealment (selection bias)Unclear riskNo details reported.Blinding (performance bias and detection bias) All outcomesLow risk\"The children and field workers were unaware of treatment group assignment\".Incomplete outcome data (attrition bias) All outcomesLow risk90% (226/250) of randomized participants were evaluated. *"*No differences were detected in treatment group assignment, initial age, anthropometry, SES, and worm status between the 228 children who remained in the trial and the 18 who dropped out." Sample size for nutritional data is smaller due to missing data. Inclusion of all randomized participants (number evaluable/number randomized): 90% (226/250).Selective reporting (reporting bias)Low riskPre‐specified outcomes reported.Other biasLow riskNo other obvious source of bias.[@CD000371-bbs2-0043]MethodsRCT\
Length of follow‐up: 12 monthsParticipantsAll children living in endemic area\
Number analysed for primary outcome: 268\
Age range: 6 to 91 months\
Inclusion criteria: pre‐school children from Ubiri village who attended clinic and produced a stool sample\
Exclusion criteria: none statedInterventionsMultiple doses\
Levamisole syrup: 2.5 mg/kg every 3 months;Flavoured sucrose syrup: every 3 months.OutcomesGrowth rates in both groups, and subgroup of those infected; these have been corrected for various factors using analysis of covariance (unadjusted data are not reported and the growth rates are not presented with any measure of variance).\
Measured but not reported: height; length; stool egg count in subgroup (Kato method); growth rates using least square method.NotesLocation: Tanzania\
Community category: 3\
Source of funding: Research and Publications Committee, University of Dar es Salaam. Analysis was supported by a training grant (HL 05998‐04) from the National Heart, Lung and Blood Institute, NIH, DHEW Bethesda, MD.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskRandom‐numbers table.Allocation concealment (selection bias)Unclear riskNo details reported.Blinding (performance bias and detection bias) All outcomesLow risk\"children were weighed and measured as before by a person unaware of their treatment status\"; placebo and treatment given as a flavoured syrup.Incomplete outcome data (attrition bias) All outcomesHigh risk78% (268/341) of randomized participants were evaluated; inclusion of all randomized participants (number evaluable/number randomized): 78% (268/341).Selective reporting (reporting bias)High riskNot all pre‐specified outcomes reported.Other biasLow riskNo obvious other source of bias.[@CD000371-bbs2-0044]MethodsCluster RCT\
Method to adjust for clustering: primary outcome of BMI was not adjusted for clustering\
Cluster unit: household\
Average cluster size: 4\
ICCs: not reported\
Length of follow‐up: 21 monthsParticipantsAll children living in endemic area\
Number analysed for primary outcome: 954 households containing 855 participants\
Age range/mean age: Children aged 19 years and less\
Inclusion criteria: all household in members except those \< 2 years old or pregnant\
Exclusion criteria: none statedInterventionsSingle dose vs placebo\
Albendazole: 3 x 400 mg for 3 consecutive days;Matching placebo.OutcomesBMI^a^;Adverse events.\
^a^BMI measured in children aged 19 years and less.\
Not included in review: Malaria‐like symptoms questionnaire, finger prick blood test for malaria, skin prick tests, symptoms of asthma and atopic dermatitis, stool sample for *Tichuris* and hookworms.NotesLocation: Ende district of Flores Island, Indonesia\
Community category: 1\
Source of funding: The Royal Netherlands Academy of Arts and Science (KNAW), European, Prof. Dr. P.C. Flu Foundation.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low risk\"Random Allocation software\" used.Allocation concealment (selection bias)Unclear riskNo details reported.Blinding (performance bias and detection bias) All outcomesUnclear riskParticipants and personnel blinded. \"The treatment code was concealed from trial investigators and participants. The un‐blinding of treatment codes occurred after all laboratory results had been entered into the database.\"\
Not reported whether the assessors for height and weight were blinded.Incomplete outcome data (attrition bias) All outcomesUnclear riskNumber of children randomized was not reported.Selective reporting (reporting bias)Low riskAll stated outcomes reported.Other biasLow riskRecruitment bias: low (unlikely to change households)\
Baseline imbalance: low (no differences apparent)\
Loss of clusters: low (ITT analysis done; in the albendazole arm 61 people moved to a house that was assigned to placebo while in the placebo arm 62 people moved to a house that was assigned to albendazole)\
Incorrect analysis: cluster adjusted (low risk)\
Comparability with RCTs randomizing individuals: unclear[@CD000371-bbs2-0045]MethodsRCTRCT\
Length of follow‐up: 6 monthsParticipantsInfected children identified by screening\
Number analysed for primary outcome: 194\
Age range: 9 to 12 years\
Inclusion criteria: children aged 9 to 12 years from 5 primary schools, with at least one type of STH infection.\
Exclusion criteria: deworming treatment within 6 months before the current trial.InterventionsSingle dose vs placebo\
Albendazole: 3 x 400 mg for 3 consecutive days;Matching placebo.OutcomesPhysical fitness (10 m shuttle run and VO~2~ max);Physical strength (grip strength and standing broad jump test);Height;Weight;Triceps and subscapular skinfold thickness;Haemoglobin.\
Not included in review: parasitological examination.NotesLocation: Bulanghsam township bordering Myanmar, a sub‐division of Menghai county in Xishuangbanna Dai autonomous prefecture, situated in Yunnan province, P.R. China\
Community category: N/A\
Source of funding: Swiss Tropical and Public Health Institute in Basel, Switzerland and the National Institute of Parasitic Diseases, Chinese Center of Diseases Control and Prevention in Shanghai, P.R. China.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low risk\"The treatment allocation sequence was generated by a statistician using block randomization with randomly varying block sizes of 2, 4, and 6.\"Allocation concealment (selection bias)Low risk\"Albendazole and placebo tablets were packaged by staff not involved in the field work into sealed envelopes marked with unique identifiers.\"Blinding (performance bias and detection bias) All outcomesUnclear riskParticipants and personnel blinded.\
Not reported whether the assessors for height and weight were blinded.Incomplete outcome data (attrition bias) All outcomesLow riskInclusion of all randomized participants (number evaluable/number randomized): 92% (194/211).Selective reporting (reporting bias)Low riskAll stated outcomes reported.Other biasLow riskNo other obvious risk of bias.[^7]

Characteristics of excluded studies \[ordered by study ID\] {#CD000371-sec2-0024}
===========================================================

StudyReason for exclusion[@CD000371-bbs2-0046]Not a RCT.[@CD000371-bbs2-0047]Not a comparison of deworming with placebo or no treatment.[@CD000371-bbs2-0048]Treatment regimen comprised of albendazole for soil‐transmitted helminths and praziquantel against schistosomiasis vs placebo.[@CD000371-bbs2-0049]Treatment regimen comprised of albendazole for soil‐transmitted helminths and praziquantel against schistosomiasis vs placebo.[@CD000371-bbs2-0050]Population with significant comorbidity -- 6 to 24 month old children with severe anaemia (\<70 g/L). In population with severe anaemia.[@CD000371-bbs2-0051]Factorial‐designed RCT with children allocated to deworming and iron supplementation, and in which the analysis compares the results for the levamisole and iron group against all the other groups combined. Thus the analysis is confounded by the iron co‐intervention (Included in the [@CD000371-bbs2-0149] Cochrane Review).[@CD000371-bbs2-0052]Trial of allergy with no outcomes of interest.[@CD000371-bbs2-0053]Not a RCT.[@CD000371-bbs2-0054]3% (1097/37,165) of randomized participants were evaluated in 46% (22/48) of the original parishes from the initial [@CD000371-bbs2-0001] trial. All children were offered treatment after the initial trial, and therefore potentially all of these children received treatment for deworming.[@CD000371-bbs2-0055]Intervention comprised mebendazole, vitamin A, and iron supplementation and metronidazole as a combined intervention vs placebo.[@CD000371-bbs2-0056]Treatments randomized, but some placebo groups accessed treatment. Analysis was by the treatment received, and randomization was ignored (included in the [@CD000371-bbs2-0149] Cochrane Review).[@CD000371-bbs2-0057]2 villages allocated to treatment or no treatment on the basis of a coin toss. Essentially a cluster‐RCT with 2 large clusters (Included in the [@CD000371-bbs2-0149] Cochrane Review, which reported that no conclusions could be drawn from the results due to selective reporting).[@CD000371-bbs2-0058]Treatment regimen comprised of 3 days of albendazole vs 1 day of albendazole and 2 days of placebo vs 1 day of pyrantel and 2 days of placebo.[@CD000371-bbs2-0059]Combined treatment regimen albendazole for soil‐transmitted helminths and praziquantel for *Schistosoma mansoni* vs placebo.[@CD000371-bbs2-0060]Population consisted of adults.[@CD000371-bbs2-0061]Only two units of allocation for relevant comparison. Children randomly divided into 4 groups, \"taking care that age distribution was similar in each group\". The 4 groups were then allocated 1 of 4 different single treatment regimens; no details given.[@CD000371-bbs2-0062]Cluster‐RCT with 2 units of allocation to mebendazole and placebo. Trial authors stated that there were differences in environmental sanitary conditions in the clusters (Included in the [@CD000371-bbs2-0149] Cochrane Review, but it was noted that the groups were not comparable and there was high loss to follow‐up).[@CD000371-bbs2-0063]Treatment regimen comprised of albendazole for soil‐transmitted helminths and iron vs placebo.[@CD000371-bbs2-0064]No relevant outcomes.[@CD000371-bbs2-0065]Treatment regimen comprised of albendazole for soil‐transmitted helminths and praziquantel against schistosomiasis vs placebo.[@CD000371-bbs2-0066]Treatment regimen comprised of albendazole for soil‐transmitted helminths and praziquantel against schistosomiasis vs placebo.[@CD000371-bbs2-0067]Not a RCT.[@CD000371-bbs2-0068]Not a RCT.[@CD000371-bbs2-0069]The researchers were unable to collect outcome data after treatment due to major floods in the area.[@CD000371-bbs2-0070]Population with schistosomiasis treated with praziquantel.[@CD000371-bbs2-0071]Treatment regimen comprised of mebendazole and metronidazole vs placebo.[@CD000371-bbs2-0072]Treatment regimen albendazole for soil‐transmitted helminths and praziquantel for schistosomiasis vs placebo.[@CD000371-bbs2-0073]Not a comparison of deworming with placebo or no treatment.[@CD000371-bbs2-0074]Not described as randomized; conference proceedings.[@CD000371-bbs2-0075]Treatment regimen albendazole for soil‐transmitted helminths and praziquantel for schistosomiasis vs placebo.[@CD000371-bbs2-0076]No relevant outcomes.[@CD000371-bbs2-0077]Treatment consisted of levamisole with no untreated controls.[@CD000371-bbs2-0078]Treatment regimen metrifonate used to treat *Schistosoma haematobium* vs placebo.[@CD000371-bbs2-0079]No relevant outcomes.[@CD000371-bbs2-0080]The only randomization is the timing of the deworming medicine.[@CD000371-bbs2-0081]Treatment regimen albendazole for soil‐transmitted helminths and praziquantel for *S. haematobium* vs placebo.[@CD000371-bbs2-0082]3/21 intervention villages were not randomly allocated, and unclear how intervention and control villages were allocated as there was a large imbalance (8 intervention and 13 non‐intervention villages).[@CD000371-bbs2-0083]Trial in population with malaria.[@CD000371-bbs2-0084]No relevant outcomes.[@CD000371-bbs2-0085]Did not consider nutritional or cognitive outcome measures.

Characteristics of ongoing studies \[ordered by study ID\] {#CD000371-sec2-0025}
==========================================================

[@CD000371-bbs2-0086]Trial name or titleRelative efficacy of two regimens of ante‐helminthic treatmentMethodsClinical trialParticipantsTotal enrolment: 200\
Inclusion criteria: age 2 to 5 years; not suffering from serious chronic illness; stool test positive for STHs; not taken any anthelminthic drug in previous 6 months; parents/guardian agree their child\'s participation\
Exclusion criteria: age \< 2 years and \> 5 years; stool test negative for any intestinal helminth; suffering from serious chronic illness; parents/guardian not willing to give consent for their child\'s participation; if he/she receives any anthelminthic drug after survey but before the trial interventionsInterventionsConventional treatment of 400 mg of albendazole in a single dose at 6‐month interval;Intervention group: 400 mg of albendazole in a single‐dose treatment at 3‐month interval.OutcomesPrimary\
To determine the relative efficacy of de‐worming at every 3 months vs every 6 month single dose of albendazole treatment.\
Secondary\
To compare additional morbidity information such as diarrhoeal diseases, respiratory tract infections, nutritional status and *E. histolytica* associated morbidity between 2 groups.Starting dateNot yet recruitingContact informationMohammad M Alam MBBS, Principal Investigator, ICDDR,B: Centre for Health and Population Research, masud_icddrb\@yahoo.comNotesClinicalTrials.gov identifier: NCT00367627\
Sources of support: International Centre for Diarrhoeal Disease Research, Bangladesh (sponsor)

DTR wrote the protocol, applied inclusion criteria, assessed quality, extracted data, conducted data analysis, and wrote the first draft of the review. KSW and NM applied inclusion criteria, assessed quality, extracted data, conducted data analysis, and drafted the results of the update. SD assessed risk of bias and extracted data for a subset of the trials, and contributed to the analysis and the writing of the review. PG provided advice at all stages of the review production, applied inclusion criteria, assessed quality, quality assured data extraction, helped construct the comparisons, and helped write the review.

Internal sources {#CD000371-sec2-0021}
================

Liverpool School of Tropical Medicine, UK.

External sources {#CD000371-sec2-0022}
================

Department for International Development, UK.Evidence and Programme Guidance Unit, Department of Nutrition for Health and Development, WHO, Switzerland.

This Cochrane Review is supported by a DFID grant aimed at ensuring the best possible systematic reviews, particularly Cochrane Reviews, are completed on topics relevant to the poor, particularly women, in low‐ and middle‐income countries. DFID does not participate in the selection of topics, in the conduct of the review, or in the interpretation of findings. The grant provides partial salary support for PG, SD, and the funds for the contract with Enhance Reviews Ltd.

PG receives additional salary support from the COUNTDOWN Research Consortium, which is funded by the DFID. COUNTDOWN is committed to trials and development of mass treatment programmes related to NTDs.

Not applicable.

[^1]: Editorial Group: Cochrane Infectious Diseases Group.

[^2]: ^1^Four cluster‐RCTs (302 clusters) and six individually RCTs (2552 participants). ^2^Downgraded by 1 for risk of bias: trials had high or unclear risk of selection bias. ^3^Downgraded by 1 for inconsistency. One trial had a large effect and in a sensitivity analysis only including high quality trials the heterogeneity was considerably reduced. This trial was from a low prevalence setting ([@CD000371-bbs2-0002]; 0.98 kg). A subsequent trial in the same trial area as [@CD000371-bbs2-0002] found no effect. ^4^Two cluster‐RCTs (174 clusters) and five individually RCT (1861 participants). ^5^Downgraded by 1 for risk of bias: two trials were considered at high risk of selection bias ([@CD000371-bbs2-0003]; [@CD000371-bbs2-0002]), and in the remaining trials the risk was unclear. ^6^All individually RCTs. In a re‐analysis of one large quasi‐experimental design ([@CD000371-bbs2-0026]; [@CD000371-bbs2-0089]) no difference in anaemia between deworming and control groups was reported. ^7^Downgraded by 1 for risk of bias: two trials ([@CD000371-bbs2-0003]; [@CD000371-bbs2-0018]) were considered at high risk of selection bias; in the remaining trials the risk was low or unclear. ^8^Downgrade by 1 for indirectness: trials were conducted in low‐ and moderate‐prevalence settings, where any putative effect may be attenuated.

    ^9^[@CD000371-bbs2-0003], with a follow‐up of two years, reported that there was no difference in development between treatment groups in terms of proportion with \"normal\" development. [@CD000371-bbs2-0027] measured a range of cognitive tests with a follow‐up post‐treatment and found no effect of deworming. [@CD000371-bbs2-0026] measured a range of cognitive tests with a follow‐up of two years, but no deworming effect was demonstrated. [@CD000371-bbs2-0039], with a follow‐up of 12 months, found that treatment had no significant effect on motor or language development. [@CD000371-bbs2-0042], with a follow‐up of six months, found no difference on any of the tests between treatment groups. ^10^One cluster‐RCT, and four individually RCTs. ^11^Downgraded by 1 for risk of bias: two trials were considered at high risk of selection bias ([@CD000371-bbs2-0003]; [@CD000371-bbs2-0026]), and in the remaining trials the risk was low or unclear. ^12^These are the corrected effects from the Aitken replication on the 3ie website. ^13^One cluster‐RCT (50 clusters (20,000 participants) and one individually RCT (226 participants). The meta‐analysis includes the two year follow‐up for [@CD000371-bbs2-0026]. The trial has one‐year follow‐up on two other quasi‐randomized comparisons. These results are shown in [Table 17](#CD000371-tbl-0017){ref-type="table"}. These demonstrate higher participation in both arms (9.3% and 5.4%) but these estimates are not independent because the control group in one comparison becomes the intervention group in the subsequent year. One additional trial showed no effect but did not provide measures of variance. ^14^Downgraded by 1 for risk of bias: [@CD000371-bbs2-0026] had a high risk of bias for sequence generation, allocation concealment and blinding. ^15^Downgraded by 1 for imprecision: CIs include 4% lower attendance with deworming to 8% higher. ^16^Downgraded by 1 for indirectness: the intervention included a comprehensive health education programme in schools, and it not possible to determine which component of the complex intervention led to effects on attendance. ^17^Downgraded by 1 for risk of bias. A number of previously documented problems with the trial design. ^18^Neither trial demonstrates an effect, with narrow CIs. ^19^Two cluster‐RCTs (122 clusters) and one individually RCT (1423 participants). DEVTA dwarfs the other trials, none of which were adequately powered. ^20^Downgraded by 1 for risk of bias: none of the trials adequately described allocation concealment to be considered \"low risk of bias\". ^21^Downgraded by 1 indirectness: DEVTA was conducted in a low prevalence area and the findings may not be generalizable to higher prevalence areas.

[^3]: ^1^Downgraded by 1 for risk of bias: none of the trials adequately described allocation concealment. ^2^Downgraded by 1 for inconsistency: there is a high level of heterogeneity. ^3^Downgraded by 1 for indirectness: one of the trials showing large effects is from a highly endemic area in Kenya with intense worm loads and conducted 20 years ago. ^4^Downgraded by 2 for risk of bias and 1 for indirectness: two trials measured cognitive functioning: i) Kvalsvig 1991a, with a follow‐up of one month, did not clearly report the changes in cognitive scores since \"the dose of mebendazole was inadequate to free children from infection\"; and ii) [@CD000371-bbs2-0029], with a follow‐up of nine weeks, reported that results of a multiple regression suggest a greater improvement in treated children in 3/10 tests (fluency, digit span forwards, digit span backwards). These two trials are not easily generalized to other settings. ^5^ Downgraded by 1 for indirectness: Small differences in Harvard Step tests in two older trials in Kenya; no differences detected in VO~2~ and other parameters in a third trial with a small number of participants suggested no differences ([Table 18](#CD000371-tbl-0018){ref-type="table"}). ^6^Downgraded by 2 for risk of bias: only one of the trials adequately described allocation concealment to be considered low risk of selection bias. Two trials conducted Harvard step tests on small non‐random samples of larger trials.

[^4]: ^1^Downgraded by 1 for risk of bias: none of the trials were classified as having low risk of bias. ^2^Downgraded by 1 for indirectness: only two trials have assessed these outcomes and the results are not easily generalized to other settings. In the Philippines [@CD000371-bbs2-0035] reported deworming either had no effect or a negative effect on cognitive test scores, and in Vietnam [@CD000371-bbs2-0028] reported no difference detected. We could not combine data.

[^5]: ^a^CIDG Specialized Register. ^b^Search terms used in combination with the search strategy for retrieving trials developed by Cochrane ([@CD000371-bbs2-0131]).

[^6]: ^a^Of any worm infection. ^b^Of moderate to heavy infections.

[^7]: CI: confidence interval; Community category: a measure of the prevalence and intensity of infection (see [Table 11](#CD000371-tbl-0011){ref-type="table"}); NCHS: National Center for Health Statistics; SD: standard deviation; SEM: standard error of the mean.
